

(19) **DANMARK**

(10) **DK/EP 3294319 T3**



(12)

Oversættelse af europæisk patentskrift

Patent- og
Varemærkestyrelsen

-
- (51) Int.Cl.: **A 61 K 38/17 (2006.01)** **A 61 K 39/395 (2006.01)** **C 07 K 16/28 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2024-07-22**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2024-04-24**
- (86) Europæisk ansøgning nr.: **16722891.5**
- (86) Europæisk indleveringsdag: **2016-05-13**
- (87) Den europæiske ansøgnings publiceringsdag: **2018-03-21**
- (86) International ansøgning nr.: **EP2016060919**
- (87) Internationalt publikationsnr.: **WO2016180982**
- (30) Prioritet: **2015-05-13 US 201562160794 P**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Ablynx NV, Technologiepark 21, 9052 Ghent-Zwijnaarde, Belgien**
- (72) Opfinder: **VAN HOORICK, Diane, Warande 118, 9270 Laarne, Belgien**
ROOBROUCK, Annelies, Noenendal 25, 9700 Oudenaarde, Belgien
VIEIRA, Joao, 52 Miles East, OX11 6EE Didcot, Storbritannien
- (74) Fuldmægtig i Danmark: **RWS Group, Europa House, Chiltern Park, Chiltern Hill, Chalfont St Peter, Bucks SL9 9FG, Storbritannien**
- (54) Benævnelse: **T-CELLE-REKRUTTERENDE POLYPEPTIDER BASERET PÅ CD3-REAKTIVITET**
- (56) Fremdragne publikationer:
WO-A1-2011/119484
WO-A1-2012/066058
WO-A1-2015/044386
WO-A2-99/42077
M. AMANN ET AL: "Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3", CANCER RESEARCH, vol. 68, no. 1, 1 January 2008 (2008-01-01), pages 143-151, XP55287977, US ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-2182
LOEFFLER ANJA ET AL: "A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 6, 15 March 2000 (2000-03-15), pages 2098-2103, XP002299904, ISSN: 0006-4971

Description**FIELD OF THE INVENTION**

[0001] The present invention provides multispecific T cell recruiting polypeptides as defined by the claims binding CD3 on a T cell and at least one antigen on a target cell. The present invention also relates to the monovalent T cell recruiting polypeptides as defined by the claims for use in these multispecific polypeptides. The disclosure also provides methods for treatment and kits providing the same.

BACKGROUND

[0002] Cancer takes an enormous human toll around the world. It is nowadays the world's leading cause of death, followed by heart disease and stroke. Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. The number of new cases is expected to rise by about 70% over the next 2 decades (source: WHO Cancer). The total economic impact of premature death and disability from cancer worldwide was about \$900 billion in 2008, representing 1.5% of the world's gross domestic product.

[0003] Available treatment regimens for solid tumours typically include a combination of surgical resection chemotherapy and radiotherapy. In 40 years of clinical experience little progress has been achieved, especially in advanced stages of cancer.

[0004] New therapies combatting cancer are eagerly awaited.

[0005] Antibody therapy is now an important part of the physician's armamentarium to battle diseases and especially cancer. Monoclonal antibodies have been established as a key therapeutic approach for a range of diseases already for several years. All of the contemporaneously approved antibody therapies rely on monospecific monoclonal antibodies (mAbs). Until today, most of the targets of the mAbs require either an agonistic or an antagonistic approach. Whereas targeting of cell-surface antigens themselves can mediate antitumor activity through the induction of apoptosis, most mAb-based activity against hematologic malignancies is reliant on either Fc-mediated effector functions such as complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

[0006] Immunotherapy has emerged as a rapidly growing area of cancer research. Immunotherapy is directing the body's immune surveillance system, and in particular T cells, to cancer cells.

[0007] Cytotoxic T cells (CTL) are T lymphocytes that kill cancer cells, cells that are infected (particularly with viruses), or cells that are damaged in other ways. T lymphocytes (or T cells) express the T cell receptor or TCR molecule and the CD3 receptor on the cell surface. The $\alpha\beta$ TCR-CD3 complex (or "TCR complex") is composed of six different type I single-spanning transmembrane proteins: the TCR α and TCR β chains that form the TCR heterodimer responsible for ligand recognition, and the non-covalently associated CD3 γ , CD3 δ , CD3 ϵ and ζ chains, which bear cytoplasmic sequence motifs that are phosphorylated upon receptor activation and recruit a large number of signalling components (Call et al. 2004, Molecular Immunology 40: 1295-1305).

[0008] Both α and β chains of the T cell receptor consist of a constant domain and a variable domain. Physiologically, the $\alpha\beta$ chains of the T cell receptor recognize the peptide loaded MHC complex and couple upon engagement to the CD3 chains. These CD3 chains subsequently transduce the engagement signal to the intracellular environment.

[0009] Considering the potential of naturally occurring Cytotoxic T lymphocytes (CTLs) to mediate cell lysis, various strategies have been explored to recruit CTLs to mediate tumour cell killing. Since T lymphocytes lack the expression of Fc receptors, they are not recruited to a tumour site through the Fc tail of an anti-tumour monoclonal. As an alternative, the patient's T cells were modified with a second TCR of known specificity for a defined tumour antigen. This adoptive cell transfer is by nature highly personalized and labour intensive. However, the main problem of T cell therapies remains the large number of immune escape mechanisms known to occur in cancer patients (Nagorsen et al. 2012, Pharmacology & Therapeutics 136: 334-342).

[0010] Rather than eliciting specific T cell responses, which rely on expression by cancer cells of MHC molecules and the presence, generation, transport and display of specific peptide antigens, more recent developments have attempted to combine the advantages of immunotherapy with antibody therapy by engaging all cytotoxic T cells of a patient in a polyclonal fashion via recombinant antibody based technologies: "bispecifics".

[0011] Bispecific antibodies have been engineered that have a tumour recognition part on the one arm (target-binding arm) whereas the other arm of the molecule has specificity for a T cell antigen (effector-binding arm), mostly CD3. Through the simultaneous binding of the two arms to their respective target antigens, T lymphocytes are directed towards and activated at the tumour cell where they can exert their cytolytic function.

[0012] The concept of using bispecific antibodies to activate T cells against tumour cells was described more than 20 years ago, but manufacturing problems and clinical failures sent the field into stagnation. Smaller format bispecifics were developed, which more easily penetrate tissues and tumours than conventional antibodies. In addition, the smaller format

is better at creating the cytotoxic synapses, which kill the target cell. It was thought that the smaller format bispecifics would be easier to manufacture and less immunogenic than conventional antibodies. However, the smaller bispecific BiTE molecules, consisting of two single chain variable fragments (scFvs) joined by a 5 amino acid peptide linker, present a lack of stability (scFvs tend to aggregate), low expression titres and poor solubility. Moreover, the first clinical trials of Blinatumomab (a BiTE molecule), which recognizes CD3 chains, were prematurely stopped due to neurologic adverse events, cytokine release syndrome and infections on the one hand and the absence of objective clinical responses or robust signs of biological activity on the other hand. Efficacy aside, BiTEs must be continuously infused -- probably due to the lack of an Fc domain -- which does not contribute to a patient compliance. The same problem holds true for DARTs (dual affinity retargeting molecules developed by MacroGenics), in which the heavy variable domain from one antibody (Ab) is linked with the light variable domain of another Ab. MacroGenics now attempts to solve this problem by fusing an Fc domain onto its next generation DARTs, which makes the molecule not only bigger, but also results in manufacturing problems and importation of other Fc functions. The larger format with Fc will have a better PK, but re-introduces the risk of off-target activity. (Garber 2014, Nature reviews 13: 799-801)

[0013] WO 2012/066058 A1 refers to different CD3 specific conventional antibodies which can be used as a source for a CD3-binding domain.

[0014] WO 99/42077 A2 describes polypeptides that bind CD3 and a second target, e.g., selected from CD4-CD5, CD19-CD22 or CD45.

[0015] There remains the need for alternative bispecific formats.

SUMMARY OF THE INVENTION

[0016] The invention, as defined by the claims, solves this problem by providing multispecific polypeptides as defined by the claims comprising a first and at least one further immunoglobulin single variable domain (ISV), wherein said first ISV has high affinity for/binds to CD3; said at least one further ISV has high affinity for/binds to an antigen present on a target cell. In a particular aspect, the binding of the first ISV will activate the inherent cytolytic potential of the T cell against the target cell independently of MHC1.

[0017] Thus, in a first aspect the present invention provides a polypeptide comprising a first and a second immunoglobulin single variable domain (ISV), wherein

- said first ISV has high affinity for/binds to cluster of differentiation 3 (CD3) present on a T cell
- said second ISV has high affinity for/binds to a first antigen on a target cell; wherein said first antigen is different from said CD3; and

wherein said target cell is different from said T cell, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NOs: 81-87; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ. ID NO: 81; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 101-109; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ. ID NO: 101; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NOs: 123-127; and
- (f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ. ID NO: 123.

[0018] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said polypeptide directs the T-cell to the target cell.

[0019] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said polypeptide induces T cell activation.

[0020] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said T cell activation is independent from MHC recognition.

5 **[0021]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said T cell activation depends on presenting said polypeptide bound to said first antigen on a target cell to a T cell.

[0022] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said T cell activation causes one or more cellular response of said T cell, wherein said cellular response is selected from the group consisting of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, expression of activation markers and redirected target cell lysis.

10 **[0023]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said T cell activation causes inhibition of an activity of said target cell by more than about 10%, such as 20%, 30%, or 40% or even more than 50%, such as more than 60%, such as 70%, 80%, or even more than 90%, such as 100%.

15 **[0024]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV binds to CD3 γ (SEQ ID NO: 292), to CD3 δ (SEQ ID NO: 291) and/or CD3 ϵ (SEQ ID NO: 293) of the TCR complex, or polymorphic variants or isoforms thereof.

[0025] Alternatively, the present invention provides a polypeptide as defined by the claims, wherein said first ISV binds to CD3 γ (SEQ ID NO: 379), to CD3 δ (SEQ ID NO: 291) and/or CD3 ϵ (SEQ ID NO: 380) of the TCR complex, or polymorphic variants or isoforms thereof.

20 **[0026]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said polypeptide and/or first ISV has an on rate constant (K_{on}) for binding to said CD3 selected from the group consisting of at least about $10^2 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^3 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^4 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^5 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^6 \text{ M}^{-1}\text{s}^{-1}$, $10^7 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^8 \text{ M}^{-1}\text{s}^{-1}$, at least about $10^9 \text{ M}^{-1}\text{s}^{-1}$, and at least about $10^{10} \text{ M}^{-1}\text{s}^{-1}$, preferably as measured by surface plasmon resonance.

25 **[0027]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said polypeptide and/or first ISV has an off rate constant (K_{off}) for binding to said CD3 selected from the group consisting of at most about 10^{-3}s^{-1} , at most about 10^{-4}s^{-1} , at most about 10^{-5}s^{-1} , at most about 10^{-6}s^{-1} , at most about 10^{-7}s^{-1} , at most about 10^{-8}s^{-1} , at most about 10^{-9}s^{-1} , and at most about 10^{-10}s^{-1} preferably as measured by surface plasmon resonance.

30 **[0028]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV binds to said CD3 with an EC50 value of between 100 nM and 1 pM, such as at an average EC50 value of 100 nM or less, even more preferably at an average EC50 value of 90 nM or less, such as less than 80, 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM or even less, such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5 pM, or even less, such as less than 4 pM, preferably as measured by flow cytometry.

35 **[0029]** In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV binds to said CD3 with an average KD value of between 100 nM and 10 pM, such as at an average KD value of 90 nM or less, even more preferably at an average KD value of 80 nM or less, such as less than 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM, such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20 pM, or even less such, as less than 10 pM. Preferably, the KD is determined by SPR, for instance as determined by Proteon.

40 **[0030]** The present invention provides a polypeptide as defined by the claims, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

45 (a) SEQ ID NOs: 81-87; and
(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81; and/or

50 (ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; and
(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101; and/or

55 (iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; and

(f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0031] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 81-87; or (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; or (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; or (f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123, provided that the polypeptide comprising the CDR3 with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0032] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 81; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A.

[0033] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 101; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P.

[0034] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 123; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P.

[0035] Preferably, the polypeptide comprising the one or more CDRs with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDRs without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0036] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 81; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A,

provided that the polypeptide comprising the CDR1 with 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 101; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P,

provided that the polypeptide comprising the CDR2 with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 123; and

(b) amino acid sequences that have 1, or 2 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P,

provided that the polypeptide comprising the CDR3 with 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0037] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 81, CDR2 is represented by SEQ ID NO: 101, and CDR3 is represented by SEQ ID NO: 123.

[0038] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV is chosen from the group consisting of SEQ ID NOs: 1-50.

[0039] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV cross-blocks the binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 1-50.

[0040] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which said first ISV is cross-blocked from binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 1-50.

[0041] Disclosed but not part of the invention is a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is SEQ ID NO: 88.

[0042] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR2 is SEQ ID NO: 110.

[0043] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR3 is SEQ ID NO: 128.

[0044] In a further aspect, the present disclosure provides a polypeptide as described herein, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NO: 88; and

(b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 88; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NO: 110; and

(d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 110; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NO: 128; and

(f) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 128.

[0045] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 88; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 88, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 110; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 110, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 128; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 128, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0046] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 88, CDR2 is represented by SEQ ID NO: 110, and CDR3 is represented by SEQ ID NO: 128.

[0047] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV is SEQ ID NOs: 51.

[0048] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV cross-blocks the binding to CD3 by the polypeptide with SEQ ID NOs: 51.

[0049] In a further aspect, the present disclosure provides a polypeptide as described herein in which said first ISV is cross-blocked from binding to CD3 by the polypeptide with SEQ ID NOs: 51.

[0050] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is SEQ ID NO: 90.

[0051] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 112; and

(b) amino acid sequence that has 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A.

[0052] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR3 is SEQ ID NO: 130.

[0053] Preferably, the polypeptide comprising the one or more CDRs with 1 amino acid difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDRs without the 1 amino acid difference, said affinity as measured by surface plasmon resonance.

[0054] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is SEQ ID NO: 90; and

and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 112; and

(b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A,

provided that the polypeptide comprising the CDR2 with 1 amino acid difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 1 amino acid difference, said affinity as measured by surface plasmon resonance; and in which

(iii) CDR3 is SEQ ID NO: 130.

[0055] In a further aspect, the present disclosure provides a polypeptide as described herein, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NO: 90; and
- (b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 112-113; and
- (d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 112; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NO: 130; and
- (f) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 130.

[0056] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NOs: 90; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 112-113; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 112, provided that the polypeptide comprising the CDR2

with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NOs: 130; and
- (f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 130, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0057] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 90, CDR2 is represented by SEQ ID NO: 112, and CDR3 is represented by SEQ ID NO: 130.

[0058] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV is chosen from the group consisting of SEQ ID NOs: 53-56.

[0059] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV cross-blocks the binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 53-56.

[0060] In a further aspect, the present disclosure provides a polypeptide as described herein in which said first ISV is cross-blocked from binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 53-56.

[0061] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV

essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is SEQ ID NO: 89.

[0062] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR2 is SEQ ID NO: 111.

[0063] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR3 is SEQ ID NO: 129.

[0064] In a further aspect, the present disclosure provides a polypeptide as described herein, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NO: 89; and
- (b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 89; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NO: 111; and
- (d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 111; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NO: 129; and
- (f) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 129.

[0065] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NOs: 89; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 89, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 111; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 111, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NOs: 129; and
- (f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 129, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0066] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 89, CDR2 is represented by SEQ ID NO: 111, and CDR3 is represented by SEQ ID NO: 129.

[0067] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV is SEQ ID NOs: 52.

[0068] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV cross-blocks the binding to CD3 by the polypeptide with SEQ ID NOs: 52.

[0069] In a further aspect, the present disclosure provides a polypeptide as described herein in which said first ISV is cross-blocked from binding to CD3 by the polypeptides with SEQ ID NOs: 52.

[0070] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

- (a) SEQ ID NO: 91; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T.

[0071] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

- (a) SEQ ID NO: 114; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 114, wherein

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K.

[0072] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

- (a) SEQ ID NO: 131; and
- (b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 131, wherein

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V.

[0073] Preferably, the polypeptide comprising the one or more CDRs with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDRs without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0074] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

- (i) CDR1 is chosen from the group consisting of

- (a) SEQ ID NO: 91; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T,

provided that the polypeptide comprising the CDR1 with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 114; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 114, wherein

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K,

provided that the polypeptide comprising the CDR2 with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 131; and

(b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 131, wherein

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V,

provided that the polypeptide comprising the CDR3 with 1 amino acid difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 1 amino acid difference, said affinity as measured by surface plasmon resonance.

[0075] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 91-93; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 91; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 114-117; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 114; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 131-133; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 131.

[0076] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 91-93; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 91, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 114-117; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 114, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 131-133; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 131, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0077] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 91, CDR2 is represented by SEQ ID NO: 114, and CDR3 is represented by SEQ ID NO: 131.

[0078] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV is chosen from the group consisting of SEQ ID NOs: 57-65.

[0079] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV cross-blocks the binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 57-65.

[0080] In a further aspect, the present disclosure provides a polypeptide as described herein in which said first ISV is cross-blocked from binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 57-65.

[0081] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 94; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 94, wherein

- at position 3 the S has been changed into T, A or G;
- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M.

[0082] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 118; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 118, wherein

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F.

[0083] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions

(CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 134; and

(b) amino acid sequences that have 1, 2, 3, 4 or 5 amino acid(s) difference with SEQ ID NO: 134, wherein

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or
- at position 14 the V has been changed into I.

[0084] Preferably, the polypeptide comprising the one or more CDRs with 5, 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDRs without the 5, 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0085] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 94; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid difference(s) with SEQ ID NO: 94, wherein

- at position 3 the S has been changed into T, A or G;
- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M,

provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 118; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 118, wherein

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F,

provided that the polypeptide comprising the CDR2 with 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 134; and

(b) amino acid sequences that have 1, 2, 3, 4 or 5 amino acid difference(s) with SEQ ID NO: 134, wherein

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or

- at position 14 the V has been changed into I,

provided that the polypeptide comprising the CDR3 with 5, 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 5, 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0086] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 94-100; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 94; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 118-122; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 134-143; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 134.

[0087] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 94-100; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 94, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 118-122; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 134-143; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 134, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0088] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions

(CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 94, CDR2 is represented by SEQ ID NO: 118, and CDR3 is represented by SEQ ID NO: 134.

[0089] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV is chosen from the group consisting of SEQ ID NOs: 66-80.

[0090] In a further aspect, the present disclosure provides a polypeptide as described herein, in which said first ISV cross-blocks the binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 66-80.

[0091] In a further aspect, the present disclosure provides a polypeptide as described herein in which said first ISV is cross-blocked from binding to CD3 by at least one of the polypeptides with SEQ ID NOs: 66-80.

[0092] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first antigen on a target cell is a tumour antigen, preferably a tumour associated antigen (TAA).

[0093] In a further aspect, the present invention provides a polypeptide as defined by the claims, further comprising a third ISV, which has high affinity for/binds to a second antigen on a target cell, wherein said second antigen is different from said first antigen.

[0094] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said second antigen on a target cell is a tumour antigen, preferably a tumour associated antigen (TAA).

[0095] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first antigen and said second antigen are present on the same target cells.

[0096] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first antigen and said second antigen are present on different target cells.

[0097] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said TAA's are independently chosen from the group consisting of Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Fibroblast Activation Protein (FAP), MART-1, carcinoembryonic antigen (CEA), gp100, MAGE-1, HER-2, Lewis^y antigens, CD123, CD44, CLL-1, CD96, CD47, CD32, CXCR4, Tim-3, CD25, TAG-72, Ep-CAM, PSMA, PSA, GD2, GD3, CD4, CD5, CD19, CD20, CD22, CD33, CD36, CD45, CD52, CD147, growth factor receptors including ErbB3 and ErbB4, Cytokine receptors including Interleukin-2 receptor gamma chain (CD132 antigen), Interleukin-10 receptor alpha chain (IL-10R-A), Interleukin-10 receptor beta chain (IL-10R-B), Interleukin-12 receptor beta-1 chain (IL-12R-beta1), Interleukin-12 receptor beta-2 chain (IL-12 receptor beta-2), Interleukin-13 receptor alpha-1 chain (IL-13R-alpha-1) (CD213a1 antigen), Interleukin-13 receptor alpha-2 chain (Interleukin-13 binding protein), Interleukin-17 receptor (IL-17 receptor), Interleukin-17B receptor (IL-17B receptor), Interleukin 21 receptor precursor (IL-21R), Interleukin-1 receptor type I (IL-1R-1) (CD121a), Interleukin-1 receptor type II (IL-1R-beta) (CDw121b), Interleukin-1 receptor antagonist protein (IL-1ra), Interleukin-2 receptor alpha chain (CD25 antigen), Interleukin-2 receptor beta chain (CD122 antigen), Interleukin-3 receptor alpha chain (IL-3R-alpha) (CD123 antigen), CD30, IL23R, IGF-1R, IL5R, IgE, CD248 (endosialin), CD44v6, gpA33, Ron, Trop2, PSCA, claudin 6, claudin 18.2, CLEC12A, CD38, ephA2, c-Met, CD56, MUC16, EGFRvIII, AGS-16, CD27L, Nectin-4, SLITRK6, mesothelin, folate receptor, tissue factor, axl, glypican-3, CA9, Cripto, CD138, CD37, MUC1, CD70, gastrin releasing peptide receptor, PAP, CEACAM5, CEACAM6, CXCR7, N-cadherin, FXYD2 gamma a, CD21, CD133, Na/K-ATPase, mIgM (membrane-bound IgM), mIgA (membrane-bound IgA), Mer, Tyro2, CD120, CD95, CA 195, DR5, DR6, DcR3 and CAIX, including related polymorphic variants and isoforms.

[0098] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said TAA is CD20 (UniProt 11836), HER2 (Uniprot P04626), polymorphic variants or isoforms thereof.

[0099] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first antigen and said second antigen are chosen from the group consisting of:

- EGFR as a first antigen and CEA as a second antigen;
- CD19 as a first antigen and CD20 as a second antigen;
- CD19 as a first antigen and CD22 as a second antigen;
- CD123 as a first antigen and Tim-3 as a second antigen; and
- CD132 as a first antigen and CD69 as a second antigen.

[0100] In a further aspect, the present invention provides a polypeptide as defined by the claims, further comprising a serum protein binding moiety.

[0101] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said serum protein binding moiety binds serum albumin.

[0102] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said serum protein binding moiety is an ISV binding serum albumin.

[0103] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV binding serum albumin essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which CDR1 is SFGMS (SEQ ID NO: 373), CDR2 is

SISGSGSDTLYADSVKG (SEQ ID NO: 374) and CDR3 is GGSLSR (SEQ ID NO: 375), CDR determined according to Kabat definition; and/or in which CDR1 is GFTFSSFGMS (SEQ ID NO: 376) or GFTFRSFGMS (SEQ ID NO: 377), CDR2 is SISGSGSDTL (SEQ ID NO: 378) and CDR3 is GGSLSR (SEQ ID NO: 375), CDR determined according to Kontermann 2010.

[0104] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV binding serum albumin is selected from Alb8, Alb23, Alb129, Alb132, Alb11, Alb11 (S112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG, and Alb82-GGG (SEQ ID NOs: 348 to 360). In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISVs are directly linked to each other or are linked via a linker.

[0105] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV and/or said second ISV and/or possibly said third ISV and/or possibly said ISV binding serum albumin are linked via a linker.

[0106] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said linker is chosen from the group consisting of linkers of 5GS, 7GS, 9GS, 10GS, 15GS, 18GS, 20GS, 25GS, 30GS and 35GS (SEQ ID NOs: 362 to 372).

[0107] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said serum protein binding moiety is a non-antibody based polypeptide.

[0108] In a further aspect, the present invention provides a polypeptide as defined by the claims, further comprising PEG.

[0109] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV is a Nanobody®, a V_{HH}, a humanized V_{HH}, or a camelized V_H.

[0110] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV is chosen from the group consisting of SEQ ID NOs: 1 to 50.

[0111] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said first ISV is chosen from the group consisting of SEQ ID NOs: 1 to 50, and wherein said second ISV is chosen from the group consisting of SEQ ID NOs: 297 to 304.

[0112] In a further aspect, the present invention provides a polypeptide chosen from the group consisting of SEQ ID NOs: 265-267, 273, 279-283, 286, 288-289, 322-324, 330, 336-340 and 345-346.

[0113] In a further aspect, the present invention provides a polypeptide that specifically binds CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 81-87; or

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NOs: 81, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; or

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NOs: 101, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; or

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NOs: 123, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0114] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which CDR1 is

chosen from the group consisting of

- (a) SEQ ID NO: 81; and
- (b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A.

[0115] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which CDR2 is chosen from the group consisting of

- (a) SEQ ID NO: 101; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P.

[0116] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which CDR3 is chosen from the group consisting of

- (a) SEQ ID NO: 123; and
- (b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P.

[0117] In a further aspect, the present invention provides a polypeptide as defined by the claims, in which: CDR1 is represented by SEQ ID NO: 81, CDR2 is represented by SEQ ID NO: 101, and CDR3 is represented by SEQ ID NO: 123.

[0118] In a further aspect, the present disclosure provides a polypeptide as described herein, in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NOs: 88; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 88, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 110; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 110, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NOs: 128; and
- (f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 128, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3

without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0119] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is SEQ ID NO: 88.

[0120] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR2 is SEQ ID NO: 110.

[0121] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR3 is SEQ ID NO: 128.

[0122] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 88, CDR2 is represented by SEQ ID NO: 110, and CDR3 is represented by SEQ ID NO: 128.

[0123] In a further aspect, the present disclosure provides a polypeptide as described herein, in which:

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 90; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 112-113; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 112, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NO: 130; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 130, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0124] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is SEQ ID NO: 90.

[0125] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 112; and

(b) amino acid sequence that has 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A.

[0126] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR3 is SEQ ID NO: 130.

[0127] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 90, CDR2 is represented by SEQ ID NO: 112, and CDR3 is represented by SEQ ID NO: 130.

[0128] In a further aspect, the present disclosure provides a polypeptide as described herein, in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 89; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 89, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1

without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 111; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 111, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 129; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 129, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0129] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is SEQ ID NO: 89.

[0130] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR2 is SEQ ID NO: 111.

[0131] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR3 is SEQ ID NO: 129.

[0132] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 89, CDR2 is represented by SEQ ID NO: 111, and CDR3 is represented by SEQ ID NO: 129.

[0133] The present disclosure also provides a polypeptide as described herein, in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 91-93; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 91, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 114-117; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 114, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 131-133; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 131, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0134] In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 91; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T.

5 **[0135]** In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR2 is chosen from the group consisting of

- (a) SEQ ID NO: 114; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 114, wherein

10

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K.

15 **[0136]** In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR3 is chosen from the group consisting of

- (a) SEQ ID NO: 131; and
- (b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 131, wherein

20

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V.

25 **[0137]** In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 91, CDR2 is represented by SEQ ID NO: 114, and CDR3 is represented by SEQ ID NO: 131.

[0138] The present disclosure also provides a polypeptide as described herein, in which:

(i) CDR1 is chosen from the group consisting of:

30

- (a) SEQ ID NOs: 94-100; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 94, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

35

(ii) CDR2 is chosen from the group consisting of:

40

- (c) SEQ ID NOs: 118-122; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

45

(iii) CDR3 is chosen from the group consisting of:

50

- (e) SEQ ID NOs: 134-143; and
- (f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 134, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0139] In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR1 is chosen from the group consisting of

55

- (a) SEQ ID NO: 94; and
- (b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 94, wherein
- at position 3 the S has been changed into T, A or G;

- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M.

5 **[0140]** In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR2 is chosen from the group consisting of

- (a) SEQ ID NO: 118; and
- (b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 118, wherein

10

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F.

15

[0141] In a further aspect, the present disclosure provides a polypeptide as described herein, in which CDR3 is chosen from the group consisting of

- (a) SEQ ID NO: 134; and
- (b) amino acid sequences that have 1, 2, 3, 4 or 5 amino acid(s) difference with SEQ ID NO: 134, wherein

20

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or
- at position 14 the V has been changed into I.

25

[0142] In a further aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 94, CDR2 is represented by SEQ ID NO: 118, and CDR3 is represented by SEQ ID NO: 134.

30

[0143] In a further aspect, the present invention provides a polypeptide as defined by the claims, which is a Nanobody, a V_{HH} , a humanized V_{HH} , or a camelized V_H .

[0144] In a further aspect, the present invention provides a polypeptide as defined by the claims, further comprising a serum protein binding moiety.

35

[0145] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said serum protein binding moiety binds serum albumin.

[0146] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said serum protein binding moiety is an ISV that binds serum albumin.

[0147] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV that binds serum albumin essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which CDR1 is SFGMS (SEQ ID NO: 373), CDR2 is SISGSGSDTLY-ADSVKG (SEQ ID NO: 374) and CDR3 is GGSLSR (SEQ ID NO: 375), CDR as determined according to Kabat definition; and/or in which CDR1 is GFTFSSFGMS (SEQ ID NO: 376) or GFTFRSFGMS (SEQ ID NO: 377), CDR2 is SISGSGSDTL (SEQ ID NO: 378) and CDR3 is GGSLSR (SEQ ID NO: 375), CDR as determined according to Kontermann 2010.

40

[0148] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV that binds serum albumin is selected from Alb8, Alb23, Alb129, Alb132, Alb11, Alb11 (S112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG, and Alb82-GGG (SEQ ID NOs: 348 to 360).

[0149] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said ISV is directly linked or is linked via a linker.

50

[0150] In a further aspect, the present invention provides a polypeptide as defined by the claims, wherein said linker is chosen from the group consisting of linkers of 5GS, 7GS, 9GS, 10GS, 15GS, 18GS, 20GS, 25GS, 30GS and 35GS (SEQ ID NOs: 362 to 372).

[0151] In a further aspect, the present invention provides a polypeptide as defined by the claims, further comprising a PEG moiety.

55

[0152] In a further aspect, the present invention provides a nucleic acid or nucleic acid sequence encoding a polypeptide as defined by the claims.

[0153] In a further aspect, the present invention provides vector comprising a nucleic acid or nucleic acid sequence as defined by the claims.

[0154] In a further aspect, the present invention provides a host cell transformed or transfected with the nucleic acid or nucleic acid sequence as defined by the claims or with the vector as defined by the claims.

[0155] In a further aspect, the present invention provides a process for the production of the polypeptide as defined by the claims, said process comprising culturing a host cell as defined by the claims under conditions allowing the expression of the polypeptide as defined by the claims and recovering the produced polypeptide from the culture.

[0156] In a further aspect, the present invention provides a pharmaceutical composition comprising the polypeptide as defined by the claims, or the polypeptide produced according to the process as defined by the claims.

[0157] In a further aspect, the present invention provides a polypeptide as defined by the claims for use in treating a subject in need thereof.

[0158] In a further aspect, the present disclosure provides a method for delivering a prophylactic or therapeutic polypeptide to a specific location, tissue or cell type in the body, the method comprising the steps of administering to a subject a polypeptide as described herein, or produced as described herein.

[0159] In a further aspect, the present invention provides a polypeptide as defined by the claims for use in the prevention, treatment or amelioration of a disease selected from the group consisting of a proliferative disease, an inflammatory disease, an infectious disease and an autoimmune disease.

[0160] In a further aspect, the present disclosure provides a method for the prevention, treatment or amelioration of a disease selected from the group consisting of a proliferative disease, an inflammatory disease, an infectious disease and an autoimmune disease, comprising the step of administering to a subject in need thereof the polypeptide as described herein, or produced as described herein.

[0161] In a further aspect, the present invention provides a polypeptide for use in or a method for the prevention, treatment or amelioration of a disease as defined by the claims, wherein said proliferative disease is cancer.

[0162] In a further aspect, the present invention provides a polypeptide for use in or a method for the prevention, treatment or amelioration of a disease as defined by the claims, wherein said cancer is chosen from the group consisting of carcinomas, gliomas, mesotheliomas, melanomas, lymphomas, leukemias, adenocarcinomas: breast cancer, ovarian cancer, cervical cancer, glioblastoma, multiple myeloma (including monoclonal gammopathy of undetermined significance, asymptomatic and symptomatic myeloma), prostate cancer, and Burkitt's lymphoma, head and neck cancer, colon cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, cancer of the esophagus, stomach cancer, pancreatic cancer, hepatobiliary cancer, cancer of the gallbladder, cancer of the small intestine, rectal cancer, kidney cancer, bladder cancer, prostate cancer, penile cancer, urethral cancer, testicular cancer, vaginal cancer, uterine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, pancreatic endocrine cancer, carcinoid cancer, bone cancer, skin cancer, retinoblastomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, multicentric Castleman's disease or AIDS-associated primary effusion lymphoma, neuroectodermal tumors, rhabdomyosarcoma; as well as any metastasis of any of the above cancers.

[0163] In a further aspect, the present invention provides a polypeptide as defined by the claims for use in or a method for the prevention, treatment or amelioration of a disease, wherein the treatment is a combination treatment.

[0164] In a further aspect, the present invention provides a kit comprising a polypeptide as defined by the claims, a nucleic acid or nucleic acid sequence as defined by the claims, a vector as defined by the claims, or a host cell as defined by the claims.

FIGURE LEGENDS

[0165]

Figure 1: QC of human TCR/CD3 and human CD3 transfected cell lines using 100nM of anti-human TCR α/β antibody (clone BW242/412) (black) and 100nM anti-human CD3 antibody (clone OKT-3) (grey). The MCF value (mean channel fluorescence) is plotted for each cell line.

Figures 2A and 2B: Dose dependent binding of monovalent CD3 Nanobodies to human TCR/CD3 expressed on CHO-K1 cells (Figure 2A) and to purified primary human T cells (Figure 2B). The MCF value (mean channel fluorescence) is plotted against the concentration of the Nanobody.

Figure 3: Dose dependent binding of monovalent CD3 Nanobodies to HEK293H human TCR(2IAL)/CD3 (closed circle), HEK293H human CD3 (cross) and to HEK293H parental cell line (open circles). The MCF value (mean channel fluorescence) is plotted against the concentration of the Nanobody.

Figures 4A and 4B: T cell activation data of bead coupled monovalent CD3 Nanobodies (Figure 4A). T cell activation data of monovalent CD3 Nanobodies presented in solution (Figure 4B). Activation is measured by monitoring the CD69 upregulation on primary human T cells. The MCF value (mean channel fluorescence) is plotted for each

Nanobody.

Figures 5A-5C: Binding of a dilution series of CD20xCD3 (full line) and CD3xCD20 (dotted line) bispecific Nanobodies to human TCR/CD3 expressed on CHO-K1 cells (Figure 5A), primary human T cells (Figure 5B) and Ramos cells (Figure 5C). The MCF value (mean channel fluorescence) is plotted against the concentration of the Nanobody.

Figures 6A and 6B: Dose-dependent killing effect of CD20xCD3 (full line) and CD3xCD20 (dotted line) bispecific Nanobodies in a flow cytometry based human T cells mediated Ramos (Figure 6A) and Raji (Figure 6B) B cell killing assay. The % cell death (% of TOPRO positive cells) is plotted against the concentration of the Nanobody.

Figure 7: Dose-dependent binding of the anti-CD20 Nanobody on human CD20 Ramos (open symbols) and Raji (closed symbols) cells. The MCF value (mean channel fluorescence) is plotted against the concentration of the Nanobody.

Figure 8: Dose-dependent killing effect of CD20xCD3 (full line) and CD3xCD20 (dotted line) bispecific Nanobodies in the xCELLigence based human T cells mediated CHO-K1 human CD20 killing assay. The CI is plotted against the concentration of Nanobody.

Figure 9: Killing effect of 1 μ M of CD20xCD3 and an irrelevant construct in a xCELLigence based killing assay using CHO-K1 human CD20 cells (black bars) and using CHO-K1 parental cell line (grey bars) to illustrate TAA dependent killing. The cell index (CI) is plotted against the concentration of the Nanobody.

Figure 10: Dose-dependent killing effect of CD20xCD3 Nanobodies with 9GS linker (open circles - dotted line) and a 35GS linker (closed squares - dotted line) and the CD3xCD20 Nanobody with a 35GS linker (closed diamonds - solid line) in a flow cytometry based killing assay using Ramos. The % cell death (TORPRO positive cells) is plotted against the concentration of Nanobody.

Figure 11: Dose-dependent killing of T017000062 in a flow cytometry based human T cells mediated Ramos B cell killing assay using different effector (E) to target (T) ratio's (E:T ratio 10:1 - closed circles, E:T ratio 5:1 - open squares, E:T ratio 2:1 - closed triangles and E:T ratio 1:1 - open diamonds). The % cell death (% of TOPRO positive cells) is plotted against the concentration of the Nanobody.

Figure 12: Time-dependent cytolytic activity of CD20/CD3 in the purified primary human T cells mediated killing assay in xCELLigence using CHO-K1 human CD20 target cells. The % specific lysis is plotted against the concentration of the construct. The different curves represent the analysis time after addition of the T cells.

Figures 13A-13C: Binding of a serial dilution of HLE constructs to human TCR/CD3 expressed on CHO-K1 cells (Figure 13A), primary human T cells (Figure 13B) and Ramos cells (Figure 13C). The MCF value (mean channel fluorescence) is plotted against the concentration of the Nanobody.

Figures 14A-14D: Dose-dependent killing of CD20xCD3 bispecific Nanobody (solid line-diamonds) versus CD20xCD3xALB11 constructs (solid line - closed triangle) (Figure 14A, Figure 14C) and dose-dependent killing effect of CD20xCD3xALB11 constructs in the absence (solid line - closed triangle) or presence of 30 μ M HSA (dotted line - open triangle) in a flow cytometry based human T cells mediated Ramos B cell killing assay (Figure 14B, Figure 14D). The % cell death (% of TOPRO positive cells) is plotted against the concentration of the Nanobody.

Figure 15: Binding of 100nM monovalent anti-HER2 Nanobody (5F07) to SK-BR-3, MCF-7 and MDA-MB-468 cell lines in flow cytometry to compare HER2 expression levels. The MCF value (mean channel fluorescence) is plotted for each cell line.

Figure 16: Dose-dependent killing effect of bispecific CD3xHER2 Nanobodies (dotted line) and bispecific HER2xCD3 (full line) in an xCELLigence based human T cells mediated cell killing assay. Data were analysed using at 18h. The Cell index (CI) was plotted against the concentration of the Nanobody.

Figure 17: Dose-dependent INF- γ production by human T cells after incubation of human CD20 positive CHO-K1 cells with bispecific CD20xCD3 Nanobodies in flow cytometry based killing assay. Data were analysed after 72h incubation. The OD at 405nm was plotted against the concentration of the Nanobody.

Figure 18: Study design PBMC B cell depletion model. PBMCs were injected intraperitoneally to animals on day 3 (D3). Mice were treated from D3 to D7 with T017000084 (CD3/CD20) IV Q1Dx5 or T017000088 IV Q1Dx5 (irrelevant Nanobody).

Figure 19: Absolute PBMC-derived B cell count on log scale. Individual animal results are depicted. The number of B-cells is shown in function of the different treatment groups.

Figure 20: Study design Ramos model. Ramos cells were injected intravenously to mice on D1. PBMCs were injected intraperitoneally to animals on D3. Mice were treated from D3 to D7 with T017000084 (CD3/CD20) IV Q1Dx5 or T017000088 IV Q1Dx5 (irrelevant Nanobody).

Figure 21: Absolute Ramos B cell count on log scale. Individual animal results are depicted. The open circles on top of the graph show which active doses were statistically significant different from the irrelevant NB (T017000088) based on the F-tests from the mixed-effects ANOVA analysis. All effects are statistically significant at the 5% level of significance.

Figure 22: Absolute PBMC-derived B cell count on log scale. Individual animal results are depicted. The open circles on top of the graph show which active doses were statistically significant different from the irrelevant NB (T017000088) based on the F-tests from the mixed-effects ANOVA analysis. All effects are statistically significant at the 5% level of significance.

Figures 23A and 23B: Determination of EGFR (Figure 23A; Santa Cruz, sc-120 PE) or CEACAM5 (Figure 23B; Sino Biological, 11077-MM02-P) expression level on HER14, Hela, LoVo and LS174-T cell lines in flow cytometry. The MCF value (mean channel fluorescence) is plotted for each cell line.

DETAILED DESCRIPTION OF THE INVENTION

[0166] The present inventors realized that formats bringing T cells and tumour cells together to induce an immune response should comply with various and frequently opposing requirements. The format should be broadly applicable. In particular, the format should preferably be useful in a broad range of patients and preferably also against a broad range of tumours. The format should preferably be safe and only target the intended cells. In addition, the format should preferably be small enough to easily penetrate tissues and tumours, while on the other hand the format should be patient friendly. For instance, the format should have an extended half-life, such that the format is not removed instantaneously upon administration by renal clearance. However, extending the half-life should preferably not introduce off-target activity and side effects or limit the penetration into tissues and tumours. Additionally, it was recognized that tumour cells often create escape mechanisms by the down-regulation of targeted antigens within a therapy. Accordingly, in a further preferred version, the format should target simultaneously multiple antigens.

[0167] The present invention realizes at least one of these requirements.

[0168] In particular, it was hypothesized that immunoglobulin single variable domains (ISVs) would in principle be ideal candidates, since they are small enough to easily penetrate (tumour) tissue and can be combined with other ISVs as building blocks. Next, ISVs directed against CD3, and in particular CD3 ϵ , should have broad applicability.

[0169] Six clusters of related ISVs were identified, which had an unexpected range of advantageous features. First, the ISVs were unexpectedly broadly applicable, i.e. the CD3 ISVs were able to bind to T cells from different donors with high affinity. Formatted in a multispecific polypeptide, the CD3 ISVs enabled tumour cell killing with different tumour associated antigens. Hence, the CD3 ISVs can be used against a multitude of cancers. In addition, the multispecific polypeptides comprising the CD3 ISVs remained active when bound to albumin. This contributes to a favourable PK profile and patient compliance, while minimizing side effects. The polypeptides of the invention only showed effects when bound both to the T cell and the target cell, which is indicative of its safety.

[0170] The present inventors considered that the simultaneous targeting of multiple antigens reduces the probability of generating tumour escape variants, because of which the therapeutic activity of T cell engaging strategy is improved. Multispecific polypeptides are provided which comprise a CD3 ISV combined with immunoglobulin single variable domains against different target antigens and/or different epitopes on a particular antigen (biparatopic).

[0171] Immunoglobulin sequences, such as antibodies and antigen binding fragments derived there from (e.g., immunoglobulin single variable domains or ISVs) are used to specifically target their respective antigens in research and therapeutic applications. The generation of immunoglobulin single variable domains such as e.g., VHHs or Nanobodies may involve the immunization of an experimental animal such as a Llama, construction of phage libraries from immune tissue, selection of phage displaying antigen binding immunoglobulin single variable domains and screening of said domains and engineered constructs thereof for the desired specificities (WO 94/04678). Alternatively, similar immu-

noglobulin single variable domains such as e.g., dAbs can be generated by selecting phage displaying antigen binding immunoglobulin single variable domains directly from naive or synthetic libraries and subsequent screening of said domains and engineered constructs thereof for the desired specificities (Ward et al., Nature, 1989, 341: 544-6; Holt et al., Trends Biotechnol., 2003, 21(11):484-490; as well as for example WO 06/030220, WO 06/003388 and other published patent applications of Domantis Ltd.). Unfortunately, the use of monoclonal and/or heavily engineered antibodies also carries a high manufacturing cost and may result in suboptimal tumor penetration compared to other strategies.

[0172] The present invention provides multispecific polypeptides as defined by the claims that specifically bind to CD3 of the T cell receptor complex, with an unexpected range of advantageous features. First, the polypeptides are easy to manufacture. Moreover, the ISVs are unexpectedly broad applicable, i.e. the CD3 ISVs were able to bind to T cells from different donors with high affinity. Formatted in a multispecific polypeptide, the CD3 ISVs enabled tumour cell killing with different tumour associated antigens. In contrast, no killing was observed when the polypeptides were not bound to T cells and target cell which underscores the safety of the polypeptides of the invention. Hence, the CD3 ISVs can be used against a multitude of cancers. Moreover, the CD3 ISVs can be considered as safe. In addition, the multispecific polypeptides comprising the CD3 ISVs remained active when bound to albumin. This will contribute to a favourable PK profile and patient compliance, while minimizing side effects.

[0173] Accordingly, the present invention relates to a polypeptide as defined by the claims comprising a first and a second immunoglobulin single variable domain (ISV), wherein the first ISV has high affinity for/binds to CD3 and the second ISV has high affinity for/binds to an antigen on a cell (target cell), preferably a tumour cell. The antigen is preferably specific for said target cell, such as e.g. a tumour associated antigen (TAA). The multispecific polypeptide of the invention directs the T cell to the cell, e.g. a tumour cell and induces T cell activation in order to allow said T cell to inhibit or kill said target cell, e.g. said tumour cell. "Polypeptides of the invention" are polypeptides as defined by the claims.

Definitions:

[0174]

a) Unless indicated or defined otherwise, all terms used have their usual meaning in the art, which will be clear to the skilled person. Reference is for example made to the standard handbooks mentioned in paragraph a) on page 46 of WO 08/020079.

b) The term "immunoglobulin single variable domain", interchangeably used with "single variable domain" and "ISV", defines molecules wherein the antigen binding site is present on, and formed by, a single immunoglobulin domain. This sets immunoglobulin single variable domains apart from "conventional" immunoglobulins or their fragments (such as Fabs, scFvs, etc.), wherein two immunoglobulin domains, in particular two variable domains, interact to form an antigen binding site. Typically, in conventional immunoglobulins, a heavy chain variable domain (VH) and a light chain variable domain (VL) interact to form an antigen binding site. In this case, the complementarity determining regions (CDRs) of both VH and VL will contribute to the antigen binding site, i.e. a total of 6 CDRs will be involved in antigen binding site formation. In contrast, the binding site of an immunoglobulin single variable domain is formed by a single VH or VL domain. Hence, the antigen binding site of an immunoglobulin single variable domain is formed by no more than three CDRs.

[0175] The terms "immunoglobulin single variable domain", "single variable domain", and "ISV" hence do not comprise conventional immunoglobulins or their fragments which require interaction of at least two variable domains for the formation of an antigen binding site. However, these terms do comprise fragments of conventional immunoglobulins wherein the antigen binding site is formed by a single variable domain.

[0176] The term "immunoglobulin single variable domain" or "ISV" includes (without being limiting) antigen-binding domains or fragments such as V_{HH} domains or V_H or V_L domains, respectively. The terms antigen-binding molecules or antigen-binding protein are used interchangeably and include also the term Nanobodies. The immunoglobulin single variable domains can be light chain variable domain sequences (e.g., a V_L -sequence), or heavy chain variable domain sequences (e.g., a V_H -sequence); more specifically, they can be heavy chain variable domain sequences that are derived from a conventional four-chain antibody or heavy chain variable domain sequences that are derived from a heavy chain antibody. Accordingly, the immunoglobulin single variable domains can be domain antibodies, or immunoglobulin sequences that are suitable for use as domain antibodies, single domain antibodies, or immunoglobulin sequences that are suitable for use as single domain antibodies, "dAbs", or immunoglobulin sequences that are suitable for use as dAbs, or Nanobodies, including but not limited to V_{HH} sequences, humanized VHH sequences or camelized VH sequences.. The invention includes immunoglobulin sequences of different origin, comprising mouse, rat, rabbit, donkey, human and camelid immunoglobulin sequences. The immunoglobulin single variable domain includes fully human, humanized, otherwise sequence optimized or chimeric immunoglobulin sequences. The immunoglobulin single variable domain and

structure of an immunoglobulin single variable domain can be considered - without however being limited thereto - to be comprised of four framework regions or "FR's", which are referred to in the art and herein as "Framework region 1" or "FR1"; as "Framework region 2" or "FR2"; as "Framework region 3" or "FR3"; and as "Framework region 4" or "FR4", respectively; which framework regions are interrupted by three complementary determining regions or "CDR's", which are referred to in the art as "Complementarity Determining Region 1" or "CDR1"; as "Complementarity Determining Region 2" or "CDR2"; and as "Complementarity Determining Region 3" or "CDR3", respectively. It is noted that the terms Nanobody or Nanobodies are registered trademarks of Ablynx N.V. and thus may also be referred to as Nanobody® or Nanobodies®, respectively.

[0177] c) Unless indicated otherwise, the terms "immunoglobulin sequence", "sequence", "nucleotide sequence" and "nucleic acid" are as described in paragraph b) on page 46 of WO 08/020079.

[0178] d) Unless indicated otherwise, all methods, steps, techniques and manipulations that are not specifically described in detail can be performed and have been performed in a manner known per se, as will be clear to the skilled person. Reference is for example again made to the standard handbooks and the general background art mentioned herein and to the further references cited therein; as well as to for example the following reviews Presta 2006 (Adv. Drug Deliv. Rev. 58 (5-6):640-656), Levin and Weiss 2006 (Mol. Biosyst. 2(1):49-57), Irving et al. 2005 (J. Immunol. Methods 248(1-2):31-45), Schmitz et al. 2000 (Placenta 21 Suppl. A: S106-112, Gonzales et al. 2005 (Tumour Biol. 26(1):31-43), which describe techniques for protein engineering, such as affinity maturation and other techniques for improving the specificity and other desired properties of proteins such as immunoglobulins.

[0179] e) Amino acid residues will be indicated according to the standard three-letter or one-letter amino acid code. Reference is made to Table A-2 on page 48 of the International application WO 08/020079 of Ablynx N.V. entitled "Immunoglobulin single variable domains directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signalling".

[0180] f) For the purposes of comparing two or more nucleotide sequences, the percentage of "sequence identity" between a first nucleotide sequence and a second nucleotide sequence may be calculated or determined as described in paragraph e) on page 49 of WO 08/020079, such as by dividing [the number of nucleotides in the first nucleotide sequence that are identical to the nucleotides of the corresponding positions in the second nucleotide sequence] by [the total number of nucleotides in the first nucleotide sequence] and multiplying by [100%], in which each deletion, insertion, substitution or addition of a nucleotide in the second nucleotide sequence - compared to the first nucleotide sequence - is considered as a difference at a single nucleotide (position); or using a suitable computer algorithm or technique, again as described in paragraph e) on pages 49 of WO 08/020079.

[0181] g) For the purposes of comparing two or more immunoglobulin single variable domains or other amino acid sequences such e.g. the polypeptides of the invention etc., the percentage of "sequence identity" between a first amino acid sequence and a second amino acid sequence (also referred to herein as "amino acid identity") may be calculated or determined as described in paragraph f) on pages 49 and 50 of WO 08/020079, such as by dividing [the number of amino acid residues in the first amino acid sequence that are identical to the amino acid residues of the corresponding positions in the second amino acid sequence] by [the total number of amino acid residues in the first amino acid sequence] and multiplying by [100%], in which each deletion, insertion, substitution or addition of an amino acid residue in the second amino acid sequence - compared to the first amino acid sequence - is considered as a difference at a single amino acid residue (position), i.e., as an "amino acid difference" as defined herein; or using a suitable computer algorithm or technique, again as described in paragraph f) on pages 49 and 50 of WO 08/020079).

[0182] Also, in determining the degree of sequence identity between two immunoglobulin single variable domains, the skilled person may take into account so-called "conservative" amino acid substitutions, as described on page 50 of WO 08/020079.

[0183] Any amino acid substitutions applied to the polypeptides described herein may also be based on the analysis of the frequencies of amino acid variations between homologous proteins of different species developed by Schulz et al. 1978 (Principles of Protein Structure, Springer-Verlag), on the analyses of structure forming potentials developed by Chou and Fasman 1975 (Biochemistry 13: 211) and 1978 (Adv. Enzymol. 47: 45-149), and on the analysis of hydrophobicity patterns in proteins developed by Eisenberg et al. 1984 (Proc. Natl. Acad. Sci. USA 81: 140-144), Kyte & Doolittle 1981 (J Molec. Biol. 157: 105-132), and Goldman et al. 1986 (Ann. Rev. Biophys. Chem. 15: 321-353) Information on the primary, secondary and tertiary structure of Nanobodies is given in the description herein and in the general background art cited above. Also, for this purpose, the crystal structure of a V_{HH} domain from a llama is for example given by Desmyter et al. 1996 (Nature Structural Biology, 3: 803), Spinelli et al. 1996 (Natural Structural Biology 3: 752-757), and Decanniere et al. 1999 (Structure, 7: 361). Further information about some of the amino acid residues that in conventional V_H domains form the V_H/V_L interface and potential camelizing substitutions on these positions can be found in the prior art cited above.

[0184] h) Immunoglobulin single variable domains and nucleic acid sequences are said to be "exactly the same" if they have 100% sequence identity (as defined herein) over their entire length.

[0185] i) When comparing two immunoglobulin single variable domains, the term "amino acid difference" refers to an

insertion, deletion or substitution of a single amino acid residue on a position of the first sequence, compared to the second sequence; it being understood that two immunoglobulin single variable domains can contain one, two or more such amino acid differences.

[0186] j) When a nucleotide sequence or amino acid sequence is said to "comprise" another nucleotide sequence or amino acid sequence, respectively, or to "essentially consist of" another nucleotide sequence or amino acid sequence, this has the meaning given in paragraph i) on pages 51-52 of WO 08/020079.

[0187] k) The term "in essentially isolated form" has the meaning given to it in paragraph j) on pages 52 and 53 of WO 08/020079.

[0188] l) The terms "domain" and "binding domain" have the meanings given to it in paragraph k) on page 53 of WO 08/020079.

[0189] m) The terms "antigenic determinant" and "epitope", which may also be used interchangeably herein, have the meanings given to it in paragraph l) on page 53 of WO 08/020079.

[0190] n) As further described in paragraph m) on page 53 of WO 08/020079, an amino acid sequence (such as an antibody, a polypeptide of the invention, or generally an antigen-binding protein or polypeptide or a fragment thereof) that can (specifically) bind to, that has affinity for and/or that has specificity for a specific antigenic determinant, epitope, antigen or protein (or for at least one part, fragment or epitope thereof) is said to be "*against*" or "*directed against*" said antigenic determinant, epitope, antigen or protein.

[0191] o) The term "*specificity*" refers to the number of different types of antigens or antigenic determinants to which a particular antigen-binding molecule or antigen-binding protein (such as an ISV, Nanobody or a polypeptide of the invention) can bind. The specificity of an antigen-binding protein can be determined based on affinity and/or avidity.

[0192] The affinity, represented by the equilibrium constant for the dissociation of an antigen with an antigen-binding protein (K_D or K_D), is a measure for the binding strength between an antigenic determinant, i.e. the target, and an antigen-binding site on the antigen-binding protein, i.e. the ISV or Nanobody: the lesser the value of the K_D , the stronger the binding strength between an antigenic determinant and the antigen-binding molecule (alternatively, the affinity can also be expressed as the affinity constant (K_A), which is $1/K_D$). As will be clear to the skilled person (for example on the basis of the further disclosure herein), affinity can be determined in a manner known per se, depending on the specific antigen of interest.

[0193] Avidity is the affinity of the polypeptide, i.e. the ligand is able to bind via two (or more) pharmacophores (ISV) in which the multiple interactions synergize to enhance the "apparent" affinity. Avidity is the measure of the strength of binding between the polypeptide of the invention and the pertinent antigens. The polypeptide of the invention is able to bind via its two (or more) building blocks, such as ISVs or Nanobodies, to the at least two targets, in which the multiple interactions, e.g. the first building block, ISV or Nanobody binding to the first target and the second building block, ISV, or Nanobody binding to the second target, synergize to enhance the "apparent" affinity. Avidity is related to both the affinity between an antigenic determinant and its antigen binding site on the antigen-binding molecule and the number of pertinent binding sites present on the antigen-binding molecules. For example, and without limitation, polypeptides that contain two or more building blocks, such as ISVs or Nanobodies directed against different targets on a cell may (and usually will) bind with higher avidity than each of the individual monomers or individual building blocks, such as, for instance, the monovalent ISVs or Nanobodies, comprised in the polypeptides of the invention.

[0194] Any K_D value greater than 10^{-4} mol/liter (or any K_A value lower than 10^4 M⁻¹) liters/mol is generally considered to indicate non-specific binding.

[0195] The polypeptides of the invention comprise a first and a second building block, e.g. a first and a second ISV, or a first and a second Nanobody. Preferably the affinity of each building block, e.g. ISV or Nanobody, is determined individually. In other words, the affinity is determined for the monovalent building block, ISV or Nanobody, independent of avidity effects due to the other building block, ISV or Nanobody, which might or might not be present. The affinity for a monovalent building block, ISV or Nanobody can be determined on the monovalent building block, ISV or Nanobody per se, i.e. when said monovalent building block, ISV or Nanobody is not comprised in the polypeptide of the invention. In the alternative or in addition, the affinity for a monovalent building block, ISV or Nanobody can be determined on one target while the other target is absent.

[0196] The binding of an antigen-binding protein to an antigen or antigenic determinant can be determined in any suitable manner known per se, including, for example, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays, and the different variants thereof known per se in the art; as well as the other techniques mentioned herein.

[0197] The dissociation constant may be the actual or apparent dissociation constant, as will be clear to the skilled person. Methods for determining the dissociation constant will be clear to the skilled person, and for example include the techniques mentioned herein. In this respect, it will also be clear that it may not be possible to measure dissociation constants of more than 10^{-4} moles/liter or 10^{-3} moles/liter (e.g., of 10^{-2} moles/liter). Optionally, as will also be clear to the skilled person, the (actual or apparent) dissociation constant may be calculated on the basis of the (actual or apparent) association constant (K_A), by means of the relationship $[K_D = 1/K_A]$.

[0198] The affinity denotes the strength or stability of a molecular interaction. The affinity is commonly given as by the K_D , or dissociation constant, which has units of mol/liter (or M). The affinity can also be expressed as an association constant, K_A , which equals $1/K_D$ and has units of $(\text{mol/liter})^{-1}$ (or M^{-1}). In the present specification, the stability of the interaction between two molecules (such as an amino acid sequence, Nanobody or polypeptide of the invention and its intended target) will mainly be expressed in terms of the K_D value of their interaction; it being clear to the skilled person that in view of the relation $K_A = 1/K_D$, specifying the strength of molecular interaction by its K_D value can also be used to calculate the corresponding K_A value. The K_D -value characterizes the strength of a molecular interaction also in a thermodynamic sense as it is related to the free energy (ΔG) of binding by the well-known relation $\Delta G = RT \cdot \ln(K_D)$ (equivalently $\Delta G = -RT \cdot \ln(K_A)$), where R equals the gas constant, T equals the absolute temperature and $\ln$ denotes the natural logarithm.

[0199] The K_D for biological interactions which are considered meaningful (e.g. specific) are typically in the range of 10^{-10}M (0.1 nM) to 10^{-5}M (10000 nM). The stronger an interaction is, the lower is its K_D .

[0200] The K_D can also be expressed as the ratio of the dissociation rate constant of a complex, denoted as k_{off} , to the rate of its association, denoted k_{on} (so that $K_D = k_{\text{off}}/k_{\text{on}}$ and $K_A = k_{\text{on}}/k_{\text{off}}$). The off-rate k_{off} has units s^{-1} (where s is the SI unit notation of second). The on-rate k_{on} has units $\text{M}^{-1}\text{s}^{-1}$. The on-rate may vary between $10^2 \text{M}^{-1}\text{s}^{-1}$ to about $10^7 \text{M}^{-1}\text{s}^{-1}$, approaching the diffusion-limited association rate constant for biomolecular interactions. The off-rate is related to the half-life of a given molecular interaction by the relation $t_{1/2} = \ln(2)/k_{\text{off}}$. The off-rate may vary between 10^{-6}s^{-1} (near irreversible complex with a $t_{1/2}$ of multiple days) to 1s^{-1} ($t_{1/2} = 0.69\text{s}$).

[0201] The affinity of a molecular interaction between two molecules can be measured via different techniques known per se, such as the well-known surface plasmon resonance (SPR) biosensor technique (see for example Ober et al. 2001, Intern. Immunology, 13: 1551-1559). The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, where one molecule is immobilized on the biosensor chip and the other molecule is passed over the immobilized molecule under flow conditions yielding k_{on} , k_{off} measurements and hence K_D (or K_A) values. This can for example be performed using the well-known BIAcore(R) system (BIAcore International AB, a GE Healthcare company, Uppsala, Sweden and Piscataway, NJ). For further descriptions, see Jonsson et al. 1993 (Ann. Biol. Clin. 51: 19-26), Jonsson et al. 1991 (Biotechniques 11: 620-627), Johnsson, et al. 1995 (J. Mol. Recognit. 8: 125-131), and Johnsson, et al. 1991 (Anal. Biochem. 198: 268-277).

[0202] Alternatively, affinities can be measured in Kinetic Exclusion Assay (KinExA) (see for example Drake et al. 2004, Anal. Biochem., 328: 35-43), using the KinExA® platform (Sapidyne Instruments Inc, Boise, USA). The term "KinExA", as used herein, refers to a solution-based method to measure true equilibrium binding affinity and kinetics of unmodified molecules. Equilibrated solutions of an antibody/antigen complex are passed over a column with beads precoated with antigen (or antibody), allowing the free antibody (or antigen) to bind to the coated molecule. Detection of the antibody (or antigen) thus captured is accomplished with a fluorescently labeled protein binding the antibody (or antigen).

[0203] It will also be clear to the skilled person that the measured K_D may correspond to the apparent K_D if the measuring process somehow influences the intrinsic binding affinity of the implied molecules for example by artefacts related to the coating on the biosensor of one molecule. Also, an apparent K_D may be measured if one molecule contains more than one recognition site for the other molecule. In such situation the measured affinity may be affected by the avidity of the interaction by the two molecules.

[0204] Another approach that may be used to assess affinity is the 2-step ELISA (Enzyme-Linked Immunosorbent Assay) procedure of Friguet et al. 1985 (J. Immunol. Methods, 77: 305-19). This method establishes a solution phase binding equilibrium measurement and avoids possible artefacts relating to adsorption of one of the molecules on a support such as plastic.

[0205] However, the accurate measurement of K_D may be quite labour-intensive and, as consequence, often apparent K_D values are determined to assess the binding strength of two molecules. It should be noted that as long all measurements are made in a consistent way (e.g. keeping the assay conditions unchanged) apparent K_D measurements can be used as an approximation of the true K_D and hence, in the present document, K_D and apparent K_D should be treated with equal importance or relevance.

[0206] Finally, it should be noted that in many situations the experienced scientist may judge it to be convenient to determine the binding affinity relative to some reference molecule. For example, to assess the binding strength between molecules A and B, one may e.g. use a reference molecule C that is known to bind to B and that is suitably labelled with a fluorophore or chromophore group or other chemical moiety, such as biotin for easy detection in an ELISA or FACS (Fluorescent activated cell sorting) or other format (the fluorophore for fluorescence detection, the chromophore for light absorption detection, the biotin for streptavidin-mediated ELISA detection). Typically, the reference molecule C is kept at a fixed concentration and the concentration of A is varied for a given concentration or amount of B. As a result an IC_{50} value is obtained corresponding to the concentration of A at which the signal measured for C in absence of A is halved. Provided $K_{D \text{ ref}}$, the K_D of the reference molecule, is known, as well as the total concentration c_{ref} of the reference

molecule, the apparent K_D for the interaction A-B can be obtained from following formula: $K_D = IC_{50} / (1 + c_{ref} / K_{D ref})$. Note that if $c_{ref} \ll K_{D ref}$, $K_D \approx IC_{50}$. Provided the measurement of the IC_{50} is performed in a consistent way (e.g. keeping c_{ref} fixed) for the binders that are compared, the strength or stability of a molecular interaction can be assessed by the IC_{50} and this measurement is judged as equivalent to K_D or to apparent K_D throughout this text.

[0207] p) The half-life of an amino acid sequence, compound or polypeptide of the invention can generally be defined as described in paragraph o) on page 57 of WO 08/020079 and as mentioned therein refers to the time taken for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, *in vivo*, for example due to degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms. The *in vivo* half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art, and may for example generally be as described in paragraph o) on page 57 of WO 08/020079. As also mentioned in paragraph o) on page 57 of WO 08/020079, the half-life can be expressed using parameters such as the $t_{1/2}$ -alpha, $t_{1/2}$ -beta and the area under the curve (AUC). Reference is for example made to the Experimental Part below, as well as to the standard handbooks, such as Kenneth et al. 1996 (Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists) and Peters et al. 1996 (Pharmacokinetic analysis: A Practical Approach). Reference is also made to Gibaldi & Perron 1982 (Pharmacokinetics, Dekker M, 2nd Rev. edition). The terms "increase in half-life" or "increased half-life" are as defined in paragraph o) on page 57 of WO 08/020079 and in particular refer to an increase in the $t_{1/2}$ -beta, either with or without an increase in the $t_{1/2}$ -alpha and/or the AUC or both.

[0208] q) In respect of a target or antigen, the term "interaction site" on the target or antigen means a site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on the target or antigen that is a site for binding to a ligand, receptor or other binding partner, a catalytic site, a cleavage site, a site for allosteric interaction, a site involved in multimerisation (such as homomerization or heterodimerization) of the target or antigen; or any other site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on the target or antigen that is involved in a biological action or mechanism of the target or antigen. More generally, an "interaction site" can be any site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on the target or antigen to which an amino acid sequence or polypeptide of the invention can bind such that the target or antigen (and/or any pathway, interaction, signalling, biological mechanism or biological effect in which the target or antigen is involved) is modulated.

[0209] r) An immunoglobulin single variable domain or polypeptide is said to be "*specific for*" a first target or antigen compared to a second target or antigen when it binds to the first antigen with an affinity/avidity (as described above, and suitably expressed as a K_D value, K_A value, K_{off} rate and/or K_{on} rate) that is at least 10 times, such as at least 100 times, and preferably at least 1000 times, and up to 10.000 times or more better than the affinity with which said amino acid sequence or polypeptide binds to the second target or polypeptide. For example, the first antigen may bind to the target or antigen with a K_D value that is at least 10 times less, such as at least 100 times less, and preferably at least 1000 times less, such as 10.000 times less or even less than that, than the K_D with which said amino acid sequence or polypeptide binds to the second target or polypeptide. Preferably, when an immunoglobulin single variable domain or polypeptide is "*specific for*" a first target or antigen compared to a second target or antigen, it is directed against (as defined herein) said first target or antigen, but not directed against said second target or antigen.

[0210] s) The terms "*cross-block*", "*cross-blocked*" and "*cross-blocking*" are used interchangeably herein to mean the ability of an immunoglobulin single variable domain or polypeptide to interfere with the binding of the natural ligand to its receptor(s). The extent to which an immunoglobulin single variable domain or polypeptide of the invention is able to interfere with the binding of another compound such as the natural ligand to its target and therefore whether it can be said to cross-block according to the invention, can be determined using competition binding assays. One particularly suitable quantitative cross-blocking assay uses a FACS- or an ELISA-based approach or Alphascreen to measure competition between the labelled (e.g., His tagged or biotinylated) immunoglobulin single variable domain or polypeptide according to the invention and the other binding agent in terms of their binding to the target. The experimental part generally describes suitable FACS-, ELISA- or Alphascreen-displacement-based assays for determining whether a binding molecule cross-blocks or is capable of cross-blocking an immunoglobulin single variable domain or polypeptide according to the invention. It will be appreciated that the assay can be used with any of the immunoglobulin single variable domains or other binding agents described herein. Thus, in general, a cross-blocking amino acid sequence or other binding agent according to the invention is for example one which will bind to the target in the above cross-blocking assay such that, during the assay and in the presence of a second amino acid sequence or other binding agent of the invention, the recorded displacement of the immunoglobulin single variable domain or polypeptide according to the invention is between 60% and 100% (e.g., in ELISA/Alphascreen based competition assay) or between 80% to 100% (e.g., in FACS based competition assay) of the maximum theoretical displacement (e.g. displacement by cold (e.g., unlabeled) immunoglobulin single variable domain or polypeptide that needs to be cross-blocked) by the to be tested potentially cross-blocking agent that is present in an amount of 0.01 mM or less (cross-blocking agent may be another conventional monoclonal antibody such as IgG, classic monovalent antibody fragments (Fab, scFv) and engineered variants (e.g., diabodies, triabodies, minibodies, VHHs, dAbs, VHs, VLs)).

[0211] t) An amino acid sequence such as e.g. an immunoglobulin single variable domain or polypeptide according to the invention is said to be a "*VHH1 type immunoglobulin single variable domain*" or "*VHH type 1 sequence*", if said VHH1 type immunoglobulin single variable domain or VHH type 1 sequence has 85% identity (using the VHH1 consensus sequence as the query sequence and use the blast algorithm with standard setting, i.e., blosum62 scoring matrix) to the VHH1 consensus sequence (QVQLVESGGGLVQPGGSLRLSCAASGFTLDYYAIGWFRQAPGKEREGVSCISSD GSTYYADSVKGRFTISRDNKNTVYLQMNSLKPEDTAVYYCAA) (SEQ ID NO: 361), and mandatorily has a cysteine in position 50, i.e., C50 (using Kabat numbering).

[0212] u) An amino acid sequence such as e.g., an immunoglobulin single variable domain or polypeptide according to the invention is said to be "*cross-reactive*" for two different antigens or antigenic determinants (such as serum albumin from two different species of mammal, such as human serum albumin and cynomolgus monkey serum albumin) if it is specific for (as defined herein) both these different antigens or antigenic determinants.

[0213] v) As further described in paragraph q) on pages 58 and 59 of WO 08/020079, the amino acid residues of an immunoglobulin single variable domain are numbered according to the general numbering for V_H domains given by Kabat et al. ("Sequence of proteins of immunological interest", US Public Health Services, NIH Bethesda, MD, Publication No. 91), as applied to V_{HH} domains from Camelids in the article of Riechmann and Muyldermans, 2000 (J. Immunol. Methods 240 (1-2): 185-195; see for example Figure 2 of this publication). It should be noted that - as is well known in the art for V_H domains and for VHH domains - the total number of amino acid residues in each of the CDRs may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (that is, one or more positions according to the Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed for by the Kabat numbering). This means that, generally, the numbering according to Kabat may or may not correspond to the actual numbering of the amino acid residues in the actual sequence. The total number of amino acid residues in a VH domain and a VHH domain will usually be in the range of from 110 to 120, often between 112 and 115. It should however be noted that smaller and longer sequences may also be suitable for the purposes described herein.

[0214] Determination of CDR regions may also be done according to different methods. In the CDR determination according to Kabat, FR1 of an immunoglobulin single variable domain comprises the amino acid residues at positions 1-30, CDR1 of an immunoglobulin single variable domain comprises the amino acid residues at positions 31-35, FR2 of an immunoglobulin single variable domain comprises the amino acids at positions 36-49, CDR2 of an immunoglobulin single variable domain comprises the amino acid residues at positions 50-65, FR3 of an immunoglobulin single variable domain comprises the amino acid residues at positions 66-94, CDR3 of an immunoglobulin single variable domain comprises the amino acid residues at positions 95-102, and FR4 of an immunoglobulin single variable domain comprises the amino acid residues at positions 103-113.

[0215] In the present application, however, unless indicated otherwise, CDR sequences were determined according to Kontermann and Dübel (Eds. 2010, Antibody Engineering, vol 2, Springer Verlag Heidelberg Berlin, Martin, Chapter 3, pp. 33-51). According to this method, FR1 comprises the amino acid residues at positions 1-25, CDR1 comprises the amino acid residues at positions 26-35, FR2 comprises the amino acids at positions 36-49, CDR2 comprises the amino acid residues at positions 50-58, FR3 comprises the amino acid residues at positions 59-94, CDR3 comprises the amino acid residues at positions 95-102, and FR4 comprises the amino acid residues at positions 103-113.

[0216] w) The Figures, Sequence Listing and the Experimental Part/Examples are only given to further illustrate the invention and should not be interpreted or construed as limiting the scope of the invention and/or of the appended claims in any way, unless explicitly indicated otherwise herein.

[0217] x) The half maximal inhibitory concentration (IC₅₀) is a measure of the effectiveness of a compound in inhibiting a biological or biochemical function, e.g. a pharmacological effect. This quantitative measure indicates how much of the ISV or Nanobody (inhibitor) is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor, chemotaxis, anaplasia, metastasis, invasiveness, etc) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC₅₀). The IC₅₀ of a drug can be determined by constructing a dose-response curve and examining the effect of different concentrations of antagonist such as the ISV or Nanobody of the invention on reversing agonist activity. IC₅₀ values can be calculated for a given antagonist such as the ISV or Nanobody of the invention by determining the concentration needed to inhibit half of the maximum biological response of the agonist.

[0218] The term half maximal effective concentration (EC₅₀) refers to the concentration of a compound which induces a response halfway between the baseline and maximum after a specified exposure time. In the present context it is used as a measure of a polypeptide's, ISV's or Nanobody's potency. The EC₅₀ of a graded dose response curve represents the concentration of a compound where 50% of its maximal effect is observed. Concentration is preferably expressed in molar units.

[0219] In biological systems, small changes in ligand concentration typically result in rapid changes in response, following a sigmoidal function. The inflection point at which the increase in response with increasing ligand concentration begins to slow is the EC₅₀. This can be determined mathematically by derivation of the best-fit line. Relying on a graph

for estimation is convenient in most cases. In case the EC50 is provided in the examples section, the experiments were designed to reflect the KD as accurate as possible. In other words, the EC50 values may then be considered as KD values. The term "average KD" relates to the average KD value obtained in at least 1, but preferably more than 1, such as at least 2 experiments. The term "average" refers to the mathematical term "average" (sums of data divided by the number of items in the data).

[0220] It is also related to IC50 which is a measure of a compound's inhibition (50% inhibition). For competition binding assays and functional antagonist assays, IC50 is the most common summary measure of the dose-response curve. For agonist/stimulator assays the most common summary measure is the EC50.

[0221] y) It must be noted that as used herein, the singular forms "a", "an", and "the", include plural references unless the context clearly indicates otherwise. Thus, for example, reference to "a reagent" includes one or more of such different reagents and reference to "the method" includes reference to equivalent steps and methods known to those of ordinary skill in the art that could be modified or substituted for the methods described herein.

[0222] Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series.

[0223] The term "and/or" wherever used herein includes the meaning of "and", "or" and "all or any other combination of the elements connected by said term".

[0224] The term "about" or "approximately" as used herein means within 20%, preferably within 15%, more preferably within 10%, and most preferably within 5% of a given value or range.

[0225] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integer or step. When used herein the term "comprising" can be substituted with the term "containing" or "including" or sometimes when used herein with the term "having".

[0226] The present invention relates to a polypeptide as defined by the claims comprising at least a first and at least one further immunoglobulin single variable domain (ISV), wherein said at least first ISV has high affinity for/binds to cluster of differentiation 3 (CD3) and said at least one further ISV has high affinity for/binds to an antigen on a target cell.

[0227] Typically, the multispecific polypeptides of the invention combine high affinity antigen recognition on the target cell with T cell activation, resulting in an activation that is independent of the T cells' natural specificity. The mode of action of the binding molecules that binds both to a cell surface molecule on a target cell such as a tumour antigen and to the T cell co-receptor CD3 is commonly known. Bringing a T cell in close vicinity to a target cell, i.e., engaging said T cell results in killing of the target cell by the T cell. In the present invention this process is exploited in fighting against proliferative disease, inflammatory disease, infectious disease and autoimmune disease. Generally T cells are equipped with granules containing a deadly combination of pore-forming proteins, called perforins, and cell death-inducing proteases, called granzymes. Preferably, these proteins are delivered into target cells via a cytolytic synapse that forms if T cells are in close vicinity with a target cell that is aimed to be killed. Normally, close vicinity between a T cell and a target cell is achieved by the T cell binding to an MHC/peptide complex using its matching T cell receptor. The polypeptides of the invention bring a T cell into such close vicinity to a target cell in the absence of T cell receptor/MHC interaction.

[0228] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said polypeptide directs the T cell to the target cell.

[0229] With one arm (first ISV), the multispecific polypeptide has high affinity for / binds to CD3, a protein component of the signal-transducing complex of the T cell receptor on T-cells. With another arm (second ISV and/or third ISV, etc.), the multispecific polypeptide recognizes, has high affinity for / binds an antigen(s) on target cells. Preferably, T cell activation is only seen when the multispecific polypeptides are presented to T cells on the surface of target cells. Antigen dependence on target cells for activation results in a favourable safety profile. In an embodiment, the multispecific polypeptides transiently tether T cells and target cells. Preferably, the multispecific polypeptide can induce resting polyclonal T cells, such as CD4⁺ and/or CD8⁺ T cells into activation, for highly potent redirected lysis of target cells. Preferably, the T cell is directed to a next target cell after lysis of the first target cell.

[0230] Proteins and polypeptides that comprise or essentially consist of two or more immunoglobulin single variable domains (such as at least two immunoglobulin single variable domains of the invention) will be referred to herein as "multivalent" proteins or polypeptides or as "multivalent constructs". Some non-limiting examples of such multivalent constructs will become clear from the further description herein. The polypeptides of the invention are "multivalent", i.e. comprising two or more building blocks or ISVs of which at least the first building block, ISV or Nanobody and the second building block, ISV or Nanobody are different, and directed against different targets, such as antigens or antigenic determinants. Polypeptides of the invention that contain at least two building blocks, ISVs or Nanobodies, in which at least one building block, ISV or Nanobody is directed against a first antigen (i.e., against the first target, such as e.g. CD3) and at least one building block, ISV or Nanobody is directed against a second antigen (i.e., against the second target which is different from the first target, such as e.g. a TAA, e.g. CD20 or HER2), will also be referred to as "multispecific" polypeptides of the invention, and the building blocks, ISVs or Nanobodies present in such polypeptides

will also be referred to herein as being in a "multivalent format" or "multispecific format". Thus, for example, a "bispecific" polypeptide of the invention is a polypeptide that comprises at least one building block, ISV or Nanobody directed against a first target (e.g. CD3) and at least one further building block, ISV or Nanobody directed against a second target (*i.e.*, directed against a second target different from said first target, such as e.g. a TAA, e.g. CD20 or HER2), whereas a "trispecific" polypeptide of the invention is a polypeptide that comprises at least one building block, ISV or Nanobody directed against a first target (e.g., CD3), a second building block, ISV or Nanobody directed against a second target different from said first target (e.g. a TAA, such as CD20 or HER2) and at least one further building block, ISV or Nanobody directed against a third antigen (*i.e.*, different from both the first and the second target, such as another TAA); etc. As will be clear from the description, the invention is not limited to bispecific polypeptides, in the sense that a multispecific polypeptide of the invention may comprise at least a first building block, ISV or Nanobody against a first target, a second building block, ISV or Nanobody against a second target and any number of building blocks, ISVs or Nanobodies directed against one or more targets, which may be the same or different from the first and/or second target, respectively. The building blocks, ISVs or Nanobodies can optionally be linked via linker sequences.

[0231] The terms bispecific polypeptide, bispecific format, bispecific construct, bispecific Nanobody construct, bispecific and bispecific antibody are used interchangeably herein.

[0232] As will be clear from the further description above and herein, the immunoglobulin single variable domains of the invention can be used as "building blocks" to form polypeptides of the invention, *e.g.*, by suitably combining them with other groups, residues, moieties or binding units, in order to form compounds or constructs as described herein (such as, without limitations, the bi-/tri-/tetra-/ multivalent and bi-/tri-/tetra-/multispecific polypeptides of the invention described herein) which combine within one molecule one or more desired properties or biological functions.

[0233] It will be appreciated (as is also demonstrated in the Example section) that the ISV binding CD3 and the ISV binding the antigen on a target cell can be positioned in any order in the polypeptide of the invention. More particularly, in one embodiment, the ISV binding CD3 is positioned N-terminally and the ISV binding the antigen on a target cell is positioned C-terminally. In another embodiment, the ISV binding the antigen on a target cell is positioned N-terminally and the ISV binding CD3 is positioned C-terminally.

[0234] In a preferred aspect, the polypeptide of the invention comprises at least a first, at least a second and at least a third immunoglobulin single variable domain (ISV), wherein said at least a first ISV has high affinity for/binds to CD3; said at least a second ISV has high affinity for/binds to a first antigen on a target cell, and said at least a third ISV has high affinity for/binds to a second antigen on a target cell, wherein said second antigen is different from said first antigen. Said first antigen and said second antigen can be on the same or on different target cells.

[0235] It will be appreciated (as is also demonstrated in the Example section) that the ISV binding CD3 and the ISVs binding the first and second antigen on a target cell can be positioned in any order in the polypeptide of the invention. More particularly, in one embodiment, the ISV binding CD3 is positioned N-terminally, the ISV binding the first antigen on a target cell is positioned centrally and the ISV binding the second antigen on a target cell is positioned C-terminally. In another embodiment, the ISV binding CD3 is positioned N-terminally, the ISV binding the second antigen on a target cell is positioned centrally and the ISV binding the first antigen on a target cell is positioned C-terminally. In another embodiment, the ISV binding the first antigen on a target cell is positioned N-terminally, the ISV binding the second antigen on a target cell is positioned centrally and the ISV binding CD3 is positioned C-terminally. In another embodiment, the ISV binding the first antigen on a target cell is positioned N-terminally, the ISV binding CD3 is positioned centrally and the ISV binding the second antigen on a target cell is positioned C-terminally. In another embodiment, the ISV binding the second antigen on a target cell is positioned N-terminally, the ISV binding CD3 is positioned centrally and the ISV binding the first antigen on a target cell is positioned C-terminally. In another embodiment, the ISV binding the second antigen on a target cell is positioned N-terminally, the ISV binding the first antigen on a target cell is positioned centrally and the ISV binding CD3 is positioned C-terminally.

[0236] The invention further relates to compounds or constructs, and in particular proteins or polypeptides that comprise or essentially consist of one or more ISVs or polypeptides of the invention, and optionally further comprise one or more other groups, residues, moieties or binding units. As will become clear to the skilled person from the further disclosure herein, such further groups, residues, moieties, binding units or amino acid sequences may or may not provide further functionality to the polypeptide of the invention (and/or to the compound or construct in which it is present) and may or may not modify the properties of the polypeptide of the invention.

[0237] The compounds, constructs or polypeptides of the invention can generally be prepared by a method which comprises at least one step of suitably linking the one or more immunoglobulin single variable domains of the invention to the one or more further groups, residues, moieties or binding units, optionally via one or more suitable linkers, so as to provide the compound, construct or polypeptide of the invention. Polypeptides of the invention can also be prepared by a method which generally comprises at least the steps of providing a nucleic acid that encodes a polypeptide of the invention, expressing said nucleic acid in a suitable manner, and recovering the expressed polypeptide of the invention. Such methods can be performed in a manner known *per se*, which will be clear to the skilled person, for example on the basis of the methods and techniques further described herein.

[0238] The process of designing/selecting and/or preparing a compound, construct or polypeptide of the invention, starting from an amino acid sequence of the invention, is also referred to herein as "*formatting*" said amino acid sequence of the invention; and an amino acid of the invention that is made part of a compound, construct or polypeptide of the invention is said to be "*formatted*" or to be "*in the format of*" said compound, construct or polypeptide of the invention. Examples of ways in which an amino acid sequence of the invention can be formatted and examples of such formats will be clear to the skilled person based on the disclosure herein; and such formatted immunoglobulin single variable domains or polypeptides form a further aspect of the invention.

[0239] For example, such further groups, residues, moieties or binding units may be one or more additional immunoglobulin single variable domains, such that the compound or construct is a (fusion) protein or (fusion) polypeptide. In a preferred but non-limiting aspect, said one or more other groups, residues, moieties or binding units are immunoglobulin sequences. Even more preferably, said one or more other groups, residues, moieties or binding units are chosen from the group consisting of domain antibodies, immunoglobulin single variable domains that are suitable for use as a domain antibody, single domain antibodies, immunoglobulin single variable domains (ISVs) that are suitable for use as a single domain antibody, "dAb"s, immunoglobulin single variable domains that are suitable for use as a dAb, or Nanobodies. Alternatively, such groups, residues, moieties or binding units may for example be chemical groups, residues, moieties, which may or may not by themselves be biologically and/or pharmacologically active. For example, and without limitation, such groups may be linked to the one or more immunoglobulin single variable domains or polypeptides of the invention so as to provide a "derivative" of an ISV or polypeptide of the invention, as further described herein.

[0240] Also within the scope of the present invention are compounds or constructs, which comprise or essentially consist of one or more derivatives as described herein, and optionally further comprise one or more other groups, residues, moieties or binding units, optionally linked via one or more linkers. Preferably, said one or more other groups, residues, moieties or binding units are immunoglobulin single variable domains. In the compounds or constructs described above, the one or more immunoglobulin single variable domains of the invention and the one or more groups, residues, moieties or binding units may be linked directly to each other and/or via one or more suitable linkers or spacers. For example, when the one or more groups, residues, moieties or binding units are immunoglobulin single variable domains, the linkers may also be immunoglobulin single variable domains, so that the resulting compound or construct is a fusion protein or fusion polypeptide.

[0241] In some embodiments, the polypeptides comprise at least two or more immunoglobulin single variable domains disclosed herein. In some embodiments, the polypeptides essentially consist of two or more immunoglobulin single variable domains disclosed herein. A polypeptide that "essentially consists of" two or more immunoglobulin single variable domains, is a polypeptide that in addition to the two or more immunoglobulin single variable domains disclosed herein does not have additional immunoglobulin single variable domains. For instance, a polypeptide that essentially consists of two immunoglobulin single variable domains does not include any additional immunoglobulin single variable domains. However, it should be appreciated that a polypeptide that essentially consists of two or more immunoglobulin single variable domains may include additional functionalities, such as a label, a toxin, one or more linkers, a binding sequence, etc. These additional functionalities include both amino acid based and non-amino acid based groups. In some embodiments, the polypeptides consist of one or more immunoglobulin single variable domains disclosed herein. It should be appreciated that the terms "polypeptide construct" and "polypeptide" can be used interchangeably herein (unless the context clearly dictates otherwise).

[0242] In some embodiments, the polypeptides include multivalent or multispecific constructs comprising immunoglobulin single variable domains disclosed herein. In some embodiments, the polypeptides comprise one or more antibody based-scaffolds and/or non-antibody based scaffolds disclosed herein. In some embodiments, the polypeptides comprise a serum binding protein moiety. In some embodiments, the serum binding protein moiety is an immunoglobulin single variable domain. In some embodiments, the immunoglobulin single variable domain is a Nanobody®.

[0243] It will be appreciated that the order of the building blocks, such as e.g. a first building block, a second building block, a third building block etc., on the polypeptide (orientation) can be chosen according to the needs of the person skilled in the art, as well as the relative affinities which may depend on the location of these building blocks in the polypeptide. Whether the polypeptide comprises a linker, is a matter of design choice. However, some orientations, with or without linkers, may provide preferred binding characteristics in comparison to other orientations. For instance, the order of a first and a second building block in the polypeptide of the invention can be (from N-terminus to C-terminus): (i) first building block (e.g. a first ISV such as a first Nanobody) - [linker] - second building block (e.g. a second ISV such as a second Nanobody); or (ii) second building block (e.g. a second ISV such as a second Nanobody) - [linker] - first building block (e.g. a first ISV such as a first Nanobody); (wherein the linker is optional). All orientations are encompassed by the invention. Polypeptides that contain an orientation of building blocks that provides desired (binding) characteristics can be easily identified by routine screening, for instance as exemplified in the experimental section.

[0244] The first immunoglobulin single variable domain (ISV) of the polypeptide of the invention has high affinity for/binds to an effector cell, preferably the TCR complex of said effector cell, and even more preferably CD3.

[0245] An effector cell is a cell comprising a TCR complex, preferably an immune cell, such as a T-helper cell, monocyte,

macrophage, or dendritic cell, preferably a CD4⁺ T-helper cell (also known as CD4 cell, T-helper cell or T4 cell), more preferably a Cytotoxic T cell (also known as T_C cell, CTL or CD8⁺ T cells), Natural Killer T cells (NKT cells) or Natural Killer cells (NK cells). In some embodiments, the cell is present *in vivo*. In some embodiments, the cell is present *in vitro*. The effector cell of the disclosure relates in particular to mammalian cells, preferably to primate cells, and even more preferably to human cells.

[0246] As used herein, the terms "TCR complex" or " $\alpha\beta$ TCR-CD3 complex" refers to the T cell receptor complex presented on the surface of T cells (see Kuhns et al. 2006, Immunity 24:133-139). The TCR complex is composed of six different type I single-spanning transmembrane proteins: the TCR α and TCR β chains that form the TCR heterodimer responsible for ligand recognition, and the non-covalently associated CD3 γ , CD3 δ , CD3 ϵ and ζ chains, which bear cytoplasmic sequence motifs that are phosphorylated upon receptor activation and recruit a large number of signalling components. Both α and β chains of the T cell receptor consist of a constant domain and a variable domain. The sequences for the human CD3 and the human TCR α/β constant domains are provided in Table A-10 (SEQ ID NOs: 291-296; cf. UniProtKB: CD3 delta: P04234, CD3 gamma: P09693, CD3 epsilon: P07766, CD3 zeta: P20963, TCR alpha: P01848 and TCR beta: P01850).

[0247] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said first ISV binds to CD3 γ (SEQ ID NO: 292), to CD3 δ (SEQ ID NO: 291) and/or CD3 ϵ (SEQ ID NO: 293) of the TCR complex, or polymorphic variants or isoforms thereof.

[0248] Alternatively, the present invention provides a polypeptide as defined by the claims, wherein said first ISV binds to CD3 γ (SEQ ID NO: 379), to CD3 δ (SEQ ID NO: 291) and/or CD3 ϵ (SEQ ID NO: 380) of the TCR complex, or polymorphic variants or isoforms thereof.

[0249] Isoforms are alternative protein sequences that can be generated from the same gene by a single or by the combination of biological events such as alternative promoter usage, alternative splicing, alternative initiation and ribosomal frameshifting, all as known in the art.

[0250] "T cell activation" as used herein refers to one or more cellular response(s) of a T cell, e.g. a cytotoxic T cell, such as selected from: proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, expression of activation markers, and redirected target cell lysis. The polypeptides of the invention are capable of inducing T cell activation. Suitable assays to measure T cell activation are known in the art described herein, for instance as described in WO 99/54440 or by Schlereth et al. 2005 (Cancer Immunol. Immunother. 20: 1-12), or as exemplified in the examples or below.

[0251] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said polypeptide induces T cell activation. Preferably, the polypeptide of the invention induces T cell activation only when said second and/or further ISV is bound to an antigen on a target cell.

[0252] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said T cell activation depends on presenting said polypeptide bound to said first antigen on a target cell to a T cell.

[0253] T cell activation by the polypeptides of the invention can be monitored by upregulation of CD69, CD25 and various cell adhesion molecules, de novo expression and/or release of cytokines (e.g., IFN- γ , TNF- α , IL-6, IL-2, IL-4 and IL-10), upregulation of granzyme and perforin expression, and/or cell proliferation, membrane blebbing, activation of procaspases 3 and/or 7, fragmentation of nuclear DNA and/or cleavage of caspase substrate poly (ADPribose) polymerase. Preferably, redirected lysis of target cells by multispecific polypeptides is independent of T cell receptor specificity, presence of MHC class I and/or β 2 microglobulin, and/or of any co-stimulatory stimuli.

[0254] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said T cell activation is independent from MHC recognition.

[0255] The polypeptides of the invention show redirected lysis *in vitro* with previously unstimulated peripheral polyclonal CD8⁺- and CD4⁺-positive T cells. The redirected lysis of target cells via the recruitment of T cells by the polypeptides of the invention involves cytolytic synapse formation and delivery of perforin and granzymes. Cell lysis by T cells has been described, e.g. by Atkinson and Bleackley 1995 (Crit. Rev. Immunol 15(3-4):359-384). Preferably, the engaged T cells are capable of serial target cell lysis, and are not affected by immune escape mechanisms interfering with peptide antigen processing and presentation, or clonal T cell differentiation (see, for example, WO 2007/042261). *In vitro*, redirected lysis is seen at low picomolar concentrations, suggesting that very low numbers of the polypeptides of the invention need to be bound to target cells for triggering T cells. As demonstrated in the examples, the low effector to target ratio might be indicative for serial target cell lysis. Accordingly, the present invention relates to potent polypeptides as defined by the claims. Preferably, the polypeptide of the invention mediates killing of target cells, e.g. cancer cells, such as stimulating T cells in pore-forming and delivering pro-apoptotic components of cytotoxic T cell granules.

[0256] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said T cell activation causes one or more cellular response of said T cell, wherein said cellular response is selected from the group consisting of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, expression of activation markers and redirected target cell lysis.

[0257] As used herein, the term "potency" is a measure of the biological activity of an agent, such as a polypeptide,

ISV or Nanobody. Potency of an agent can be determined by any suitable method known in the art, such as for instance as described in the experimental section. Cell culture based potency assays are often the preferred format for determining biological activity since they measure the physiological response elicited by the agent and can generate results within a relatively short period of time. Various types of cell based assays, based on the mechanism of action of the product, can be used, including but not limited to proliferation assays, cytotoxicity assays, cell killing assays, reporter gene assays, cell surface receptor binding assays, and assays to measure induction/inhibition of functionally essential protein or other signal molecules (such as phosphorylated proteins, enzymes, cytokines, cAMP and the like), Ramos B-cell depletion model, T cell mediated tumour cell killing assay (for instance as set out in the Examples section), all well known in the art. Results from cell based potency assays can be expressed as "relative potency" as determined by comparison of the multispecific polypeptide of the invention to the response obtained for the corresponding reference monovalent ISV, e.g. a polypeptide comprising only one ISV or one Nanobody, optionally further comprising an irrelevant Nanobody (cf. experimental section).

[0258] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said T cell activation causes inhibition of an activity of said target cell, such as to delay or minimize the spread of the target cell, to inhibit or delay growth and/or proliferation of the target cell, and/or to kill the target cell (e.g., cause regression of the disorder and/or symptoms) by more than about 10%, such as 20%, 30%, or 40% or even more than 50%, such as more than 60%, such as 70%, 80%, or even more than 90%, such 100%.

[0259] The first building block, ISV, Nanobody or VHH of the invention has a high affinity for its target, i.e. CD3. The first building block, ISV or Nanobody of the invention may for example be directed against an antigenic determinant, epitope, part, domain, subunit or conformation (where applicable) of said first target. The first building block, e.g. the first ISV, Nanobody or VHH, is preferably chosen for its high affinity for its target per se, disregarding the influence of any avidity effects.

[0260] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said first ISV binds to CD3 with an average KD value of between 100 nM and 10 pM, such as at an average KD value of 90 nM or less, even more preferably at an average KD value of 80 nM or less, such as less than 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM, such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20 pM, or even less, such as less than 10 pM. Preferably, the KD is determined by Kinexa or SPR, for instance as determined by a Proteon. For instance, said KD is determined as set out in the Examples section.

[0261] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said first ISV has a high affinity when measured as a monovalent. Preferably said average KD is measured by surface plasmon resonance (SPR) on recombinant protein.

[0262] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said polypeptide has a dissociation constant (K_D) to (or for binding) said CD3 selected from the group consisting of: at most about 10^{-5} M, at most about 10^{-6} M, at most about 10^{-7} M, at most about 10^{-8} M, at most about 10^{-9} M, at most about 10^{-10} M, at most about 10^{-11} M, and at most about 10^{-12} M, preferably as measured by surface plasmon resonance.

[0263] The present invention also relates to a polypeptide as defined by the claims, wherein said first ISV binds to said CD3 with an EC50 value of between 100 nM and 1 pM, such as at an average EC50 value of 100 nM or less, even more preferably at an average EC50 value of 90 nM or less, such as less than 80, 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM or even less, such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5 pM, or even less, such as less than 4 pM.

[0264] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said average KD is determined by FACS, Biacore, ELISA, on a monovalent first ISV, such as a Nanobody, or a polypeptide comprising a monovalent first ISV, such as a Nanobody, for instance said EC50 is determined as set out in the Examples section.

[0265] It has been shown in the examples that the KD correlates well with the EC50.

[0266] In an embodiment, the present invention relates to a polypeptide as defined by the claims, wherein said polypeptide has an on rate constant (K_{on}) to (or for binding) said CD3 selected from the group consisting of at least about 10^2 $M^{-1}s^{-1}$, at least about 10^3 $M^{-1}s^{-1}$, at least about 10^4 $M^{-1}s^{-1}$, at least about 10^5 $M^{-1}s^{-1}$, at least about 10^6 $M^{-1}s^{-1}$, 10^7 $M^{-1}s^{-1}$, at least about 10^8 $M^{-1}s^{-1}$, at least about 10^9 $M^{-1}s^{-1}$, and at least about 10^{10} $M^{-1}s^{-1}$, preferably as measured by surface plasmon resonance or as performed in the examples section.

[0267] In an embodiment the present invention relates to a polypeptide as defined by the claims, wherein said polypeptide has an off rate constant (K_{off}) to (or for binding) said CD3 selected from the group consisting of at most about $10^{-3}s^{-1}$, at most about $10^{-4}s^{-1}$, at most about $10^{-5}s^{-1}$, at most about $10^{-6}s^{-1}$, at most about $10^{-7}s^{-1}$, at most about $10^{-8}s^{-1}$, at most about $10^{-9}s^{-1}$, and at most about $10^{-10}s^{-1}$, preferably as measured by surface plasmon resonance or as performed in the examples section.

[0268] Amino acid sequence modifications of the binding molecules, ISVs, or polypeptides described herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody or ISV. Amino acid sequence variants of the binding molecules, ISVs, or polypeptides are prepared by introducing appropriate nucleotide changes into the binding molecules, ISVs, or polypeptides nucleic acid, or by peptide synthesis.

[0269] Such modifications include, for example, deletions from, and/or insertions into, and/or substitutions of, residues within the amino acid sequences of the binding molecules, ISVs, or polypeptides. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid changes also may alter post-translational processes of the binding molecules, such as changing the number or position of glycosylation sites. Preferably, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids may be substituted in a CDR, while 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 amino acids may be substituted in the framework regions (FRs), with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123. The substitutions are preferably conservative substitutions as described herein. Additionally or alternatively, 1, 2, 3, 4, 5, or 6 amino acids may be inserted or deleted in each of the CDRs (of course, dependent on their length), while 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 amino acids may be inserted or deleted in each of the FRs, with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0270] A useful method for identification of certain residues or regions of the binding molecules, ISVs or polypeptides, that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells 1989 (Science 244: 1081-1085). Here, a residue or group of target residues within the binding molecule is/are identified (e.g. charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with the epitope. Those amino acid locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se needs not to be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at a target codon or region and the expressed binding molecule variants are screened for the desired activity.

[0271] Preferably, amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 residues to polypeptides containing a hundred or more residues.

[0272] Another type of variant is an amino acid substitution variant. These variants have preferably at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid residues in the binding molecule, ISV or polypeptide replaced by a different residue, with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123. The sites of greatest interest for substitution mutagenesis include the CDRs, in particular the hyper-variable regions, but FR alterations are also contemplated. For example, if a CDR sequence encompasses 6 amino acids, it is envisaged that one, two or three of these amino acids are substituted. Similarly, if a CDR sequence encompasses 15 amino acids it is envisaged that one, two, three, four, five or six of these amino acids are substituted, with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0273] Generally, if amino acids are substituted in one or more or all of the CDRs, it is preferred that the then-obtained "substituted" sequence is at least 60%, more preferably 65%, even more preferably 70%, particularly preferably 75%, more particularly preferably 80% or even more than 90% identical to the "original" CDR sequence, with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123. This means that it is dependent of the length of the CDR to which degree it is identical to the "substituted" sequence. For example, a CDR having 5 amino acids is preferably 80% identical to its substituted sequence in order to have at least one amino acid substituted. Accordingly, the CDRs of the binding molecule may have different degrees of identity to their substituted sequences, e.g., CDR1 may have 80%, while CDR3 may have 90%.

[0274] Preferred substitutions (or replacements) are conservative substitutions. However, any substitution (including non-conservative substitution or one or more from the "exemplary substitutions" listed in Table B-1 below) is envisaged

as long as the polypeptide retains its capability to bind to CD3 present on a T cell via the first ISV and to a first antigen on a target cell via the second ISV and/or its CDRs have an identity to the then substituted sequence (at least 60%, more preferably 65%, even more preferably 70%, particularly preferably 75%, more particularly preferably 80% identical to the "original" CDR sequence), with the proviso that, in the first ISV of the polypeptide comprising a first and a second ISV as claimed or in the polypeptide that specifically binds CD3 as claimed, CDR1 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, CDR2 may only have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101 and/or CDR3 may only have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0275] Conservative substitutions are shown in Table B-1 below.

Table B-1: Amino Acid Substitutions

Original	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val, leu, ile	val
Arg (R)	lys, gin, asn	lys
Asn (N)	gin, his, asp, lys, arg	gln
Asp (D)	glu, asn	glu
Cys (C)	ser, ala	ser
Gln (Q)	asn, glu	asn
Glu (E)	asp, gin	asp
Gly (G)	ala	ala
His (H)	asn, gin, lys, arg	arg
Ile (I)	leu, val, met, ala, phe	leu
Leu (L)	norleucine, ile, val, met, ala	ile
Lys (K)	arg, gln, asn	arg
Met (M)	leu, phe, ile	leu
Phe (F)	leu, val, ile, ala, tyr	tyr
Pro (P)	ala	ala
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr, phe	tyr
Tyr (Y)	trp, phe, thr, ser	phe
Val (V)	ile, leu, met, phe, ala	leu

[0276] Sequence analysis further revealed that there are only a limited number of sequence variations in the CDRs (cf. Example 4.2 and Tables A-1 to A-6).

[0277] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 81-87; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; and

(f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0278] CDR sequences shown in Table A-8 and falling within the scope of the claims are preferred. The combinations of CDR's listed in Table A-8 (i.e. those mentioned on the same line in Table A-4) are, insofar they fall within the scope of the claims, preferred. Thus, it is generally preferred that, when a CDR in an ISV falling within the scope of the claims is a CDR sequence mentioned in Table A-8 or suitably chosen from the group consisting of CDR sequences that have 4, 3, 2 or only 1 amino acid difference(s) with a CDR sequence listed in Table A-8, that at least one and preferably both of the other CDR's are suitably chosen from the CDR sequences that belong to the same combination in Table A-8 (i.e. mentioned on the same line in Table A-8) or are suitably chosen from the group consisting of CDR sequences that have 4, 3, 2 or only 1 amino acid difference(s) with the CDR sequence(s) belonging to the same combination.

[0279] Sequence analysis of the resulting binders further resulted in the identification of 6 distinct clusters. Corresponding alignments are provided (see Table A-1, Table A-2, Table A-3, Table A-4, Table A-5 and Table A-6). Clustering was based on sequence similarities and differences in CDR2 and CDR3. Cluster A is the most prominent comprising 50 clones (SEQ ID NO:s 1-50), cluster B and cluster D are each represented by only 1 clone (SEQ ID NO: 51 and SEQ ID NO: 52, respectively), cluster C comprises 4 clones (SEQ ID NO:s 53-56), cluster E comprises 9 clones (SEQ ID NO:s 57-65) and cluster F comprises 15 clones (SEQ ID NO:s 66-80). The clustering based on the structural similarities and differences in the amino acid sequence translated into functional similarities and differences as revealed by the examples. Representatives of all clusters were isolated based on high affinity binding to CD3 (Examples 3 & 4) and human T cell activation (Example 4.2). In general cluster A representatives demonstrated the best EC50 values. Although cluster C representatives had somewhat less favourable EC50 values than cluster B representatives, cluster C representatives had lower IC50 values in a flow cytometry based T cell mediated Ramos killing assay (cf. Example 10).

[0280] Accordingly, the present invention relates to a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 81; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A.

[0281] Accordingly, the present invention relates to a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 101; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P.

[0282] Accordingly, the present invention relates to a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 123; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P.

[0283] In an embodiment, the invention relates to a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NOs: 81-87; and
- (b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 101-109; and
- (d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NOs: 123-127; and
- (f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123.

[0284] In an embodiment, the invention relates to a polypeptide as defined by the claims, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 81, CDR2 is represented by SEQ ID NO: 101, and CDR3 is represented by SEQ ID NO: 123.

[0285] Nanobodies belonging to cluster B are represented by 1 clone.

[0286] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NO: 88; and
- (b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 88; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NO: 110; and
- (d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 110; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NO: 128; and
- (f) amino acid sequences that have 1, 2, or 3 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 128.

[0287] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 88, CDR2 is represented by SEQ ID NO: 110, and CDR3

is represented by SEQ ID NO: 128.

[0288] Nanobodies of cluster C show very limited sequence variability in the CDRs.

[0289] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

- (a) SEQ ID NO: 112; and
- (b) amino acid sequence that has 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A.

[0290] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NO: 90; and
- (b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NOs: 112-113; and
- (d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 112; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NO: 130; and
- (f) amino acid sequences that have 1, 2, or 3 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 130.

[0291] In an aspect, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 90, CDR2 is represented by SEQ ID NO: 112, and CDR3 is represented by SEQ ID NO: 130.

[0292] Nanobodies belonging to cluster D are represented by 1 clone.

[0293] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

- (a) SEQ ID NO: 89; and
- (b) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 89; and/or

(ii) CDR2 is chosen from the group consisting of:

- (c) SEQ ID NO: 111; and
- (d) amino acid sequences that have 1, 2, 3, or 4 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 111; and/or

(iii) CDR3 is chosen from the group consisting of:

- (e) SEQ ID NO: 129; and
- (f) amino acid sequences that have 1, 2, or 3 amino acid(s) difference with the amino acid sequence of SEQ

ID NO: 129.

[0294] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 89, CDR2 is represented by SEQ ID NO: 111, and CDR3 is represented by SEQ ID NO: 129.

[0295] Cluster E comprises 9 clones.

[0296] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 91; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T.

[0297] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 114; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 114, wherein

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K.

[0298] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 131; and

(b) amino acid sequences that have 1 or 2 amino acid(s) difference with SEQ ID NO: 131, wherein

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V.

[0299] In an embodiment, the disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 91-93; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 91; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 114-117; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 114; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 131-133; and

(f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 131.

[0300] In an embodiment, the disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 91, CDR2 is represented by SEQ ID NO: 114, and CDR3 is represented by SEQ ID NO: 131.

[0301] Nanobodies belonging to cluster F are represented by 15 clones.

[0302] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 94; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 94, wherein

- at position 3 the S has been changed into T, A or G;
- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M.

[0303] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 118; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 118, wherein

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F.

[0304] Accordingly, the present disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 134; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 134, wherein

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or
- at position 14 the V has been changed into I.

[0305] In an embodiment, the disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 94-100; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 94; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 118-122; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118; and/or

5 (iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 134-143; and

(f) amino acid sequences that have 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 134.

10

[0306] In an embodiment, the disclosure relates to a polypeptide as described herein, in which said first ISV essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which: CDR1 is represented by SEQ ID NO: 94, CDR2 is represented by SEQ ID NO: 118, and CDR3 is represented by SEQ ID NO: 134.

15 **[0307]** The second immunoglobulin single variable domain (ISV) of the polypeptide of the invention has a high affinity for/binds to an antigen on a target cell, preferably a cancer cell. A "target cell" as referred to herein, is a cell that presents a particular antigen on its surface. In a preferred aspect, the "target cell" is a cancer cell.

[0308] The membrane (also called plasma membrane or phospholipid bilayer) surrounds the cytoplasm of a cell, which is the outer boundary of the cell, i.e. the membrane is the surface of the cell. This membrane serves to separate and protect a cell from its surrounding environment and is made mostly from a double layer of phospholipids. Embedded within this membrane is a variety of protein molecules, such as channels, pumps and cellular receptors. Since the membrane is fluid, the protein molecules can travel within the membrane. The term "antigen on a target cell" as used herein denotes a molecule, which is displayed on the surface of a cell. In most cases, this molecule will be located in or on the plasma membrane of the cell such that at least part of this molecule remains accessible from outside the cell in tertiary form. A non-limiting example of a cell surface molecule, which is located in the plasma membrane, is a trans-membrane protein comprising, in its tertiary conformation, regions of hydrophilicity and hydrophobicity. Here, at least one hydrophobic region allows the cell surface molecule to be embedded, or inserted in the hydrophobic plasma membrane of the cell while the hydrophilic regions extend on either side of the plasma membrane into the cytoplasm and extracellular space, respectively.

25 **[0309]** Said antigen can be any target on a cell, e.g. a tumour antigen. In a preferred embodiment, said antigen is specific for said target cell, e.g. cancer cell, such as a tumour associated antigen (TAA) on said cancer cell.

[0310] The term "tumour antigen" as used herein may be understood as those antigens that are presented on tumour cells. These antigens can be presented on the cell surface with an extracellular part, which is often combined with a transmembrane and cytoplasmic part of the molecule. These antigens can sometimes be presented only by tumour cells and never by a normal or healthy cell. Tumour antigens can be exclusively expressed on tumour cells or might represent a tumour specific mutation compared to normal cells. In this case, they are called tumour-specific antigens. However, this will not be the case generally. More common are antigens that are presented by tumour cells and normal cells, and they are called "tumour-associated antigens (TAA)". These tumour-associated antigens can be overexpressed on tumour cells compared to normal cells or are better accessible for antibody binding in tumour cells due to the less compact structure of the tumour tissue compared to normal tissue. TAA are preferably antigens that are expressed on cells of particular tumours, but that are preferably not expressed in normal cells. Often, TAA are antigens that are normally expressed in cells only at particular points in an organism's development (such as during fetal development) and that are being inappropriately expressed in the organism at the present point of development, or are antigens not expressed in normal tissues or cells of an organ now expressing the antigen.

35 **[0311]** In an embodiment, said first antigen on a target cell is a tumour antigen, preferably a tumour associated antigen (TAA).

[0312] In an embodiment, said second antigen on a target cell is a tumour antigen, preferably a tumour associated antigen (TAA).

[0313] In an embodiment, said antigen is present more abundantly on a cancer cell than on a normal cell. The antigen on a target cell is preferably a tumor-associated antigen (TAA). Preferred TAA include MART-1, carcinoembryonic antigen ("CEA"), gp100, MAGE-1, HER-2, CD20, Lewis^Y antigens, Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Fibroblast Activation Protein (FAP), CD19 and CD33.

[0314] Cell surface antigens that are preferentially expressed on AML LSC compared with normal hematopoietic stem cells, and thus preferred as TAA, include CD123, CD44, CLL-1, CD96, CD47, CD32, CXCR4, Tim-3 and CD25.

45 **[0315]** Other tumor-associated antigens suitable as an antigen on a target cell for binding by the second ISV within the polypeptides of the invention include: TAG-72, Ep-CAM, PSMA, PSA, glycolipids such as GD2 and GD3.

[0316] The TAA include also hematopoietic differentiation antigens, i.e. glycoproteins usually associated with cluster differentiation (CD) grouping, such as CD4, CD5, CD19, CD20, CD22, CD33, CD36, CD45, CD52, CD69 and CD147;

growth factor receptors, including HER2, ErbB3 and ErbB4; Cytokine receptors, including Interleukin-2 receptor gamma chain (CD132 antigen), Interleukin-10 receptor alpha chain (IL-10R-A), Interleukin-10 receptor beta chain (IL-10R-B), Interleukin-12 receptor beta-1 chain (IL-12R-beta1), Interleukin-12 receptor beta-2 chain (IL-12 receptor beta-2), Interleukin-13 receptor alpha-1 chain (IL-13R-alpha-1) (CD213a1 antigen), Interleukin-13 receptor alpha-2 chain (Interleukin-13 binding protein), Interleukin-17 receptor (IL-17 receptor), Interleukin-17B receptor (IL-17B receptor), Interleukin 21 receptor precursor (IL-21R), Interleukin-1 receptor type I (IL-1R-1) (CD121a), Interleukin-1 receptor type II (IL-1R-beta) (CDw121b), Interleukin-1 receptor antagonist protein (IL-1ra), Interleukin-2 receptor alpha chain (CD25 antigen), Interleukin-2 receptor beta chain (CD122 antigen), Interleukin-3 receptor alpha chain (IL-3R-alpha) (CD123 antigen); as well as others, such as CD30, IL23R, IGF-1R, IL5R, IgE, CD248 (endosialin), CD44v6, gpA33, Ron, Trop2, PSCA, claudin 6, claudin 18.2, CLEC12A, CD38, ephA2, c-Met, CD56, MUC16, EGFRvIII, AGS-16, CD27L, Nectin-4, SLITRK6, mesothelin, folate receptor, tissue factor, axl, glypican-3, CA9, Cripto, CD138, CD37, MUC1, CD70, gastrin releasing peptide receptor, PAP, CEACAM5, CEACAM6, CXCR7, N-cadherin, FXYD2 gamma a, CD21, CD133, Na/K-ATPase, mlgM (membrane-bound IgM), mlgA (membrane-bound IgA), Mer, Tyro2, CD120, CD95, CA 195, DR5, DR6, DcR3 and CAIX.

[0317] Accordingly the present invention relates to a polypeptide as defined by the claims, wherein said TAA is chosen from the group consisting of Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP), Epidermal Growth Factor Receptor (EGFR), Fibroblast Activation Protein (FAP), MART-1, carcinoembryonic antigen ("CEA"), gp100, MAGE-1, HER-2, Lewis^Y antigens, CD123, CD44, CLL-1, CD96, CD47, CD32, CXCR4, Tim-3, CD25, TAG-72, Ep-CAM, PSMA, PSA, GD2, GD3, CD4, CD5, CD19, CD20, CD22, CD33, CD36, CD45, CD52, CD147; growth factor receptors, including ErbB3 and ErbB4; Cytokine receptors, including Interleukin-2 receptor gamma chain (CD132 antigen), Interleukin-10 receptor alpha chain (IL-10R-A), Interleukin-10 receptor beta chain (IL-10R-B), Interleukin-12 receptor beta-1 chain (IL-12R-beta1), Interleukin-12 receptor beta-2 chain (IL-12 receptor beta-2), Interleukin-13 receptor alpha-1 chain (IL-13R-alpha-1) (CD213a1 antigen), Interleukin-13 receptor alpha-2 chain (Interleukin-13 binding protein), Interleukin-17 receptor (IL-17 receptor), Interleukin-17B receptor (IL-17B receptor), Interleukin 21 receptor precursor (IL-21R), Interleukin-1 receptor type I (IL-1R-1) (CD121a), Interleukin-1 receptor type II (IL-1R-beta) (CDw121b), Interleukin-1 receptor antagonist protein (IL-1ra), Interleukin-2 receptor alpha chain (CD25 antigen), Interleukin-2 receptor beta chain (CD122 antigen), Interleukin-3 receptor alpha chain (IL-3R-alpha) (CD123 antigen), CD30, IL23R, IGF-1R, IL5R, IgE, CD248 (endosialin), CD44v6, gpA33, Ron, Trop2, PSCA, claudin 6, claudin 18.2, CLEC12A, CD38, ephA2, c-Met, CD56, MUC16, EGFRvIII, AGS-16, CD27L, Nectin-4, SLITRK6, mesothelin, folate receptor, tissue factor, axl, glypican-3, CA9, Cripto, CD138, CD37, MUC1, CD70, gastrin releasing peptide receptor, PAP, CEACAM5, CEACAM6, CXCR7, N-cadherin, FXYD2 gamma a, CD21, CD133, Na/K-ATPase, mlgM (membrane-bound IgM), mlgA (membrane-bound IgA), Mer, Tyro2, CD120, CD95, CA 195, DR5, DR6, DcR3 and CAIX, and related polymorphic variants and isoforms, preferably said TAA is CD20 (UniProt 11836), HER2 (Uniprot P04626), polymorphic variants and/or isoforms thereof.

[0318] The second building block, ISV, Nanobody or VHH of the invention has a high affinity for its antigen. The second building block, ISV or Nanobody of the invention may, for example, be directed against an antigenic determinant, epitope, part, domain, subunit or conformation (where applicable) of said antigen on a target cell.

[0319] The target cell relates in particular to mammalian cells, and preferably to primate cells and even more preferably to human cells. The target cell is preferably a hyperproliferative cell such as e.g. a cancer cell.

[0320] The present invention relates to a polypeptide as defined by the claims, wherein said second or further ISV binds to an antigen on a target cell with an average KD value of between 100 nM and 10 pM, such as at an average KD value of 90 nM or less, even more preferably at an average KD value of 80 nM or less, such as less than 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM, such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20 pM, or even less such as less than 10 pM. Preferably, the KD is determined by KinExA or SPR, for instance as determined or Proteon.

[0321] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said second or further ISV has a high affinity for its antigen when measured as a monovalent.

[0322] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said average KD is measured by surface plasmon resonance (SPR) and/or KinExA or Proteon, for instance on recombinant protein, such as described in the Examples section.

[0323] The present invention also relates to a polypeptide as defined by the claims, wherein said second or further ISV binds to an antigen on a target cell with an EC50 value of between 100 nM and 1 pM, such as at an average EC50 value of 100 nM or less, even more preferably at an average EC50 value of 90 nM or less, such as less than 80, 70, 60, 50, 40, 30, 20, 10, 5 nM or even less, such as less than 4, 3, 2, or 1 nM or even less such as less than 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 5 pM, or even less such as less than 4 pM.

[0324] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said average EC50 is determined by FACS, or ELISA, on a monovalent second ISV, such as a Nanobody, or a polypeptide comprising a monovalent second ISV, such as a Nanobody.

[0325] It has been shown in the examples that the KD correlates well with the EC50.

[0326] Simultaneous targeting of multiple antigens can reduce the probability of generating tumour escape variants,

because of which the therapeutic activity of T cell engaging strategy is improved. The present invention provides multi-specific polypeptides which comprise a CD3 ISV combined with immunoglobulin single variable domains against different (target) antigens (on a target cell) (cf. Example 19). Preferred combinations of first and second antigens are provided below (it will be appreciated that the ISVs binding said antigens can be positioned in any order in the polypeptide of the invention):

first antigen	second antigen
EGFR (OMIM: 131550)	CD20 (OMIM: 112210)
EGFR (OMIM:131550)	CEA (OMIM: 114890)
EGFR (OMIM:131550)	HER2 (OMIM: 164870)
HER2 (OMIM: 164870)	CD20 (OMIM: 112210)
HER2 (OMIM: 164870)	CEA (OMIM: 114890)
CD20 (OMIM: 112210)	CEA (OMIM: 114890)

[0327] Similarly, simultaneous targeting of multiple epitopes, antigenic determinants, parts, domains, subunit or conformation of a protein or antigen on a target cell can reduce the probability of generating tumour escape variants, because of which the therapeutic activity of T cell engaging strategy is improved (cf. Example 20). The present invention provides polypeptides which comprise a anti-CD3 ISV combined with immunoglobulin single variable domains against different epitopes, antigenic determinants, parts, domains, subunit or conformation of an antigen on a target cell (also referred to as biparatopic constructs). Preferred combinations of first and second TAA ISVs are provided below (it will be appreciated that the ISVs binding said antigens can be positioned in any order in the polypeptide of the invention):

TAA1 ISV	name	SEQ ID NO:	TAA2 ISV	name	SEQ ID NO:
EGFR-1	7D12	302	EGFR-2	9G08	299
HER2-1	5F07	297	HER2-2	47D05	298
CEA-1	CEA#1	300	CEA-2	CEA#5	301

[0328] The polypeptides and compositions of the present invention can be used for the prevention and/or treatment of diseases and disorders of the present invention (herein also "diseases and disorders of the present invention") which include, but are not limited to cancer. The term "cancer" refers to the pathological condition in mammals that is typically characterized by dysregulated cellular proliferation or survival. Examples of cancer include, but are not limited to, carcinomas, gliomas, mesotheliomas, melanomas, lymphomas, leukemias, adenocarcinomas: breast cancer, ovarian cancer, cervical cancer, glioblastoma, multiple myeloma (including monoclonal gammopathy of undetermined significance, asymptomatic and symptomatic myeloma), prostate cancer, and Burkitt's lymphoma, head and neck cancer, colon cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, cancer of the esophagus, stomach cancer, pancreatic cancer, hepatobiliary cancer, cancer of the gallbladder, cancer of the small intestine, rectal cancer, kidney cancer, bladder cancer, prostate cancer, penile cancer, urethral cancer, testicular cancer, vaginal cancer, uterine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, pancreatic endocrine cancer, carcinoid cancer, bone cancer, skin cancer, retinoblastomas, Hodgkin's lymphoma, non-Hodgkin's lymphoma, Kaposi's sarcoma, multicentric Castleman's disease or AIDS-associated primary effusion lymphoma, neuroectodermal tumors, rhabdomyosarcoma (see e.g., Cancer, Principles and practice (DeVita, et al. eds 1997) for additional cancers); as well as any metastasis of any of the above cancers,

[0329] For a general description of immunoglobulin single variable domains, reference is made to the further description below, as well as to the prior art cited herein. In this respect, it should however be noted that this description and the prior art mainly describes immunoglobulin single variable domains of the so-called "V_H3 class" (i.e., immunoglobulin single variable domains with a high degree of sequence homology to human germline sequences of the V_H3 class such as DP-47, DP-51 or DP-29), which form a preferred aspect of this invention. It should, however, be noted that the invention in its broadest sense generally covers any type of immunoglobulin single variable domains and for example also covers the immunoglobulin single variable domains belonging to the so-called "V_H4 class" (i.e., immunoglobulin single variable domains with a high degree of sequence homology to human germline sequences of the V_H4 class such as DP-78), as for example described in WO 07/118670.

[0330] Generally, immunoglobulin single variable domains (in particular V_{HH} sequences and sequence optimized

immunoglobulin single variable domains) can in particular be characterized by the presence of one or more "*Hallmark residues*" (as described for example in Table B-2) in one or more of the framework sequences (again as further described herein).

Table B-2: Hallmark Residues in VHHs

Position	Human V _H 3	Hallmark Residues
11	L, V; predominantly L	L, S, V, M, W, F, T, Q, E, A, R, G, K, Y, N, P, I; preferably L
37	V, I, F; usually V	F ⁽¹⁾ , Y, V, L, A, H, S, I, W, C, N, G, D, T, P, preferably F ⁽¹⁾ or Y
44 ⁽⁸⁾	G	E ⁽³⁾ , Q ⁽³⁾ , G ⁽²⁾ , D, A, K, R, L, P, S, V, H, T, N, W, M, I; preferably G ⁽²⁾ , E ⁽³⁾ or Q ⁽³⁾ ; most preferably G ⁽²⁾ or Q ⁽³⁾ .
45 ⁽⁸⁾	L	L ⁽²⁾ , R ⁽³⁾ , P, H, F, G, Q, S, E, T, Y, C, I, D, V; preferably L ⁽²⁾ or R ⁽³⁾
47 ⁽⁸⁾	W, Y	F ⁽¹⁾ , L ⁽¹⁾ or W ⁽²⁾ G, I, S, A, V, M, R, Y, E, P, T, C, H, K, Q, N, D; preferably W ⁽²⁾ , L ⁽¹⁾ or F ⁽¹⁾
83	R or K; usually R	R, K ⁽⁵⁾ , T, E ⁽⁵⁾ , Q, N, S, I, V, G, M, L, A, D, Y, H; preferably K or R; most preferably K
84	A, T, D; predominantly A	P ⁽⁵⁾ , S, H, L, A, V, I, T, F, D, R, Y, N, Q, G, E; preferably P
103	W	W ⁽⁴⁾ , R ⁽⁶⁾ , G, S, K, A, M, Y, L, F, T, N, V, Q, P ⁽⁶⁾ , E, C; preferably W
104	G	G, A, S, T, D, P, N, E, C, L; preferably G
108	L, M or T; predominantly L	Q, L ⁽⁷⁾ , R, P, E, K, S, T, M, A, H; preferably Q or L ⁽⁷⁾
Notes: ⁽¹⁾ In particular, but not exclusively, in combination with KERE or KQRE at positions 43-46. ⁽²⁾ Usually as GLEW at positions 44-47. ⁽³⁾ Usually as KERE or KQRE at positions 43-46, e.g. as KEREL, KERE ^F , KQREL, KQRE ^F , KERE ^G , KQRE ^W or KQRE ^G at positions 43-47. Alternatively, also sequences such as TERE (for example TEREL), TQRE		

(continued)

Position	Human V _H 3	Hallmark Residues
5	(for example TQREL), KECE (for example KECEL or KECER), KQCE (for example KQCEL), RERE (for example REREG), RQRE (for example RQREL, RQREF or RQREW), QERE (for example QEREG), QQRE, (for example QQREW, QQREL or QQREF), KGRE (for example KGREG), KDRE (for example KDREV) are possible. Some other possible, but less preferred sequences include for example DECKL and NVCEL.	
10	(4) With both GLEW at positions 44-47 and KERE or KQRE at positions 43-46.	
	(5) Often as KP or EP at positions 83-84 of naturally occurring V _{HH} domains.	
15	(6) In particular, but not exclusively, in combination with GLEW at positions 44-47.	
	(7) With the proviso that when positions 44-47 are GLEW, position 108 is always Q in (non-humanized) V _{HH} sequences that also contain a W at 103.	
20	(8) The GLEW group also contains GLEW-like sequences at positions 44-47, such as for example GVEW, EPEW, GLER, DQEW, DLEW, GIEW, ELEW, GPEW, EWLP, GPER, GLER and ELEW.	

[0331] The immunoglobulins of the invention may also contain a C-terminal extension (X)_n (in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I)), for which reference is made to WO 12/175741.

[0332] Again, such immunoglobulin single variable domains may be derived in any suitable manner and from any suitable source, and may for example be naturally occurring V_{HH} sequences (i.e., from a suitable species of Camelid, e.g., llama) or synthetic or semi-synthetic VHs or VLs (e.g., from human). Such immunoglobulin single variable domains may include "humanized" or otherwise "sequence optimized" VHHs, "camelized" immunoglobulin sequences (and in particular camelized heavy chain variable domain sequences, i.e., camelized VHs), as well as human VHs, human VLs, camelid VHHs that have been altered by techniques such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, veneering, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing as further described herein.

[0333] As mentioned herein, a particularly preferred class of immunoglobulin single variable domains comprised in the polypeptide of the invention comprises immunoglobulin single variable domains with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring V_{HH} domain, but that has been "humanized", i.e. by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring V_{HH} sequence (and in particular in the framework sequences) by one or more of the amino acid residues that occur at the corresponding position(s) in a V_H domain from a conventional 4-chain antibody from a human being (e.g. indicated above). This can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the further description herein and the prior art on humanization referred to herein. Again, it should be noted that such humanized immunoglobulin single variable domains comprised in the polypeptide of the invention can be obtained in any suitable manner known per se and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring V_{HH} domain as a starting material. Another particularly preferred class of immunoglobulin single variable domains comprised in the polypeptide of the invention comprises immunoglobulin single variable domains with an amino acid sequence that corresponds to the amino acid sequence of a naturally occurring V_H domain, but that has been "camelized", i.e. by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring V_H domain from a conventional 4-chain antibody by one or more of the amino acid residues that occur at the corresponding position(s) in a V_{HH} domain of a heavy chain antibody. This can be performed in a manner known per se, which will be clear to the skilled person, for example on the basis of the description herein. Such "camelizing" substitutions are preferably inserted at amino acid positions that form and/or are present at the V_H-V_L interface, and/or at the so-called Camelidae hallmark as defined herein (see also for example WO 94/04678 and Davies and Riechmann 1994 (FEBS letters 339: 285-290) and 1996 (Protein Engineering 9: 531-537)). Preferably, the V_H sequence that is used as a starting material or starting point for generating or designing the camelized immunoglobulin single variable domains is preferably a V_H sequence from a mammal, more preferably the V_H sequence of a human being, such as a V_H3 sequence. However, it should be noted that such camelized immunoglobulin single variable domains of the invention

can be obtained in any suitable manner known per se and thus are not strictly limited to polypeptides that have been obtained using a polypeptide that comprises a naturally occurring V_H domain as a starting material.

[0334] For example, again as further described herein, both "humanization" and "camelization" can be performed by providing a nucleotide sequence that encodes a naturally occurring V_{HH} domain or V_H domain, respectively, and then changing, in a manner known per se, one or more codons in said nucleotide sequence in such a way that the new nucleotide sequence encodes a "humanized" or "camelized" immunoglobulin single variable domain of the invention, respectively. This nucleic acid can then be expressed in a manner known per se, so as to provide the desired immunoglobulin single variable domains of the invention. Alternatively, based on the amino acid sequence of a naturally occurring V_{HH} domain or V_H domain, respectively, the amino acid sequence of the desired humanized or camelized immunoglobulin single variable domains comprised in the polypeptide of the invention, respectively, can be designed and then synthesized *de novo* using techniques for peptide synthesis known per se. Also, based on the amino acid sequence or nucleotide sequence of a naturally occurring V_{HH} domain or V_H domain, respectively, a nucleotide sequence encoding the desired humanized or camelized immunoglobulin single variable domains of the invention, respectively, can be designed and then synthesized *de novo* using techniques for nucleic acid synthesis known per se, after which the nucleic acid thus obtained can be expressed in a manner known per se, so as to provide the desired immunoglobulin single variable domains comprised in the polypeptide of the invention.

[0335] Accordingly, the present invention relates to a polypeptide as defined by the claims, wherein said ISV is a Nanobody, a V_{HH} , a humanized V_{HH} , or a camelized V_H .

[0336] Generally, proteins or polypeptides that comprise or essentially consist of a single building block, single immunoglobulin single variable domain or single Nanobody will be referred to herein as "monovalent" proteins or polypeptides, as "monovalent constructs", as "monovalent building block", as "monovalent immunoglobulin single variable domain", or as "monovalent Nanobody", respectively.

[0337] In this respect, the present invention also relates to the monovalent building blocks that make up the polypeptides of the invention.

[0338] Accordingly, the present invention relates to an ISV or polypeptide that specifically binds the constant domain of the CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 81-87; or

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NO: 81, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; or

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NO: 101, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; or

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of any of SEQ ID NO: 123, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0339] As discussed above, ISVs were isolated that belong to different clusters, based on structural similarities and differences in CDR2 and CDR3.

[0340] Immunoglobulin single variable domains belonging to cluster A are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 81-87; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 81, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 101-109; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 101, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 123-127; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 123, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0341] In another aspect, in the polypeptides belonging to cluster A, CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 81; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A.

[0342] In another aspect, in the polypeptides belonging to cluster A, CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 101; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P.

[0343] In another aspect, in the polypeptides belonging to cluster A, CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 123; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P.

[0344] Accordingly, the present invention relates to an ISV or polypeptide that specifically binds CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 81; and

(b) amino acid sequences that have 1 or 2 amino acid difference(s) with SEQ ID NO: 81, wherein

- at position 1 the G has been changed into R;
- at position 3 the T has been changed into A;
- at position 4 the Y has been changed into F;
- at position 8 the S has been changed into G; and/or
- at position 10 the G has been changed into A,

and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 101; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 101, wherein

- at position 3 the V has been changed into T or A;
- at position 5 the S has been changed into T;
- at position 6 the G has been changed into D or E; and/or
- at position 9 the T has been changed into S, A or P,

and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 123; and

(b) amino acid sequences that have 1, or 2 amino acid difference(s) with SEQ ID NO: 123, wherein

- at position 2 the I has been changed into T;
- at position 9 the I has been changed into V; and/or
- at position 10 the A has been changed into P.

[0345] In another aspect, the present invention provides a polypeptide as defined by the claims, in which: CDR1 is represented by SEQ ID NO: 81, CDR2 is represented by SEQ ID NO: 101, and CDR3 is represented by SEQ ID NO: 123. Preferably the polypeptide is selected from any of SEQ ID NOs: 1 to 50.

[0346] Immunoglobulin single variable domains belonging to cluster B are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 88; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 88, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 110; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 110, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 128; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ

ID NO: 128, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0347] In another aspect, in the polypeptides belonging to cluster B, CDR1 is SEQ ID NO: 88.

[0348] In another aspect, in the polypeptides belonging to cluster B, CDR2 is SEQ ID NO: 110.

[0349] In another aspect, in the polypeptides belonging to cluster B, CDR3 is SEQ ID NO: 128.

[0350] In another aspect, the disclosure relates to a polypeptide in which: CDR1 is represented by SEQ ID NO: 88, CDR2 is represented by SEQ ID NO: 110, and CDR3 is represented by SEQ ID NO: 128. Preferably the polypeptide is SEQ ID NOs: 51.

[0351] Immunoglobulin single variable domains belonging to cluster C are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NO: 90; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 112-113; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 112, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NO: 130; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 130, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0352] In another aspect, in the polypeptides belonging to cluster C, CDR1 is SEQ ID NO: 90.

[0353] In another aspect, in the polypeptides belonging to cluster C, CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 112; and

(b) amino acid sequence that has 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A.

[0354] In another aspect, in the polypeptides belonging to cluster C, CDR3 is SEQ ID NO: 130.

[0355] Accordingly, the present disclosure relates to an ISV or polypeptide that specifically binds CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is SEQ ID NO: 90; and

and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 112; and

(b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 112, wherein

- at position 2 the V has been changed into A,

and in which

(iii) CDR3 is SEQ ID NO: 130.

[0356] In another aspect, the disclosure relates to a polypeptide in which: CDR1 is represented by SEQ ID NO: 90, CDR2 is represented by SEQ ID NO: 112, and CDR3 is represented by SEQ ID NO: 130. Preferably the polypeptide is selected from any of SEQ ID NOs: 53-56.

[0357] Immunoglobulin single variable domains belonging to cluster D are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 89; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 89, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 111; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 111, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 129; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 129, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0358] In another aspect, in the polypeptides belonging to cluster D, CDR1 is SEQ ID NO: 89.

[0359] In another aspect, in the polypeptides belonging to cluster D, CDR2 is SEQ ID NO: 111.

[0360] In another aspect, in the polypeptides belonging to cluster D, CDR3 is SEQ ID NO: 129.

[0361] In another aspect, the disclosure relates to a polypeptide in which: CDR1 is represented by SEQ ID NO: 89, CDR2 is represented by SEQ ID NO: 111, and CDR3 is represented by SEQ ID NO: 129. Preferably the polypeptide is SEQ ID NOs: 52.

[0362] Immunoglobulin single variable domains belonging to cluster E are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 91-93; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 91, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 114-117; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 114, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 131-133; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 131, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0363] In another aspect, in the polypeptides belonging to cluster E, CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 91; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T.

[0364] In another aspect, in the polypeptides belonging to cluster E, CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 114; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 114, wherein

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K.

[0365] In another aspect, in the polypeptides belonging to cluster E, CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 131; and

(b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 131, wherein

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V.

[0366] Accordingly, the present disclosure relates to an ISV or polypeptide that specifically binds CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 91; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 91, wherein

- at position 6 the R has been changed into N or T;
- at position 7 the N has been changed into H; and/or
- at position 8 the M has been changed into T,

and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 114; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 114, wherein

- at position 1 the R has been changed into Q;
- at position 3 the T has been changed into S; and/or
- at position 7 the D has been changed into A or K,

and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 131; and

(b) amino acid sequences that have 1 amino acid difference with SEQ ID NO: 131, wherein

- at position 2 the S has been changed into R; and/or
- at position 6 the S has been changed into V.

[0367] In another aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 91, CDR2 is represented by SEQ ID NO: 114, and CDR3 is represented by SEQ ID NO: 131. Preferably the polypeptide is selected from any of SEQ ID NOs: 57-65.

[0368] Immunoglobulin single variable domains belonging to cluster F are represented by polypeptides according in which:

(i) CDR1 is chosen from the group consisting of:

(a) SEQ ID NOs: 94-100; and

(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 94, provided that the polypeptide comprising the CDR1 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR1 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(ii) CDR2 is chosen from the group consisting of:

(c) SEQ ID NOs: 118-122; and

(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118, provided that the polypeptide comprising the CDR2 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR2 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance; and/or

(iii) CDR3 is chosen from the group consisting of:

(e) SEQ ID NOs: 134-143; and

(f) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 134, provided that the polypeptide comprising the CDR3 with 4, 3, 2, or 1 amino acid(s) difference binds CD3 with about the same or a higher affinity compared to the binding by the polypeptide comprising the CDR3 without the 4, 3, 2, or 1 amino acid(s) difference, said affinity as measured by surface plasmon resonance.

[0369] In another aspect, in the polypeptides belonging to cluster F, CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 94; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid(s) difference with SEQ ID NO: 94, wherein

- at position 3 the S has been changed into T, A or G;
- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M.

[0370] In another aspect, in the polypeptides belonging to cluster F, CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 118; and

(b) amino acid sequences that have 1, 2 or 3 amino acid(s) difference with SEQ ID NO: 118, wherein

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F.

[0371] In another aspect, in the polypeptides belonging to cluster F, CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 134; and

(b) amino acid sequences that have 1, 2, 3, 4 or 5 amino acid(s) difference with SEQ ID NO: 134, wherein

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or
- at position 14 the V has been changed into I.

[0372] Accordingly, the present disclosure relates to an ISV or polypeptide that specifically binds CD3 and that comprises or essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:

(i) CDR1 is chosen from the group consisting of

(a) SEQ ID NO: 94; and

(b) amino acid sequences that have 1, 2, 3 or 4 amino acid difference(s) with SEQ ID NO: 94, wherein

- at position 3 the S has been changed into T, A or G;
- at position 5 the N has been changed into S;
- at position 6 the M has been changed into T or A; and/or
- at position 9 the L has been changed into M,

and in which

(ii) CDR2 is chosen from the group consisting of

(a) SEQ ID NO: 118; and

(b) amino acid sequences that have 1, 2 or 3 amino acid difference(s) with SEQ ID NO: 118, wherein

- at position 2 the H has been changed into V;
- at position 5 the S has been changed into H or A;
- at position 8 the N has been changed into S; and/or
- at position 10 the Y has been changed into F,

and in which

(iii) CDR3 is chosen from the group consisting of

(a) SEQ ID NO: 134; and

(b) amino acid sequences that have 1, 2, 3, 4 or 5 amino acid difference(s) with SEQ ID NO: 134, wherein

- at position 6 the A has been changed into S or D;
- at position 7 the F has been changed into Y or A;
- at position 8 the R has been changed into H;
- at position 9 the S has been changed into A;
- at position 11 the G has been changed into D, T, N, S, K or R; and/or
- at position 14 the V has been changed into I.

[0373] In another aspect, the present disclosure provides a polypeptide as described herein, in which: CDR1 is represented by SEQ ID NO: 94, CDR2 is represented by SEQ ID NO: 118, and CDR3 is represented by SEQ ID NO: 134. Preferably the polypeptide is selected from any of SEQ ID NOs: 66-80.

[0374] In a further aspect, the disclosure relates to polypeptides that cross-block the binding to CD3 by at least one of the ISVs or polypeptides belonging to Cluster A, B, C, D, E or F.

[0375] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by at least one of the ISVs or polypeptides with SEQ ID NOs: 1-50.

[0376] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by the ISV or

polypeptide with SEQ ID NO: 51.

[0377] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by at least one of the ISVs or polypeptides with SEQ ID NOs: 53-56.

[0378] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by the ISV or polypeptide with SEQ ID NO: 52.

[0379] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by at least one of the ISVs or polypeptides with SEQ ID NOs: 57-65.

[0380] Accordingly, the present disclosure relates to polypeptides that cross-block the binding to CD3 by at least one of the ISVs or polypeptides with SEQ ID NOs: 66-80.

[0381] In a further aspect, the disclosure relates to polypeptides that are cross-blocked from binding to CD3 by at least one of the ISVs or polypeptides belonging to Cluster A, B, C, D, E or F.

[0382] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by at least one of the ISVs or polypeptides belonging to SEQ ID NOs: 1-50.

[0383] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by the ISV or polypeptide with SEQ ID NO: 51.

[0384] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by at least one of the ISVs or polypeptides belonging to SEQ ID NOs: 53-56.

[0385] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by the ISV or polypeptide with SEQ ID NO: 52.

[0386] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by at least one of the ISVs or polypeptides belonging to SEQ ID NOs: 57-65.

[0387] Accordingly, the present disclosure relates to polypeptides that are cross-blocked from binding to CD3 by at least one of the ISVs or polypeptides belonging to SEQ ID NOs: 66-80.

[0388] The invention further relates to compounds or constructs, and in particular proteins or polypeptides that comprise or essentially consist of one or more ISVs or polypeptides of the invention, and optionally further comprise one or more other groups, residues, moieties or binding units. As will become clear to the skilled person from the further disclosure herein, such further groups, residues, moieties, binding units or amino acid sequences may or may not provide further functionality to the polypeptide of the invention (and/or to the compound or construct in which it is present) and may or may not modify the properties of the polypeptide of the invention.

[0389] In a specific, but non-limiting aspect of the invention, which will be further described herein, the ISVs and polypeptides of the invention may have an increased half-life in serum (as further described herein) compared to the immunoglobulin single variable domain or polypeptide from which they have been derived. For example, an immunoglobulin single variable domain or polypeptide of the invention may be linked (chemically or otherwise) to one or more groups or moieties that extend the half-life (such as PEG), so as to provide a derivative of the ISV or polypeptide of the invention with increased half-life.

[0390] In a specific aspect of the invention, a compound or construct of the invention or a polypeptide of the invention may have an increased half-life, compared to the corresponding ISV or polypeptide of the invention. Some preferred, but non-limiting examples of such compounds, constructs and polypeptides will become clear to the skilled person based on the further disclosure herein, and for example comprise immunoglobulin single variable domains or polypeptides of the invention that have been chemically modified to increase the half-life thereof (for example, by means of pegylation); immunoglobulin single variable domains or polypeptides of the invention that comprise at least one additional binding site for binding to a serum protein (such as serum albumin); or constructs or polypeptides of the invention which comprise at least ISV or polypeptide of the invention that is linked to at least one moiety (and in particular at least one amino acid sequence) which increases the half-life of the ISV or polypeptide of the invention. Examples of ISVs or polypeptides of the invention which comprise such half-life extending moieties or immunoglobulin single variable domains will become clear to the skilled person based on the further disclosure herein; and for example include, without limitation, polypeptides in which the one or more immunoglobulin single variable domains or polypeptide of the invention are suitably linked to one or more serum proteins or fragments thereof (such as (human) serum albumin or suitable fragments thereof) or to one or more binding units that can bind to serum proteins (such as, for example, domain antibodies, immunoglobulin single variable domains that are suitable for use as a domain antibody, single domain antibodies, immunoglobulin single variable domains that are suitable for use as a single domain antibody, "dAb"s, immunoglobulin single variable domains that are suitable for use as a dAb, or Nanobodies that can bind to serum proteins such as serum albumin (such as human serum albumin), serum immunoglobulins such as IgG, or transferrin; reference is made to the further description and references mentioned herein); ISVs or polypeptides in which an ISV or polypeptide of the invention is linked to an Fc portion (such as a human Fc) or a suitable part or fragment thereof; or polypeptides in which the one or more immunoglobulin single variable domains or polypeptide of the invention are suitably linked to one or more small proteins or peptides that can bind to serum proteins, such as, without limitation, the proteins and peptides described in WO 91/01743, WO 01/45746, WO 02/076489, WO 08/068280, WO 09/127691 and WO 11/095545.

[0391] Generally, the compounds, constructs or polypeptides of the invention with increased half-life preferably have a half-life that is at least 1.5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, greater than the half-life of the corresponding ISV or polypeptide of the invention per se. For example, the compounds, constructs or polypeptides of the invention with increased half-life may have a half-life e.g., in humans that is increased with more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the corresponding ISV or polypeptide of the invention per se.

[0392] In a preferred, but non-limiting aspect of the invention, such compounds, constructs or polypeptides of the invention have a serum half-life e.g. in humans that is increased with more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the corresponding ISV or polypeptide of the invention per se.

[0393] In another preferred, but non-limiting aspect of the invention, such compounds, constructs or polypeptides of the invention exhibit a serum half-life in human of at least about 12 hours, preferably at least 24 hours, more preferably at least 48 hours, even more preferably at least 72 hours or more. For example, compounds, constructs or polypeptides of the invention may have a half-life of at least 5 days (such as about 5 to 10 days), preferably at least 9 days (such as about 9 to 14 days), more preferably at least about 10 days (such as about 10 to 15 days), or at least about 11 days (such as about 11 to 16 days), more preferably at least about 12 days (such as about 12 to 18 days or more), or more than 14 days (such as about 14 to 19 days).

[0394] In the present invention it was demonstrated that the inclusion of the albumin targeting binding unit in the construct as such did not have an essential impact on the obtained potency or efficacy. Although a minor loss of efficacy/potency was observed in the presence of HSA, the half-life extended CD3 multispecific polypeptides were still potent in tumour cell killing. Albumin-based drug delivery has been demonstrated to be useful for achieving improved cancer therapy, largely due to its passive target toward tumour via the enhanced permeability and retention effect and the increased demand for albumin by tumour cells as source of energy and amino acids. However, albumin lacks not only the active mechanism to overcome the cell membrane barrier, but also the ability to penetrate into tumour tissues (Qianqian Guo et al. Polym. Chem., 2013,4, 4584-4587).

[0395] In a particularly preferred but non-limiting aspect of the invention, the invention provides a polypeptide of the invention comprising a first and a second immunoglobulin single variable domain (ISV); and further comprising one or more (preferably one) serum albumin binding immunoglobulin single variable domain as described herein, e.g. the serum albumin binding immunoglobulin single variable domain referred to as Alb8, Alb23, Alb129, Alb132, Alb11, Alb11 (S112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG, Alb82-GGG (Table B-3).

Table B-3: Immunoglobulin single variable domains for use in HLE of the ISVs and polypeptides of the invention

Alb8	EVQLVESGGGLVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLTVTVSS
Alb23	EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADSV KGRFTISRDNKNTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLTVTVSS
Alb129	EVQLVESGGGVVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTATYYCTIGGSLSRSSQGTLTVTVSSA
Alb132	EVQLVESGGGVVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSSISGSGSDTLYADS VKGRFTISRDNKNTLYLQMNSLRPEDTATYYCTIGGSLSRSSQGTLTVTVSSA
Alb11	EVQLVESGGGLVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLTVTVSS
Alb11 (S112K)-A	EVQLVESGGGLVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVKVSSA
Alb82	EVQLVESGGGVVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLTVTVSS
Alb82-A	EVQLVESGGGVVQPGNSLRSLCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNKTTLYLQMNSLRPEDTALYYCTIGGSLSRSSQGTLTVTVSSA

(continued)

5	Alb82-AA	EVQLVESGGGVVQPGNSLRSLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTALYCTIGGSLRSSQGTLTVSSAA
	Alb82-AAA	EVQLVESGGGVVQPGNSLRSLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTALYCTIGGSLRSSQGTLTVSSAAA
10	Alb82-G	EVQLVESGGGVVQPGNSLRSLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTALYCTIGGSLRSSQGTLTVSSG
	Alb82-GG	EVQLVESGGGVVQPGNSLRSLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTALYCTIGGSLRSSQGTLTVSSGG
15	Alb82- GGG	EVQLVESGGGVVQPGNSLRSLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSV KGRFTISRDNAKTTLYLQMNSLRPEDTALYCTIGGSLRSSQGTLTVSSGGG

[0396] Accordingly, the present invention relates to a polypeptide as defined by the claims, further comprising a serum protein binding moiety.

[0397] The present invention relates to a polypeptide as defined by the claims, wherein said serum protein binding moiety binds serum albumin.

[0398] The present invention relates to a polypeptide as defined by the claims, wherein said serum protein binding moiety is an immunoglobulin single variable domain binding serum albumin.

[0399] The present invention relates to a polypeptide as defined by the claims, wherein said ISV binding serum albumin essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively), in which CDR1 is SFGMS (SEQ ID NO: 373), CDR2 is SISGSGSDTLYADSVKG (SEQ ID NO: 374), and in which CDR3 is GGSLSR (SEQ ID NO: 375), CDR determined according to Kabat definition; and/or in which CDR1 is GFTFSSFGMS (SEQ ID NO: 376) or GFTFRSFGMS (SEQ ID NO: 377), CDR2 is SISGSGSDTL (SEQ ID NO: 378) and CDR3 is GGSLSR (SEQ ID NO: 375), CDR determined according to Kontermann 2010.

[0400] The present invention relates to a polypeptide as defined by the claims, wherein said ISV binding serum albumin comprises Alb8, Alb23, Alb129, Alb132, Alb11, Alb11 (S112K)-A, Alb82, Alb82-A, Alb82-AA, Alb82-AAA, Alb82-G, Alb82-GG, Alb82-GGG (Table B-3).

[0401] In the polypeptides of the invention, the two or more building blocks, ISVs or Nanobodies and the optionally one or more polypeptides, one or more other groups, drugs, agents, residues, moieties or binding units may be directly linked to each other (as for example described in WO 99/23221) and/or may be linked to each other via one or more suitable spacers or linkers, or any combination thereof.

[0402] Suitable spacers or linkers for use in multivalent and multispecific polypeptides will be clear to the skilled person, and may generally be any linker or spacer used in the art to link amino acid sequences. Preferably, said linker or spacer is suitable for use in constructing proteins or polypeptides that are intended for pharmaceutical use.

[0403] Some particularly preferred spacers include the spacers and linkers that are used in the art to link antibody fragments or antibody domains. These include the linkers mentioned in the general background art cited above, as well as for example linkers that are used in the art to construct diabodies or ScFv fragments (in this respect, however, it should be noted that, whereas in diabodies and in ScFv fragments, the linker sequence used should have a length, a degree of flexibility and other properties that allow the pertinent V_H and V_L domains to come together to form the complete antigen-binding site, there is no particular limitation on the length or the flexibility of the linker used in the polypeptide of the invention, since each ISV or Nanobody by itself forms a complete antigen-binding site).

[0404] For example, a linker may be a suitable amino acid sequence, and in particular amino acid sequences of between 1 and 50, preferably between 1 and 30, such as between 1 and 10 amino acid residues. Some preferred examples of such amino acid sequences include gly-ser linkers, for example of the type $(gly_xser_y)_z$, such as (for example $(gly_4ser)_3$ or $(gly_3ser)_3$, as described in WO 99/42077 and the GS30, GS15, GS9 and GS7 linkers described in the applications by Ablynx mentioned herein (see for example WO 06/040153 and WO 06/122825), as well as hinge-like regions, such as the hinge regions of naturally occurring heavy chain antibodies or similar sequences (such as described in WO 94/04678). Preferred linkers are depicted in Table B-4.

Table 8-4: Linkers

5GS	GGGGS
7GS	SGGSGGS

(continued)

9GS	GGGGS
10GS	GGGGS
15GS	GGGGS
18GS	GGGGS
20GS	GGGGS
25GS	GGGGS
30GS	GGGGS
35GS	GGGGS
Poly-A	AAA

[0405] Some other particularly preferred linkers are poly-alanine (such as AAA), as well as the linkers GS30 (SEQ ID NO: 85 in WO 06/122825) and GS9 (SEQ ID NO: 84 in WO 06/122825).

[0406] Other suitable linkers generally comprise organic compounds or polymers, in particular those suitable for use in proteins for pharmaceutical use. For instance, poly(ethyleneglycol) moieties have been used to link antibody domains, see for example WO 04/081026.

[0407] It is encompassed within the scope of the invention that the length, the degree of flexibility and/or other properties of the linker(s) used (although not critical, as it usually is for linkers used in ScFv fragments) may have some influence on the properties of the final polypeptide of the invention, including but not limited to the affinity, specificity or avidity for CD3, or for one or more of the other antigens. Based on the disclosure herein, the skilled person will be able to determine the optimal linker(s) for use in a specific polypeptide of the invention, optionally after some limited routine experiments.

[0408] For example, in multivalent polypeptides of the invention that comprise building blocks, ISVs or Nanobodies directed against a first and second target, the length and flexibility of the linker are preferably such that it allows each building block, ISV or Nanobody of the invention present in the polypeptide to bind to its cognate target, e.g. the antigenic determinant on each of the targets. Again, based on the disclosure herein, the skilled person will be able to determine the optimal linker(s) for use in a specific polypeptide of the invention, optionally after some limited routine experiments.

[0409] It is also within the scope of the invention that the linker(s) used confer one or more other favourable properties or functionality to the polypeptides of the invention, and/or provide one or more sites for the formation of derivatives and/or for the attachment of functional groups (e.g. as described herein for the derivatives of the ISV, Nanobodies, or polypeptide of the invention). For example, linkers containing one or more charged amino acid residues can provide improved hydrophilic properties, whereas linkers that form or contain small epitopes or tags can be used for the purposes of detection, identification and/or purification. Again, based on the disclosure herein, the skilled person will be able to determine the optimal linkers for use in a specific polypeptide of the invention, optionally after some limited routine experiments.

[0410] Finally, when two or more linkers are used in the polypeptides of the invention, these linkers may be the same or different. Again, based on the disclosure herein, the skilled person will be able to determine the optimal linkers for use in a specific polypeptide of the invention, optionally after some limited routine experiments.

[0411] Usually, for easy of expression and production, a polypeptide of the invention will be a linear polypeptide. However, the invention in its broadest sense is not limited thereto. For example, when a polypeptide of the invention comprises three or more building blocks, ISV or Nanobodies, it is possible to link them by use of a linker with three or more "arms", which each "arm" being linked to a building block, ISV or Nanobody, so as to provide a "star-shaped" construct. It is also possible, although usually less preferred, to use circular constructs.

[0412] Accordingly, the present invention relates to a polypeptide as described herein, wherein said first ISV and said second ISV and possibly said third ISV and/or said ISV binding serum albumin are directly linked to each other or are linked via a linker.

[0413] The present invention relates to a polypeptide as described herein, wherein said linker is chosen from the group consisting of linkers of 5GS, 7GS, 9GS, 10GS, 15GS, 18GS, 20GS, 25GS, 30GS and 35GS. The present invention relates to a polypeptide as described herein, wherein said serum protein binding moiety is a non-antibody based polypeptide (e.g. PEG).

[0414] The invention also relates to methods for preparing the ISVs, polypeptides and constructs as defined by the claims. The ISVs, polypeptides and constructs of the invention can be prepared in a manner known per se, as will be clear to the skilled person from the further description herein. For example, the ISVs, polypeptides and constructs of the invention can be prepared in any manner known per se for the preparation of antibodies and in particular for the preparation

of antibody fragments (including but not limited to (single) domain antibodies and ScFv fragments). Some preferred, but non-limiting methods for preparing the polypeptides and constructs include the methods and techniques described herein.

[0415] The method for producing an ISV, polypeptide or protein construct of the invention may comprise the following steps:

- the expression, in a suitable host cell or host organism (also referred to herein as a "host of the invention") or in another suitable expression system of a nucleic acid that encodes said IVS, polypeptide or protein construct of the invention,

optionally followed by:

- isolating and/or purifying the ISVs, polypeptide or protein construct of the invention thus obtained.

[0416] In particular, such a method may comprise the steps of:

- cultivating and/or maintaining a host of the invention under conditions that are such that said host of the invention expresses and/or produces at least one ISVs, polypeptide or protein construct of the invention;

optionally followed by:

- isolating and/or purifying the ISVs, polypeptide or protein construct of the invention thus obtained.

[0417] Accordingly, the present invention also relates to a nucleic acid or nucleotide sequence that encodes an ISV, polypeptide or protein construct of the invention (as defined by the claims, also referred to as "*nucleic acid of the invention*" or "*nucleotide sequence of the invention*"). A nucleic acid of the invention can be in the form of single or double stranded DNA or RNA, and is preferably in the form of double stranded DNA. For example, the nucleotide sequences of the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism).

[0418] According to one embodiment of the invention, the nucleic acid of the invention is in essentially isolated form, as defined herein. The nucleic acid of the invention may also be in the form of, be present in and/or be part of a vector, such as for example a plasmid, cosmid or YAC, which again may be in essentially isolated form.

[0419] The nucleic acids of the invention can be prepared or obtained in a manner known per se, based on the information on the polypeptides or protein constructs of the invention given herein, and/or can be isolated from a suitable natural source. Also, as will be clear to the skilled person, to prepare a nucleic acid of the invention, also several nucleotide sequences, such as at least one nucleotide sequence encoding an immunoglobulin single variable domain of the invention and for example nucleic acids encoding one or more linkers can be linked together in a suitable manner.

[0420] Techniques for generating the nucleic acids of the invention will be clear to the skilled person and may for instance include, but are not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more naturally occurring and/or synthetic sequences (or two or more parts thereof), introduction of mutations that lead to the expression of a truncated expression product; introduction of one or more restriction sites (e.g. to create cassettes and/or regions that may easily be digested and/or ligated using suitable restriction enzymes), and/or the introduction of mutations by means of a PCR reaction using one or more "mismatched" primers. These and other techniques will be clear to the skilled person, and reference is again made to the standard handbooks, such as Sambrook et al. and Ausubel et al., mentioned herein, as well as the Examples below.

[0421] The nucleic acid of the invention may also be in the form of, be present in and/or be part of a genetic construct, as will be clear to the person skilled in the art. Such genetic constructs generally comprise at least one nucleic acid of the invention that is optionally linked to one or more elements of genetic constructs known per se, such as for example one or more suitable regulatory elements (such as a suitable promoter(s), enhancer(s), terminator(s), etc.) and the further elements of genetic constructs referred to herein. Such genetic constructs comprising at least one nucleic acid of the invention will also be referred to herein as "*genetic constructs of the invention*".

[0422] The genetic constructs of the invention may be DNA or RNA, and are preferably double-stranded DNA. The genetic constructs of the invention may also be in a form suitable for transformation of the intended host cell or host organism, in a form suitable for integration into the genomic DNA of the intended host cell or in a form suitable for independent replication, maintenance and/or inheritance in the intended host organism. For instance, the genetic constructs of the invention may be in the form of a vector, such as for example a plasmid, cosmid, YAC, a viral vector or transposon. In particular, the vector may be an expression vector, i.e. a vector that can provide for expression *in vitro* and/or *in vivo* (e.g. in a suitable host cell, host organism and/or expression system).

[0423] In a preferred but non-limiting embodiment, a genetic construct of the invention comprises

a) at least one nucleic acid of the invention; operably connected to

b) one or more regulatory elements, such as a promoter and optionally a suitable terminator; and optionally also

c) one or more further elements of genetic constructs known per se;

in which the terms "regulatory element", "promoter", "terminator" and "operably connected" have their usual meaning in the art (as further described herein); and in which said "further elements" present in the genetic constructs may for example be 3'- or 5'-UTR sequences, leader sequences, selection markers, expression markers/reporter genes, and/or elements that may facilitate or increase (the efficiency of) transformation or integration. These and other suitable elements for such genetic constructs will be clear to the skilled person, and may for instance depend upon the type of construct used; the intended host cell or host organism; the manner in which the nucleotide sequences of the invention of interest are to be expressed (e.g. via constitutive, transient or inducible expression); and/or the transformation technique to be used. For example, regulatory sequences, promoters and terminators known per se for the expression and production of antibodies and antibody fragments (including but not limited to (single) domain antibodies and ScFv fragments) may be used in an essentially analogous manner.

[0424] Preferably, in the genetic constructs of the invention, said at least one nucleic acid of the invention and said regulatory elements, and optionally said one or more further elements, are "operably linked" to each other, by which is generally meant that they are in a functional relationship with each other. For instance, a promoter is considered "operably linked" to a coding sequence if said promoter is able to initiate or otherwise control/regulate the transcription and/or the expression of a coding sequence (in which said coding sequence should be understood as being "under the control of" said promoter). Generally, when two nucleotide sequences are operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.

[0425] The nucleic acids of the invention and/or the genetic constructs of the invention may be used to transform a host cell or host organism, i.e. for expression and/or production of the polypeptide or protein construct of the invention. The host is preferably a non-human host. Suitable hosts or host cells will be clear to the skilled person, and may for example be any suitable fungal, prokaryotic or eukaryotic cell or cell line or any suitable fungal, prokaryotic or eukaryotic organism, for example:

- a bacterial strain, including but not limited to gram-negative strains such as strains of *Escherichia coli*; of *Proteus*, for example of *Proteus mirabilis*; of *Pseudomonas*, for example of *Pseudomonas fluorescens*; and gram-positive strains such as strains of *Bacillus*, for example of *Bacillus subtilis* or of *Bacillus brevis*; of *Streptomyces*, for example of *Streptomyces lividans*; of *Staphylococcus*, for example of *Staphylococcus carnosus*; and of *Lactococcus*, for example of *Lactococcus lactis*;
- a fungal cell, including but not limited to cells from species of *Trichoderma*, for example from *Trichoderma reesei*; of *Neurospora*, for example from *Neurospora crassa*; of *Sordaria*, for example from *Sordaria macrospora*; of *Aspergillus*, for example from *Aspergillus niger* or from *Aspergillus sojae*; or from other filamentous fungi;
- a yeast cell, including but not limited to cells from species of *Saccharomyces*, for example of *Saccharomyces cerevisiae*; of *Schizosaccharomyces*, for example of *Schizosaccharomyces pombe*; of *Pichia*, for example of *Pichia pastoris* or of *Pichia methanolica*; of *Hansenula*, for example of *Hansenula polymorpha*; of *Kluyveromyces*, for example of *Kluyveromyces lactis*; of *Arxula*, for example of *Arxula adenivorans*; of *Yarrowia*, for example of *Yarrowia lipolytica*;
- an amphibian cell or cell line, such as *Xenopus oocytes*;
- an insect-derived cell or cell line, such as cells/cell lines derived from lepidoptera, including but not limited to *Spodoptera* SF9 and Sf21 cells or cells/cell lines derived from *Drosophila*, such as Schneider and Kc cells;
- a plant or plant cell, for example in tobacco plants; and/or
- a mammalian cell or cell line, for example a cell or cell line derived from a human, a cell or a cell line from mammals including but not limited to CHO-cells, BHK-cells (for example BHK-21 cells) and human cells or cell lines such as HeLa, COS (for example COS-7) and PER.C6 cells;

as well as all other hosts or host cells known per se for the expression and production of antibodies and antibody fragments (including but not limited to (single) domain antibodies and ScFv fragments), which will be clear to the skilled person. Reference is also made to the general background art cited hereinabove, as well as to for example WO 94/29457; WO 96/34103; WO 99/42077; Frenken et al. 1998 (Res. Immunol. 149: 589-99); Riechmann and Muyldermans 1999 (J. Immunol. Met. 231: 25-38); van der Linden 2000 (J. Biotechnol. 80: 261-70); Joosten et al. 2003 (Microb. Cell Fact. 2: 1); Joosten et al. 2005 (Appl. Microbiol. Biotechnol. 66: 384-92); and the further references cited herein.

[0426] For expression of the ISVs, polypeptides or constructs in a cell, they may also be expressed as so-called "intrabodies", as for example described in WO 94/02610, WO 95/22618 and US 7004940; WO 03/014960; in Cattaneo and Biocca 1997 (Intracellular Antibodies: Development and Applications. Landes and Springer-Verlag); and in Kontermann 2004 (Methods 34: 163-170).

[0427] According to one preferred, but non-limiting embodiment of the invention, the ISV, polypeptide or protein construct of the invention is produced in a bacterial cell, in particular a bacterial cell suitable for large scale pharmaceutical production, such as cells of the strains mentioned above.

[0428] According to another preferred, but non-limiting embodiment of the invention, the ISV, polypeptide or protein construct of the invention is produced in a yeast cell, in particular a yeast cell suitable for large scale pharmaceutical production, such as cells of the species mentioned above.

[0429] According to yet another preferred, but non-limiting embodiment of the invention, the ISV, polypeptide or construct of the invention is produced in a mammalian cell, in particular in a human cell or in a cell of a human cell line, and more in particular in a human cell or in a cell of a human cell line that is suitable for large scale pharmaceutical production, such as the cell lines mentioned hereinabove.

[0430] Suitable techniques for transforming a host or host cell of the invention will be clear to the skilled person and may depend on the intended host cell/host organism and the genetic construct to be used. Reference is again made to the handbooks and patent applications mentioned above.

[0431] After transformation, a step for detecting and selecting those host cells or host organisms that have been successfully transformed with the nucleotide sequence/genetic construct of the invention may be performed. This may for instance be a selection step based on a selectable marker present in the genetic construct of the invention or a step involving the detection of the polypeptide of the invention, e.g. using specific antibodies.

[0432] The transformed host cell (which may be in the form of a stable cell line) or host organisms (which may be in the form of a stable mutant line or strain) form further aspects of the present invention.

[0433] Preferably, these host cells or host organisms are such that they express, or are (at least) capable of expressing (e.g. under suitable conditions), an ISV, polypeptide or protein construct of the invention (and in case of a host organism: in at least one cell, part, tissue or organ thereof). The invention also includes further generations, progeny and/or offspring of the host cell or host organism of the invention, for instance obtained by cell division or by sexual or asexual reproduction.

[0434] Accordingly, in another aspect, the invention relates to a host or host cell that expresses (or that under suitable circumstances is capable of expressing) an ISV, polypeptide or protein construct of the invention; and/or that contains a nucleic acid encoding the same. Some preferred but non-limiting examples of such hosts or host cells can be as generally described in WO 04/041867, WO 04/041865 or WO 09/068627. For example, ISVs, polypeptides and protein constructs of the invention may with advantage be expressed, produced or manufactured in a yeast strain, such as a strain of *Pichia pastoris*. Reference is also made to WO 04/25591, WO 10/125187, WO 11/003622, and WO 12/056000 which also describes the expression/production in *Pichia* and other hosts/host cells of immunoglobulin single variable domains and polypeptides comprising the same.

[0435] To produce/obtain expression of the ISVs, polypeptides or protein constructs of the invention, the transformed host cell or transformed host organism may generally be kept, maintained and/or cultured under conditions such that the (desired) ISV, polypeptide or protein construct of the invention is expressed/produced. Suitable conditions will be clear to the skilled person and will usually depend upon the host cell/host organism used, as well as on the regulatory elements that control the expression of the (relevant) nucleotide sequence of the invention. Again, reference is made to the handbooks and patent applications mentioned above in the paragraphs on the genetic constructs of the invention.

[0436] Generally, suitable conditions may include the use of a suitable medium, the presence of a suitable source of food and/or suitable nutrients, the use of a suitable temperature, and optionally the presence of a suitable inducing factor or compound (e.g. when the nucleotide sequences of the invention are under the control of an inducible promoter); all of which may be selected by the skilled person. Again, under such conditions, the ISVs, polypeptides or protein constructs of the invention may be expressed in a constitutive manner, in a transient manner, or only when suitably induced.

[0437] It will also be clear to the skilled person that the ISV, polypeptide or protein construct of the invention may (first) be generated in an immature form (as mentioned above), which may then be subjected to post-translational modification, depending on the host cell/host organism used. Also, the ISV, polypeptide or protein construct of the invention may be glycosylated, again depending on the host cell/host organism used.

[0438] The ISV, polypeptide or protein construct of the invention may then be isolated from the host cell/host organism and/or from the medium in which said host cell or host organism was cultivated, using protein isolation and/or purification

techniques known per se, such as (preparative) chromatography and/or electrophoresis techniques, differential precipitation techniques, affinity techniques (e.g. using a specific, cleavable amino acid sequence fused with the polypeptide or construct of the invention) and/or preparative immunological techniques (i.e. using antibodies against the amino acid sequence to be isolated).

[0439] The constructs of the invention can generally be prepared by a method which comprises at least the step of suitably linking ISVs or polypeptides of the invention to the one or more further groups, residues, moieties or binding units, optionally via the one or more suitable linkers, so as to provide the constructs of the invention. The ISVs, polypeptides and constructs of the invention can then further be modified, and in particular by chemical and/or biological (e.g. enzymatical) modification, of one or more of the amino acid residues that form the polypeptides or constructs of the invention, to obtain derivatives of the polypeptides or constructs of the invention.

[0440] The invention also relates to a pharmaceutical composition comprising the ISV, polypeptide, compound or construct of the invention.

[0441] In the above methods, the amino acid sequences, ISVs, Nanobodies, polypeptides, compounds or constructs of the invention and/or the compositions comprising the same can be administered in any suitable manner, depending on the specific pharmaceutical formulation or composition to be used. Thus, the amino acid sequences, ISVs, Nanobodies, polypeptides, compounds or constructs of the invention and/or the compositions comprising the same can for example be administered orally, intraperitoneally (e.g. intravenously, subcutaneously, intramuscularly, or via any other route of administration that circumvents the gastrointestinal tract), intranasally, transdermally, topically, by means of a suppository, by inhalation, again depending on the specific pharmaceutical formulation or composition to be used. The clinician will be able to select a suitable route of administration and a suitable pharmaceutical formulation or composition to be used in such administration, depending on the disease or disorder to be prevented or treated and other factors well known to the clinician.

[0442] As used herein, the term "therapeutic agent" refers to any agent that can be used in the treatment and/or management of a hyperproliferative cell disorder, e.g., cancer, or one or more symptoms thereof. In certain embodiments, the term "therapeutic agent" refers to a multispecific polypeptide of the invention. Preferably, a therapeutic agent is an agent which is known to be useful for, or has been or is currently being used for the treatment, prevention and/or management of a hyperproliferative cell disorder, e.g., cancer, or one or more symptoms thereof.

[0443] As used herein, a "therapeutically effective amount" in the context of cancer refers to the amount of a therapy alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment and/or management of cancers. In one aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to destroy, modify, control or remove primary, regional or metastatic cancer tissue. In another aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to reduce the symptoms of a cancer. In another aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to delay or minimize the spread of cancer. In a specific embodiment, a therapeutically effective amount of a therapy is an amount of a therapy sufficient to inhibit growth or proliferation of cancer cells, kill existing cancer cells (e.g., cause regression of the cancer), and/or prevent the spread of cancer cells to other tissues or areas (e.g., prevent metastasis). In another specific embodiment, a therapeutically effective amount of a therapy is the amount of a therapy sufficient to inhibit the growth of a tumor by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% as measured by a standard method known in the art. Used in connection with an amount of a multispecific polypeptide of the invention, the term can encompass an amount that improves overall therapy, reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapy. In one embodiment, a therapeutically effective amount of a therapy reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapy by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to a control (e.g., a negative control such as phosphate buffered saline) in an assay known in the art or described herein.

[0444] As used herein, a "therapeutically effective amount" in the context of a non-cancer hyperproliferative cell disorder refers to the amount of a therapy alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment and/or management of said disorder. In one aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to destroy, modify, control or remove cells affected by a non-cancer hyperproliferative cell disorder. In another aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to reduce the symptoms of a non-cancer hyperproliferative cell disorder. In another aspect, a therapeutically effective amount refers to the amount of a therapy sufficient to delay or minimize the spread of the non-cancer hyperproliferative cell disorder. In a specific embodiment, a therapeutically effective amount of a therapy is an amount of a therapy sufficient to inhibit growth or proliferation of the non-cancer hyperproliferative cell disorder, kill existing non-cancer hyperproliferative cells (e.g., cause regression of the disorder). In another specific embodiment, a therapeutically effective amount of a therapy is the amount of a therapy sufficient to inhibit the growth of the non-cancer hyperproliferative cells by at least 5%, preferably at least

10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% as measured by a standard method known in the art. Used in connection with an amount of a multispecific polypeptide of the invention, the term can encompass an amount that improves overall therapy, reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapy. In one embodiment, a therapeutically effective amount of a therapy reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapy by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to a control (e.g., a negative control such as phosphate buffered saline) in an assay known in the art.

[0445] As used herein, the term "therapy" refers to any protocol, method and/or agent that can be used in the treatment, prevention and/or management of a hyperproliferative cell disorder, e.g., cancer. In certain embodiments, the terms "therapies" and "therapy" refer to a biological therapy, supportive therapy, and/or other therapies useful in the treatment, prevention and/or management of a hyperproliferative cell disorder, e.g., cancer, or one or more symptoms thereof known to one of skill in the art such as medical personnel.

[0446] As used herein, the terms "treat", "treatment" and "treating" in the context of administering a therapy(ies) to a subject refer to the reduction or amelioration of the progression, severity, and/or duration of a disorder associated with a hyperproliferative cell disorder, e.g., cancer, and/or the amelioration of one or more symptoms thereof resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents). In specific embodiments, the terms "treat", "treatment" and "treating" in the context of administering (a) therapy(ies) to a subject refer to the reduction or amelioration of the progression, severity, and/or duration of a hyperproliferative cell disorder, e.g., cancer, refers to a reduction in cancer cells by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% relative to a control (e.g., a negative control such as phosphate buffered saline). In other embodiments, the terms "treat", "treatment" and "treating" in the context of administering (a) therapy(ies) to a subject refer to the reduction or amelioration of the progression, severity, and/or duration of a hyperproliferative cell disorder, e.g., cancer, refers to no change in cancer cell number, a reduction in hospitalization time, a reduction in mortality, or an increase in survival time of the subject with cancer.

[0447] The amino acid sequences, ISVs, Nanobodies, polypeptides, compounds and/or constructs of the invention and/or the compositions comprising the same are administered according to a regime of treatment that is suitable for preventing and/or treating the hyperproliferative cell disorder, e.g., cancer, to be prevented or treated. The clinician will generally be able to determine a suitable treatment regimen, depending on factors such as the stage of the hyperproliferative cell disorder, e.g., cancer, to be treated, the severity of the hyperproliferative cell disorder, e.g., cancer, to be treated and/or the severity of the symptoms thereof, the specific amino acid sequence, ISV, Nanobody, polypeptide, compound and/or construct of the invention to be used, the specific route of administration and pharmaceutical formulation or composition to be used, the age, gender, weight, diet, general condition of the patient, and similar factors well known to the clinician.

[0448] Generally, the treatment regimen will comprise the administration of one or more amino acid sequences, ISVs, Nanobodies, polypeptides, compounds and/or constructs of the invention, or of one or more compositions comprising the same, in one or more pharmaceutically effective amounts or doses. The specific amount(s) or doses to be administered can be determined by the clinician, again based on the factors cited above.

[0449] Generally, for the prevention and/or treatment of a hyperproliferative cell disorder, e.g., cancer, mentioned herein and depending on the type of hyperproliferative cell disorder, e.g., cancer, and stage of the disease to be treated, the potency of the specific amino acid sequence, ISV, Nanobody, polypeptide, compound or construct of the invention to be used, the specific route of administration and the specific pharmaceutical formulation or composition used, the amino acid sequences, ISVs, Nanobodies, polypeptides, compounds or constructs of the invention will generally be administered in an amount between 1 gram and 0.01 milligram per kg body weight per day, preferably between 0.1 gram and 0.01 milligram per kg body weight per day, such as about 0.1, 1, 10, 100 or 1000 milligram per kg body weight per day, e.g. from 0.1 mg per kg to 25 mg per kg of the subject's body weight; either continuously (e.g. by infusion), as a single daily dose or as multiple divided doses during the day. The clinician will generally be able to determine a suitable daily dose, depending on the factors mentioned herein. It will also be clear that in specific cases, the clinician may choose to deviate from these amounts, for example on the basis of the factors cited above and his expert judgment. Generally, some guidance on the amounts to be administered can be obtained from the amounts usually administered for comparable conventional antibodies or antibody fragments against the same target administered via essentially the same route, taking into account however differences in affinity/avidity, efficacy, biodistribution, half-life and similar factors well known to the skilled person.

[0450] Usually, in the above method, a single amino acid sequence, ISV, Nanobody, polypeptide, compound or con-

struct of the invention will be used. It is however within the scope of the disclosure to use two or more amino acid sequences, ISVs, Nanobodies, polypeptides compounds and/or constructs of the invention in combination.

[0451] The ISVs, Nanobodies, amino acid sequences, polypeptides, compounds and/or constructs of the invention may also be used in combination with one or more further pharmaceutically active compounds or principles, *i.e.* as a combined treatment regimen, which may or may not lead to a synergistic effect. Again, the clinician will be able to select such further compounds or principles, as well as a suitable combined treatment regimen, based on the factors cited above and his expert judgement.

[0452] In particular, the amino acid sequences, ISVs, Nanobodies, polypeptides, compounds and/or constructs of the invention may be used in combination with other pharmaceutically active compounds or principles that are or can be used for the prevention and/or treatment of the hyperproliferative cell disorder, *e.g.*, cancer, disease and/or disorder cited herein, as a result of which a synergistic effect may or may not be obtained. Examples of such compounds and principles, as well as routes, methods and pharmaceutical formulations or compositions for administering them will be clear to the clinician.

[0453] When two or more substances or principles are to be used as part of a combined treatment regimen, they can be administered via the same route of administration or via different routes of administration, at essentially the same time or at different times (*e.g.* essentially simultaneously, consecutively, or according to an alternating regime). When the substances or principles are to be administered simultaneously via the same route of administration, they may be administered as different pharmaceutical formulations or compositions or part of a combined pharmaceutical formulation or composition, as will be clear to the skilled person.

[0454] In one aspect, the disclosure provides methods for the administration of immunoglobulin single variable domains and polypeptide constructs thereof comprising one or more immunoglobulin single variable domains, polypeptides, compounds and/or constructs. In some embodiments, the immunoglobulin single variable domain, polypeptide, compound and/or construct is administered as a pharmaceutical composition. The pharmaceutical composition, in addition to the immunoglobulin single variable domains and polypeptide constructs thereof includes a pharmaceutically-acceptable carrier.

[0455] As described in detail, the pharmaceutical compositions of the disclosure may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, *e.g.*, those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream or foam; sublingually; ocularly; transdermally; or nasally, pulmonary and to other mucosal surfaces.

[0456] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0457] The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.

[0458] Formulations of the disclosure include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient (*e.g.*, immunoglobulin single variable domain or polypeptide constructs thereof) which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, and the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of active ingredient, preferably from about 5% to about 70%, most preferably from about 10%

to about 30%.

[0459] In certain embodiments, a formulation comprises an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, *e.g.*, bile acids, and polymeric carriers, *e.g.*, polyesters and polyanhydrides. In certain embodiments, an aforementioned formulation renders orally bioavailable an immunoglobulin single variable domain or polypeptide construct.

[0460] Methods of preparing these formulations or compositions include the step of bringing into association an immunoglobulin single variable domain or polypeptide construct with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association an immunoglobulin single variable domain or polypeptide construct with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0461] Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of an immunoglobulin single variable domain or polypeptide construct as an active ingredient. An immunoglobulin single variable domain or polypeptide construct invention may also be administered as a bolus, electuary or paste.

[0462] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; absorbents, such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[0463] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxy-propylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made in a suitable machine in which a mixture of the powdered compound is moistened with an inert liquid diluent.

[0464] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, *e.g.*, freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

[0465] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0466] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0467] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0468] Formulations of the pharmaceutical compositions for rectal or vaginal administration may be presented as a

suppository, which may be prepared by mixing an immunoglobulin single variable domain or polypeptide construct with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

[0469] Formulations suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

[0470] Dosage forms for the topical or transdermal administration of an immunoglobulin single variable domain or polypeptide construct include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

[0471] The ointments, pastes, creams and gels may contain, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0472] Powders and sprays can contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0473] Transdermal patches have the added advantage of providing controlled delivery of an immunoglobulin single variable domain or polypeptide construct to the body. Dissolving or dispersing the compound in the proper medium can make such dosage forms. Absorption enhancers can also be used to increase the flux of the compound across the skin.

Either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel can control the rate of such flux.

[0474] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this disclosure.

[0475] Pharmaceutical compositions suitable for parenteral administration comprise one or more an immunoglobulin single variable domains or polypeptide constructs in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, anti-oxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0476] Examples of suitable aqueous and non-aqueous carriers, which may be employed in the pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0477] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0478] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0479] Injectable depot forms are made by forming microcapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly-(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue.

[0480] The invention will now be further described by means of the following non-limiting preferred aspects, examples and figures.

EXAMPLES

Example 1 TCR $\alpha\beta$ / CD3 Cell lines

[0481] Transient and stable CHO-K1 (ATCC: CCL-61), HEK293H (Life technologies 11631-017), Llana (Fibroblast

cells from llama Navel cord cells) cell lines with recombinant overexpression of all 6 chains of the full human T-cell Receptor complex were generated. For this, the coding sequences of the TCR alpha (α) and TCR beta (β) chain were cloned in a pcDNA3.1-derived vector, downstream of a CMV promotor and a 2A-like viral peptide sequence was inserted between both chains to induce ribosomal skipping during translation of the polyprotein. In the same vector, the coding sequences of the epsilon, delta, gamma and zeta chains of the CD3 complex were cloned downstream of an additional CMV promotor, also using 2A-like viral peptide sequences between the respective chains. In addition, a stable HEK293H clone with recombinant overexpression of the 4 chains of the human CD3 was generated as described above using a single gene vector.

[0482] The sequences for the human CD3 and the human TCR α/β constant domains were retrieved from UniProtKB (CD3 delta: P04234, CD3 gamma: P09693, CD3 epsilon: P07766, CD3 zeta: P20963, TCR α : P01848 and TCR β : P01850). The sequences for the human TCR α/β variable domains were retrieved from crystal structure. (PDB codes: 2IAN, 2XN9 and 3TOE).

[0483] The cell surface expression of the human T cell receptor complex was confirmed using a functional mouse IgG2b anti-human TCR α/β antibody, clone BW242/412 (Miltényi 130-098-219) and a functional mouse IgG2a anti-CD3 PE labelled antibody, clone OKT-3 (eBioscience 12-0037). (Figure 1)

Example 2 Immunization of llamas with TCR/CD3, cloning of the heavy chain-only antibody fragment repertoires and preparation of phage

2.1 Immunization

[0484] After approval of the Ethical Committee (Faculty of Veterinary Medicine of the University of Ghent, Belgium- EC2004/044 en EC2005/053), llamas (*Llama glama*) were immunized with either human peripheral blood lymphocytes (PBMC) isolated by Ficoll density centrifugation from a single buffy coat, or with mouse or human T- and NK cells enriched from PBMC by magnetic cell separation using biotin-conjugated antibodies. None of these immunization strategies resulted in specific immune response.

[0485] After approval of the Ethical Committee (CRIA, LA1400575, Belgium- EC2012#1), 3 additional llamas were immunized with a pVAX1-human TCR(2IAN)/CD3 (described in Example 1) plasmid vector (Invitrogen, Carlsbad, CA, USA) and with a pVAX1-human TCR(2XN9)/CD3 (described in Example 1) plasmid vector (Invitrogen, Carlsbad, CA, USA) according to standard protocols. Two llamas received additionally 1 subcutaneous injection of primary human T cells. Human T Cells were collected from Buffy Coat blood, from healthy volunteers (Blood bank Gent) using RosetteSep (StemCell Technologies, #15061) followed by an enrichment on Ficoll-PaqueTM PLUS (GE Healthcare #17-1440-03) according to manufactures instructions and stored in liquid nitrogen. After thawing, cells were washed, and re-suspended in D-PBS from Gibco and kept on ice prior to injection.

2.2 Cloning of the heavy chain-only antibody fragment repertoires and preparation of phages.

[0486] Per animal, blood samples were collected after the injection of one type of immunization antigen. From these blood samples, PBMC were prepared using Ficoll-Hypaque according to the manufacturer's instructions (Amersham Biosciences, Piscataway, NJ, USA). For each immunized llama, libraries were constructed by pooling the total RNA isolated from samples originating from a certain subset of the immunization schedule, *i.e.* after one type of immunization antigen.

[0487] In short, the PCR-amplified VHH repertoire was cloned via specific restriction sites into a vector designed to facilitate phage display of the VHH library. The vector was derived from pUC119. In frame with the VHH coding sequence, the vector encodes a C-terminal 3xFLAG and His6 tag. Phages were prepared according to standard protocols (see for example WO 04/041865, WO 04/041863, WO 04/062551, WO 05/044858 and other prior art and applications filed by Ablynx N.V. cited herein).

Example 3 Selection of TCR/CD3 specific VHHs via phage display

[0488] VHH repertoires obtained from all llamas and cloned as phage library were used in different selection strategies, applying a multiplicity of selection conditions. Variables included: i) the presentation form of the human TCR α/β /CD3 (on different cell backgrounds or on purified primary T cells (isolated as described in Example 2.1, ii) the antigen concentration, iii) the number of selection rounds. In brief cells were incubated for 2h with the phage libraries followed by extensive washing; bound phages were eluted with trypsin (1 mg/mL) for 15 minutes. When trypsin was used for phage elution, the protease activity was immediately neutralized by applying 0.8 mM protease inhibitor ABSF. As control, selections with parental cell line or without antigen were performed in parallel.

[0489] Phage outputs were used to infect *E. coli* for analysis of individual VHH clones. Periplasmic extracts were

prepared according to standard protocols (see for example WO 03/035694, WO 04/041865, WO 04/041863, WO 04/062551 and other prior art and applications filed by Ablynx N.V. cited herein).

Example 4 Screening

4.1 Screening for TCR/CD3 binding Nanobodies in a flow cytometry assay

[0490] Periplasmic extracts were screened for cell expressed TCR/CD3 binding using human TCR/CD3 transfected CHO-K1 or HEK293H cells and the respective CHO-K1 or HEK293H reference cell line in a mixed cell line setup. To this end, a large batch of the reference cell lines were labelled with 8 μ M PKH26 and frozen. 5×10^4 PKH labelled reference cells were mixed with 5×10^4 target cells and incubated with periplasmic extracts for 30min at 4°C, and washed 3 times. Next, cells were incubated with 1 μ g/ml monoclonal ANTI-FLAG® M2 antibody (Sigma-Aldrich, cat# F1804) for 30 min at 4°C, washed again, and incubated for 30 min at 4°C with goat anti-mouse APC labelled antibody (Jackson ImmunoResearch 115-135-164, 1:100). Samples were washed, resuspended in FACS Buffer (D-PBS from Gibco, with 10% FBS from Sigma and 0.05% sodium azide from Merck) and then analysed on a BD FACSAarray. First a P1 population which represents more than 80% of the total cell population was selected based on FSC-SSC distribution. In this gate, 20,000 cells were counted during acquisition. Based on PKH26-SSC distribution, the PKH labelled parental population and the human TCR/CD3 unlabelled target population was selected. For these 2 populations the mean APC value was calculated.

4.2 Screening for TCR/CD3 binding Nanobodies in a human T cell activation assay

[0491] After several attempts, it turned out that activation of purified human T cells by antibodies or Nanobodies according to standard protocols, *i.e.* coated onto a 96 well plate, was not sensitive enough (data not shown).

[0492] In order to assess activity, a different assay was developed, based on a bead coupled T cell activation. In short, goat anti-mouse IgG dynabeads (Life technologies #11033) were coated with mouse anti-flag IgG antibodies (Sigma F1804), (15 μ g/1E7beads). After an incubation period of 2h at 4°C, beads were washed and incubated with 80 μ l periplasmic extract for 20 min at 4°C while shaking. Non-coupled Nanobodies were washed away before adding the bead complex together with soluble mouse anti-CD28 antibody (Pelicluster CD28 - Sanquin #M1650) to purified primary human T cells (isolated as described in Example 2.1). As control condition, non-stimulated human T cells were used. In brief, goat anti-mouse IgG dynabeads coupled to mouse anti-flag IgG were incubated in 80 μ l periplasmic extract containing irrelevant Nanobodies. After removal of the non-coupled Nanobodies during a wash step the irrelevant Nanobody-bead complex was added to purified primary human T cells.

[0493] After an incubation of 24h at 37° and 5% CO₂ the activation status of the human T cells was determined by measuring the CD69 expression level in flow cytometry using monoclonal mouse anti-human CD69PE (BD # 557050).

[0494] Nanobodies which scored positive in the flow cytometric binding screen and the T cell activation assay were sequenced.

[0495] The sequence analysis resulted in the identification of 6 distinct clusters. Corresponding alignments are provided (Table A-1, Table A-2, Table A-3, Table A-4, Table A-5, Table A-6). Clustering was based on sequence similarities and differences in CDR2 and CDR3. Cluster A is the most prominent comprising 50 clones (SEQ ID NO:s 1-50), cluster B and cluster D are each represented by only 1 clone (SEQ ID NO: 51 and SEQ ID NO: 52, respectively), cluster C comprises 4 clones ((SEQ ID NO:s 53-56), cluster E comprises 9 clones (SEQ ID NO:s 57-65) and cluster F comprises 15 clones (SEQ ID NO:s 66-80).

[0496] Sequence variability of the CDRs was determined for the different clusters. For **cluster A**, the amino acid sequence of the CDRs of clone 117G03 was used as a reference, against which the CDRs of all other cluster A clones were compared. The sequence variability against 117G03 is depicted in the tables below.

117G03										
Kabat numbering	26	27	28	29	30	31	32	33	34	35
absolute numbering	1*	2	3	4	5	6	7	8	9	10
117G03 sequence	G	R	T	Y	R	G	Y	S	M	G
Variations	R		A	F				G		A

* in case position 1 is an R, then position 10 is also A

117G03										
Kabat numbering	50	51	52	52a	53	54	55	56	57	58
absolute numbering	1	2	3*	4	5	6	7	8	9	10
117G03 sequence	A	I	V	W	S	G	G	N	T	Y
variations			T		T	D			S	
variations			A			E			A	
variations									P	

* in case position 3 is an T, then position 6 is also E

117G03															
Kabat numbering	95	96	97	98	99	100	100a	100b	100c	100d	100e	100f	100g	101	102
absolute numbering	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
117G03 sequence	K	I	R	P	Y	I	F	K	I	A	G	Q	Y	D	Y
variations		T							V	P					

[0497] For **cluster B**, the amino acid sequence of the CDRs of clone 60E11 is depicted in the tables below.

60E11										
Kabat numbering	26	27	28	29	30	31	32	33	34	35
absolute numbering	1	2	3	4	5	6	7	8	9	10
60E11 sequence	G	D	I	Y	K	S	F	D	M	G

60E11													
Kabat numbering	50	51	52	52a	52b	52c	52d	53	54	55	56	57	58
absolute numbering	1	2	3	4	5	6	7	8	9	10	11	12	13
60E11 sequence	V	I	G	S	R	G	N	N	R	G	R	T	N

60E11								
Kabat numbering	95	96	97	98	99	95	101	102
absolute numbering	1	2	3	4	5	6	7	8
60E11 sequence	A	P	L	V	A	G	R	P

[0498] For **cluster C**, the amino acid sequence of the CDRs of clone 33G03 was used as a reference, against which the CDRs of all other cluster C clones were compared. The sequence variability against 33G03 is depicted in the tables below.

33G03										
Kabat numbering	26	27	28	29	30	31	32	33	34	35
absolute numbering	1	2	3	4	5	6	7	8	9	10
33G03 sequence	G	R	T	F	S	T	N	P	M	G

33G03										
Kabat numbering	50	51	52	52a	53	54	55	56	57	58
absolute numbering	1	2	3	4	5	6	7	8	9	10
33G03 sequence	A	V	R	W	A	D	G	N	T	F
Variations		A								

33G03															
Kabat numbering	95	96	97	98	99	100	100a	100b	100c	100d	100e	100f	100g	101	102
absolute numbering	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
33G03 sequence	G	R	P	W	S	A	Y	H	S	P	A	E	Y	V	H

[0499] For **cluster D**, the amino acid sequence of the CDRs of clone 11A10 is depicted in the tables below.

11A10										
Kabat numbering	26	27	28	29	30	31	32	33	34	35
absolute numbering	1	2	3	4	5	6	7	8	9	10
11A10 sequence	G	R	T	F	S	S	Y	A	M	A

11A10										
Kabat numbering	50	51	52	52a	53	54	55	56	57	58
absolute numbering	1	2	3	4	5	6	7	8	9	10
11A10 sequence	S	I	S	W	S	G	E	N	T	N

11A10																					
Kabat numbering	95	96	97	98	99	100	100 a b c d e f g h i j k l													101	102
absolute numbering	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
11A10 sequence	K	I	A	K	T	Y	P	D	N	W	Y	W	T	K	S	N	N	Y	N	Y	

[0500] For **cluster E**, the amino acid sequence of the CDRs of clone 52G04 was used as a reference, against which the CDRs of all other cluster E clones were compared. The sequence variability against 52G04 is depicted in the tables below.

52G04										
Kabat numbering	26	27	28	29	30	31	32	33	34	35
absolute numbering	1	2	3	4	5	6	7	8	9	10
52G04 sequence	G	I	R	I	S	R	N	M	M	G
sequence variations						N	H	T		
variations						T				

52G04										
Kabat numbering	50	51	52	53	54	55	56	57	58	
absolute numbering	1	2	3	4	5	6	7	8	9	
52G04 sequence	R	I	T	P	G	G	D	T	Y	
variations	Q		S				A			
variations							K			

52G04							
Kabat numbering	95	96	97	98	101	102	
absolute numbering	1	2	3	4	5	6	
52G04 sequence	Y	S	T	L	G	S	
variations		R				V	

[0501] For **cluster F**, the amino acid sequence of the CDRs of clone 50A11 was used as a reference, against which the CDRs of all other cluster F clones were compared. The sequence variability against 50A11 is depicted in the tables below.

50A11											
Kabat numbering	26	27	28	29	30	31	32	33	34	35	
absolute numbering	1	2	3	4	5	6	7	8	9	10	
50A11 sequence	G	R	S	F	N	M	N	P	L	G	
variations			T		S	T			M		
variations			A			A					
variations			G								

50A11											
Kabat numbering	50	51	52	52a	53	54	55	56	57	58	
absolute numbering	1	2	3	4	5	6	7	8	9	10	
50A11 sequence	A	H	R	W	S	D	G	N	T	Y	
variations		V			H			S		F	
variations					A						

50A11															
Kabat numbering	95	96	97	98	99	100	100a	100b	100c	100d	100e	100f	100g	101	102
absolute numbering	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
50A11 sequence	G	R	P	W	S	A	F	R	S	P	G	E	Y	V	Y
variations						S	Y	H	A		D			I	
variations						D	A				T				
variations											N				
variations											S				
variations											K				
variations											R				

[0502] The clustering based on the sequence transmuted into functional differences (see *infra*).

4.3 Purification of monovalent Nanobodies

[0503] Since it is not practicable to characterize all clones identified in Example 4.2, representative Nanobodies were selected and expressed in *E. coli* TG1 as triple Flag, His6-tagged proteins. Expression was induced by addition of 1 mM IPTG and allowed to continue for 4 hours at 37°C. After spinning the cell cultures, periplasmic extracts were prepared by freeze-thawing the pellets. These extracts were used as starting material and Nanobodies were purified via IMAC and size exclusion chromatography (SEC).

[0504] The Nanobodies were purified to 95% purity as assessed via SDS-PAGE (data not shown).

Example 5 Binding of CD3 Nanobodies to human TCR/CD3 expressed on CHO-K1 cells and to purified primary human T cells

[0505] Binding of purified monovalent CD3 Nanobodies to human TCR(2XN9)/CD3 expressed on CHO-K1 cells and to purified primary human T cells was evaluated in flow cytometry as outlined in Example 4.1. Dilution series of CD3 Nanobodies 117G03 (cluster A), 60E11 (cluster B), 33G03 (cluster C), 11A10 (cluster D), 52G04 (cluster E) and 50A11 (cluster F) starting from 1 μ M were applied to the cells.

[0506] The results are shown in Figure 2.

[0507] Nanobodies clearly bound to human TCR/CD3 expressed on CHO-K1 cells. The cluster A representative showed the best affinity, followed by the cluster B, C, F, D and E representatives.

[0508] Nanobodies bound to purified primary human T cells although with slightly lower potency compared to the CHO-K1 human TCR(2XN9)/CD3 cells. The representative of cluster A showed the best affinity on human primary T cells, in line with the data on the CHO-K1 (2XN9)/CD3. The EC₅₀ values obtained from the dose response curve are represented in Table 1.

Table 1: EC₅₀ (M) of anti-CD3 monovalent Nanobodies to CHO-K1 human TCR(2XN9)/CD3 cells and to purified primary T cells as determined in flow cytometry.

Cluster	sample ID	CHO-K1TCR(2XN9)/CD3			Primary human T cells		
		EC ₅₀ (M)	95% LCI	95% UCI	EC ₅₀ (M)	95% LCI	95% UCI
A	T0170117G03	1.8E-09	1.4E-09	2.3E-09	2.2E-08	1.8E-08	2.8E-08
B	T0170060E11	1.4E-08	1.3E-08	1.6E-08	3.4E-08	1.6E-08	7.0E-08
C	T0170033G03	>1E-07	/	/	>1E-07	/	/
D	T0170011A10	>1E-07	/	/	>1E-07	/	/
E	T0170052G04	No binding			>1E-07	/	/
F	T0170050A11	1.5E-08	3.5E-09	6.3E-08	5.6E-08	3.4E-08	9.2E-08

Example 6 Determination of binding epitope

[0509] Binding to human TCR(2IAN)/CD3 expressed on HEK293H cells was evaluated and compared with the binding to HEK293H human CD3 cells in flow cytometry as outlined in Example 5. Dilution series of CD3 Nanobodies starting from 1 μ M were applied to the cells. The parental HEK293H cell line was included as TCR/CD3 negative cell line.

[0510] The results are shown in *Figure 3*.

[0511] Binding to HEK293H transfected with human CD3 was observed for all Nanobodies. In addition, some Nbs showed binding to HEK293H transfected with human TCR/CD3. No binding to the HEK293H parental cell lines was observed. The EC₅₀ values obtained from the dose response curve are depicted in Table 2.

Table 2: EC₅₀ (M) of anti-CD3 monovalent Nanobodies to human TCR(2IAN)/CD3 or human CD3 expressed on HEK293H as determined in flow cytometry.

Cluster	sample ID	HEK293H CD3				HEK293H TCR(2IAN)/CD3			
		EC50 (M)	95% LCI	95% UCI	MCF at 1 μ M/top	EC50 (M)	95% LCI	95% UCI	MCF at 1 μ M/top
A	T0170117G03	NT	/	/	/	NT	/	/	/
A	T0170075G11	8.4E-08	3.8E-08	1.8E-07	47652	2.0E-08	1.7E-08	2.4E-08	89865
B	T0170060E11	6.1E-09	5.2E-09	7.0E-09	115329	no fit	/	/	13708
C	T0170033G03	2.9E-08	1.1E-08	7.5E-08	68578	no fit	/	/	6694
D	T0170011A10	>1E-07	/	/	3303	>1E-07	/	/	15882
E	T0170052G04	>1E-07	/	/	2852	>1E-07	/	/	4952
F	T0170050A11	1.5E-09	9.8E-10	2.4E-09	106019	no fit	/	/	7457

Example 7 Primary human T cell activation capacity of purified CD3 reactive Nanobodies

[0512] Functionality of purified monovalent CD3 Nanobodies was evaluated in the human T cell activation assay. Goat anti-mouse IgG dynabeads (Life technologies #11033) were coated with mouse anti-flag IgG antibodies (Sigma F1804), (15 μ g/1E7beads). After an incubation period of 2h at 4°C, beads were washed and incubated with a fixed (1 μ g) concentration of purified flag tagged Nanobody for 20 min at 4°C while shaking. Non-coupled Nanobodies were washed away before adding the bead complex together with soluble mouse anti-CD28 antibody (Peliccluster CD28 - Sanquin #M1650) to purified primary human T cells (isolated as described in Example 2.1) from distinct healthy donors.

[0513] In addition, the effect of monovalent CD3 binding by the Nanobodies was evaluated by the incubation of the Nanobody with the purified primary human T cells isolated from distinct healthy donors, without prior capture onto beads, in the presence of anti-CD28 antibody.

[0514] The activation status of the purified primary human T cells was monitored by measuring the CD69 expression in flow cytometry using monoclonal mouse anti-human CD69PE (BD # 557050) after an incubation of 24h at 37°C and 5% CO₂ as described in Example 4.2.

[0515] In conclusion, CD3 Nanobodies showed clear CD69 upregulation after capturing onto anti-mouse IgG dynabeads (*Figure 4A*). None of the CD3 reactive Nanobodies, when applied in solution were able to activate purified primary human T cells as measured by increased expression of CD69 (*Figure 4B*).

Example 8 Binding of bispecific CD3 polypeptides to human T cell receptor complex expressed on cells

[0516] To demonstrate that redirection of engaged T cells to tumour cells is possible by the Nanobodies, the CD20 antigen was chosen as exemplary tumour target.

[0517] Different CD3 building blocks (i.e. Nanobodies) were formatted into a bispecific construct with a human CD20 targeting Nanobody (see Table 3). The effector and tumour Nanobodies were genetically linked with 35GS linker and

subsequently expressed in the yeast *Pichia* according to standard protocols (bispecific polypeptides).

[0518] Irrelevant constructs were generated by replacing the effector or tumour Nanobody with an irrelevant anti-egg lysozyme (cablys) Nanobody (Table 3).

Table 3: Sample ID and description of bispecific constructs

Cluster	Target Nb x Effector Nb		Effector Nb x Target Nb	
	Clone ID	Description	Clone ID	Description
C	T017000016	20CD019C07-35GS-T0170033G03-FLAG3-HIS6	T017000021	T0170033G03-35GS-20CD019C07-FLAG3-HIS6
C	T017000059	20CD019C07-35GS-T0170033G03-FLAG3-HIS6	T017000045	T0170033G03-35GS-20CD019C07-FLAG3-HIS6
D	T017000017	20CD019C07-35GS-T0170011A10-FLAG3-HIS6	T017000022	T0170011A10-35GS-20CD019C07-FLAG3-HIS6
/	T017000006	20CD019C07-5GS-cAbLys3-FLAG3-HIS6		
/	T017000018	20CD019C07-35GS-cAbLys3-FLAG3-HIS6	T017000023	cAbLys3(D1E)-35GS-20CD019C07-FLAG3-HIS6
C			T017000024	T0170033G03-35GS-cAbLys3-FLAG3-HIS6
D			T017000027	T0170011A10-35GS-cAbLys3-FLAG3-HIS6
D	T017000061	20CD019C07-35GS-T0170011A10-FLAG3-HIS6	T017000047	T0170011A10-35GS-20CD019C07-FLAG3-HIS6
F	T017000057	20CD019C07-35GS-T0170050A11-FLAG3-HIS6	T017000043	T0170050A11-35GS-20CD019C07-FLAG3-HIS6
E	T017000056	20CD019C07-35GS-T0170052G04-FLAG3-HIS6	T017000048	T0170052G04-35GS-20CD019C07-FLAG3-HIS6
A	T017000066	20CD019C07-35GS-T0170061D09-FLAG3-HIS6	T017000072	T0170061D09-35GS-20CD019C07-FLAG3-HIS6
A	T017000071	20CD019C07-35GS-T0170061F07-FLAG3-HIS6	T017000034	T0170061F07-35GS-20CD019C07-FLAG3-HIS6
A	T017000052	20CD019C07-35GS-T0170061F04-FLAG3-HIS6	T017000039	T0170061F04-35GS-20CD019C07-FLAG3-HIS6
A	T017000062	20CD019C07-35GS-T0170117G03-FLAG3-HIS6	T017000036	T0170117G03-35GS-20CD019C07-FLAG3-HIS6
B	T017000053	20CD019C07-35GS-T0170060E11-FLAG3-HIS6	T017000040	T0170060E11-35GS-20CD019C07-FLAG3-HIS6

[0519] Binding of the bispecific constructs to human TCR/CD3 expressed on CHO-K1 cells, purified primary human T cells and human CD20 positive Ramos cells (ATCC: CRL-1596) was evaluated in flow cytometry as outlined in Example 5 and is presented in Figure 5.

[0520] The EC₅₀ values obtained from the dose response curve are depicted in Table 4.

Table 4: EC₅₀ (M) of anti-CD3 monovalent Nanobodies to CHO-K1 human TCR(2XN9)/CD3, primary human T cells and Ramos cells as determined in flow cytometry.

Cluster	sample ID	CHO-KL huTCR(2XN9)/CD3			hu T cells			Ramos		
		EC ₅₀ (M)	95% LCI	95% UCI	EC ₅₀ (M)	95% LCI	95% UCI	EC ₅₀ (M)	95% LCI	95% UCI
A	T017000062	1.5E-07	1.1E-07	2.1E-07	8.9E-08	7.2E-08	1.1E-07	1.9E-09	1.8E-09	2.1E-09
A	T017000036	7.6E-09	5.9E-09	9.6E-09	3.5E-08	2.8E-08	4.4E-08	2.1E-08	1.9E-08	2.3E-08
B	T017000053	1.5E-07	1.3E-07	1.7E-07	>1E-07	/	/	1.8E-09	1.6E-09	2.0E-09
B	T017000040	1.6E-07	1.5E-07	1.8E-07	>1E-07	/	/	3.2E-08	2.9E-08	3.7E-08
C	T017000016	>1E-07	/	/	>1E-07	/	/	1.5E-09	1.4E-09	1.6E-09
C	T017000021	>1E-07	/	/	5.4E-08	4.0E-08	7.3E-08	4.7E-09	4.4E-09	5.0E-09

[0521] The data indicate similar binding of the CD3xCD20 bispecific Nanobody (dotted line) compared to their monovalent counterparts, but a reduced binding of the CD20xCD3 bispecific Nanobody (full line) compared to their monovalent counterparts to CHO-K1 human TCR(2XN9)/CD3 cells and to primary human T cells. On the human CD20 Ramos cell, the bispecific CD3 Nanobodies with the CD20 at the C terminus showed reduced binding.

Example 9 Functional Characterization of bispecific CD20xCD3 polypeptides in flow cytometry based killing assay

[0522] In order to assess whether bispecific polypeptides were able to kill tumour cells, cytotoxicity assays were performed with isolated human T cells as effector cells.

[0523] Human T cells were isolated as described in Example 2.1. The quality and purity of the purified human T cells was checked with anti-CD3 (eBioscience # 12-0037-73); anti-CD8 (BD Bioscience #345775); anti-CD4 (BD Bioscience #345771); anti-CD45RO (BD Bioscience #555493); anti-CD45RA (BD Bioscience # 550855) and anti-CD19 (BD Bioscience #555413), anti-CD25 (BD Pharmigen #557138), anti-CD69 (BD Pharmigen #557050) fluorescently labelled antibodies in a flow cytometric assay. Human CD20 expressing Ramos cells and human CD20 expressing Raji cells (ECACC: 85011429), labelled with the PKH-26 membrane dye as described above were used as target cells. 2.5×10^5 effector and 2.5×10^4 target cells were co-incubated in 96-well V-bottom plates at an effector versus target ratio of 10:1. For measurement of the concentration-dependent cell lysis, serial dilutions of bispecific polypeptides (Table 3) were added to the samples and incubated for 18 h in a 5% CO₂ atmosphere at 37°C. After incubation, cells were pelleted by centrifugation and washed with FACS buffer. Subsequently, cells were resuspended in FACS buffer supplemented with 5 nM TOPRO3 (Molecular Probes cat# T3605) to distinguish live from dead cells. Cells were analysed using a FACS Array flow cytometer (BD Biosciences). Per sample, a total sample volume of 80 µl was acquired. Gating was set on PKH26 positive cells, and within this population the TOPRO3 positive cells were determined.

[0524] The CD3 bispecific polypeptides showed dose dependent killing of the Ramos cells (Figure 6A). T017000045 (cluster C, T0170033G03-35GS-20CD019C07-FLAG3-HIS6) showed a dose dependent killing on both Ramos (Figure 6A) and Raji (Figure 6B) cells confirming that the observed cytotoxic effect was not restricted to a single tumour cell line. The expression level of the tumour antigen, CD20, was determined for both cell lines (Figure 7).

[0525] The IC₅₀ values and the % lysis obtained from the dose response curve are depicted in Table 5 (% lysis = % death cells at 500nM of Nanobody minus % dead cells of the no Nanobody control).

Table 5: Average IC₅₀ (M) of the bispecific constructs in the flow cytometry based purified primary human T cell mediated Ramos killing assay using an effector to target ration of 10 to 1.

Cluster	ID monovalent Nb	ID construct (CD20xCD3)	n	IC ₅₀ (M)	%lysis	%lysis (stdev)	ID construct (CD3xCD20)	n	IC ₅₀ (M)	%lysis	%lysis (stdev)
A	T0170117G03	T017000062	6	3.9E-09	22	7	T017000036	3	5.5E-09	26	6
B	T0170060E11	T017000053	2	7.0E-09	22	3	T017000040	3	6.8E-09	29	5
C	T0170033G03	T017000016	2	9.2E-09	4	2	T017000045	1	/	0	
D	T0170011A10	T017000061	2	2.9E-08	13	0	T017000047	0			
E	T0170052G04	T017000056	2	1.5E-08	4	6	T017000048	0			
F	T0170050A11	T017000057	2	1.4E-09	3	4	T017000043	0			

[0526] These results demonstrate that the CD3 bispecific polypeptides can induce T cell mediated killing of tumour target positive cell lines. When either the targeting Nanobody or the effector Nanobody was replaced by an irrelevant no effect on the viability of the Ramos cells could be observed. There was no clear preference of the orientation between the individual binding blocks in the bispecific polypeptide.

Example 10 Functional Characterization of bispecific CD20xCD3 polypeptides in an xCELLigence based killing assay

[0527] The CD3 multispecific polypeptides (Table 3) were also tested for their cell toxicity on human CD20 transfected adherent target cells in the presence of human effector T cells using real-time electrical impedance based technique. Here, fluctuations in impedance induced by the adherence of cells to the surface of an electrode were measured. T cells are non-adherent and therefore do not impact the impedance measurements.

[0528] In brief, the xCELLigence station was placed in a 37°C incubator at 5% CO₂. 50 µl of assay medium was added to each well of E-pate 96 (ACEA Biosciences; cat#05 232 368 001) and a blank reading on the xCELLigence system was performed to measure background impedance in absence of cells. Subsequently, human CD20 transfected CHO-K1 or CHO-K1 parental cells (1×10⁴) were seeded onto the E-plates 96, and 50µl of a serial dilution of Nanobody was added. After 30 min at RT 50µl of human T cells were added per well (3×10⁵) to have an effector to target ratio of 30:1. The plate was placed in the xCELLigence station and impedance was measured every 15 min during 3 days. The data were analysed 44h after start of the assay.

[0529] The IC₅₀ values are depicted in Table 6.

[0530] The multispecific polypeptides showed tumour antigen dependent killing, they induced a dose dependent human T cell mediated killing of the human CD20 transfected CHO-K1 cells (Figure 8) but the constructs were not able to induce T cell mediated killing of CHO-K1 parental cells (Figure 9).

Table 6: Average IC₅₀ (M) of the multispecific constructs in the xCELLigence based human T cell mediated CHO-K1 CD20 killing assay using an effector to target ration of 30 to 1, analysed of 44h after seeding.

Cluster	ID monovalent Nb	sample ID (CD20xCD3)	n	IC ₅₀ (M)	sample ID (CD3xCD20)	n	IC ₅₀ (M)
A	T0170117G03	T017000062	5	7.88E-10	T017000036	2	1.04E-09
B	T0170060E11	T017000053	2	2.81E-10	T017000040	2	4.89E-10
C	T0170033G03	T017000016	3	6.81E-12	T017000021	2	1.52E-10

[0531] These results confirm the outcome obtained in the flow cytometry based killing assay of Example 9. In addition, only when the tumour target antigen is present T cell mediated killing was observed, indicating that the bispecific polypeptides are critically dependent on their target for induction of cytotoxicity.

Example 11 Linker length evaluation of the bispecific polypeptides

[0532] To evaluate the impact of the linker length used in the CD20/CD3 bispecific polypeptides on the cytotoxic capacity, the effector and tumour Nanobodies were genetically linked with a 5GS, 9GS or 35GS linker and subsequently expressed in Pichia according to standard protocols (see Table 7).

Table 7: Sample ID and description of bispecific constructs to evaluate impact of linker length

Target Nb x Effector Nb			Effector Nb x Target Nb	
Cluster	Clone ID	Description	Clone ID	Description
C	T017000004	20CD019C07-SGS-T0170033G03-FLAG3-HIS6		
D	T017000005	20CD019C07-5GS-T0170011A10-FLAG3-HIS6		
C	T017000010	20CD019C07-9GS-T0170033G03-FLAG3-HIS6	T017000020	T0170033G03-9GS-20CD019C07-FLAG3-HIS6
D	T017000011	20CD019C07-9GS-T0170011A10-FLAG3-HIS6	T017000026	T0170011A10-9GS-20CD019C07-FLAG3-HIS6
C	T017000016	20CD019C07-35GS-T0170033G03-FLAG3-HIS6	T017000021	T0170033G03-35GS-20CD019C07-FLAG3-HIS6
D	T017000017	20CD019C07-35GS-T0170011A10-FLAG3-HIS6	T017000022	T0170011A10-35GS-20CD019C07-FLAG3-HIS6
/	T017000006	20CD019C07-5GS-cAbLys3-FLAG3-HIS6		
/	T017000012	20CD019C07-9GS-cAbLys3-FLAG3-HIS6		
/	T017000018	20CD019C07-35GS-cAbLys3-FLAG3-HIS6	T017000023	cAbLys3(D1E)-35GS-20CD019C07-FLAG3-HIS6
C			T017000024	T0170033G03-35GS-cAbLys3-FLAG3-HIS6
D			T017000027	T0170011A10-35GS-cAbLys3-FLAG3-HIS6

[0533] The impact of the linker length used in the CD20/CD3 bispecific polypeptides on the human primary effector T cell induced cellular toxicity on the adherent CHO-K1 human CD20 target was evaluated using real-time electrical impedance based technique as described in Example 9.

[0534] The results are summarized in *Figure 10*.

[0535] All bispecific polypeptides, i.e. all linker lengths demonstrated specific cell killing. Little difference in potency was observed between the different linkers 9GS and 35GS linker for these bispecific polypeptides.

Example 12 Effector to target ratio evaluation of the CD3 bispecific polypeptides

[0536] To evaluate the effect of different effector to target (E:T) ratios on the killing properties of the Nanobodies, CD20xCD3 bispecific polypeptides were incubated with 2.5×10^4 PKH labelled Ramos cells in the presence of respectively 2.5×10^5 (E:T=10:1), 1.25×10^5 (E:T=5:1), 5×10^4 (E:T=2:1), 2.5×10^4 (E:T=1:1), human T cells as described Example 2.

[0537] Exemplary results are shown in *Figure 11*. The IC_{50} values are depicted in Table 8.

Table 8: IC_{50} (M) of the bispecific constructs in the flow cytometry based T cell mediated Ramos killing assay using different effector to target ratio's.

Cluster	ID monovalent Nb	sample ID (CD20xCD3)	E:T	n	IC_{50} (M)	95% LCI	95% UCI	% lysis
A	T0170117G03	T017000062	10	1	7.3E-09	5.2E-09	1.0E-08	15
A	T0170117G03	T017000062	5	1	8.7E-09	5.3E-09	1.4E-08	10
A	T0170117G03	T017000062	2	1	7.1E-09	3.1E-09	1.6E-08	6
A	T0170117G03	T017000062	1	1	2.5E-08	1.9E-09	3.3E-07	2

[0538] The bispecific construct induced killing of the human CD20 target cells at different E:T ratios, even at a ratio of 1:1, after an incubation time of 18h with little difference in potency. Although there is an impact on the E:T ratio on the % lysis, this can also be linked to the incubation time (see below).

Example 13 Time dependent cytolytic activity of CD20/CD3 bispecific constructs in the purified primary human T cell mediated assay in xCELLigence

[0539] To evaluate the impact of incubation time on the killing properties of the CD20×CD3 bispecific constructs, specific lysis of target cells was calculated for different time-points in xCELLigence. In brief, the xCELLigence station was placed in a 37°C incubator at 5% CO₂. 50 µl of assay medium was added to each well of E-pate 96 (ACEA Biosciences; cat#05 232 368 001) and a blank reading on the xCELLigence system was performed to measure background impedance in absence of cells. Subsequently, human CD20 transfected CHO-K1 or CHO-K1 parental cells (1×10⁴) were seeded onto the E-plates 96. After 20h, purified primary human T cells (described *supra*) and either 100nM or 1.5nM bispecific constructs were added, respectively. The cell index (CI) was measured every 15 min during 5 days. Using the normalized CI (The normalized Cell Index - NCI, is calculated by dividing the Cell Index value at a particular time point by the Cell Index value of the time-point when purified primary human T cells were added) specific lysis at different time points of the condition with constructs was calculated in relation to the condition lacking construct. (% specific lysis = ((NCI_{no construct} - NCI_{with construct})/NCI_{no construct}))×100.

[0540] The results are depicted in Figure 12.

[0541] Already one hour after the addition of human primary T cells and the multispecific construct, an increase of the cell index can be observed which clearly increased further upon longer incubation times. The maximal effect was clearly dependent on the incubation time but the obtained IC₅₀ value did not change with increased incubation times. The irrelevant construct did not show any killing of the human CD20 CHO-K1 cells.

Example 14 Exploration of half-life extension

[0542] It was hypothesized that HLE via albumin binding might be suitable to comply with various requirements, including (i) half-life extension (HLE) of the moiety; and (ii) efficacy of the multispecific. Preferably, the HLE function would not impair the penetration of tumours and tissues.

[0543] Alb11, a Nanobody binding to human serum albumin (HSA) was linked to the multispecific CD20×CD3 polypeptides to increase the in vivo half-life of the formatted molecules (WO 06/122787). A number of formats were generated based on the CD20 tumour targeting building block at the N-terminus, the CD3 recruiting building blocks in the middle and the albumin targeting Nanobody at the C-terminus using a 35GS linker and expressed as indicated above. An overview of the explored formats is shown in Table 9.

Table 9: Sample ID and description of HLE constructs

Cluster	Sample ID	Description
A	T017000094	20CD019C07-35GS-T0170117G03-35GS-ALB11-FLAG3-HIS6
B	T017000096	20CD019C07-35GS-T0170060E11-35GS-ALB11-FLAG3-HIS6

[0544] As the binding of HSA to the Alb11 Nanobody might have an impact on the affinity or potency of the HLE constructs, the half-life extended Nanobodies were characterized for binding to CD3 overexpressing CHO-K1 and primary human T cells. In addition, the potency in the functional T cell dependent Ramos B cell killing assay was evaluated in the presence and absence of HSA (described in 14.1 and 14.2 below).

14.1 Impact of human serum albumin on the binding properties

[0545] Analogous to the experiments described in Example 5, binding of half-life extended anti-CD3 multispecific constructs to CHO-K1 human TCR(2XN9)/CD3 cells, primary human T cells and Ramos cells was evaluated in a flow cytometric assay.

[0546] The results are provided in Figure 13. The EC₅₀ values obtained in this assay are listed in Table 10.

Table 10: Table with EC50 values of cell based binding to CHO-K1 human TCR(2XN9)/CD3, primary human T cells and Ramos cells as determined in flow cytometry

Cluster	sample ID	CHO-K1-K1 huTCR (2XN9)/CD3			hu T cells			Ramos		
		EC50 (M)	95% LCI	95% UCI	EC50 (M)	95% LCI	95% UCI	EC50 (M)	95% LCI	95% UCI
A	T017000094	>1E-07	/	/	>1E-07	/	/	1.9E-09	1.7E-09	2.1E-09
B	T017000096	1.6E-07	1.4E-07	1.8E-07	3.2E-08	2.0E-08	5.3E-08	1.7E-09	1.5E-09	1.9E-09

[0547] Comparison of the CD20-35GS-CD3 HLE construct with the non-HLE constructs showed similar binding on all three cell lines tested. The data presented showed that coupling of the Alb11 building block did not influence the binding properties.

14.2 Impact of human serum albumin on potency in human T cell mediated B cell killing Assay

[0548] The functionality of half-life extended anti-CD3 Nanobodies (Table 9) was evaluated in the human T cell mediated Ramos killing assay as described in Example 10 in the presence and absence of 30µM HSA and compared with the functionality of the non-HLE bispecific constructs.

[0549] The results are depicted in Figure 14. The IC₅₀ values obtained in this assay are listed in Table 11.

Table 11: Table with IC50 and % lysis of the CD20×CD3 Nanobodies in the T cell dependent B-cell (Ramos) killing assay to evaluate the effect of HLE

Cluster	sample ID	EC50 (M)	95% LCI	95% UCI	% lysis
A	T017000062	6.4E-10	3.5E-10	1.2E-09	15
A	T017000094	3.2E-09	1.7E-09	6.1E-09	14
A	T017000094	2.0E-09	1.2E-09	3.3E-09	14
A	T017000094 + HSA	2.0E-08	7.0E-09	5.5E-08	7
B	T017000053	1.8E-09	8.9E-10	3.8E-09	12
B	T017000096	3.8E-09	2.1E-09	7.0E-09	15
B	T017000096	2.6E-09	1.5E-09	4.7E-09	16
B	T017000096 +HSA	4.8E-09	1.1E-09	2.0E-08	6

[0550] The results indicate that the inclusion of the albumin targeting Nb in the construct as such did not have an essential impact on the obtained potency or efficacy. Although a minor loss of efficacy/potency was observed in the presence of HSA, the half-life extended CD3 bispecific polypeptides were still potent in tumour cell killing.

Example 15 Functional Characterization of multispecific polypeptides in an xCELLigence based human T cell mediated HER2-Positive Tumour Killing assay

[0551] In order to assess the general applicability of the CD3 building blocks in directing T cells to tumour cells, CD3 building blocks were combined with a different TAA, in this case a Nanobody binding to HER2.

[0552] The anti-CD3 building block was combined with a Nanobody against the HER2 solid tumour antigen in two orientations (Table 12) and characterized in the xCELLigence based human T cell mediated HER2-Positive Tumour Killing assay as described in Example 10 using two HER2 expressing cell lines: SK-BR-3 (ATCC: HTB-30), MCF-7 (ATCC: HTB-22) and a HER2 negative reference cell line, MDA-MB-468 (ATCC HTB-132) as target cell population. Human HER2 expression levels were confirmed using the monovalent anti-HER2 Nanobody HER2005F07 in flow cytometry as described in Example 9 using 100nM of anti-HER2 Nanobody and shown in Figure 15.

Table 12: Sample ID and description of HER2/CD3 constructs

Cluster	Sample ID	Description
A	T017000101	HER2005F07(Q108L)-35GS-T0170117G03-FLAG3-HIS6
A	T017000100	T0170117G03-35GS-HER2005F07(Q108L)-FLAG3-HIS6

[0553] In brief, SKBR3 (4×10^4 cells/well), MDA-MB-468 (4×10^4 cells /well) or MCF-7 (2×10^4 cells /well) were seeded in 96well E-plates and incubated with 6×10^5 cells and 3×10^5 cells human primary T cells (effector target ratio of 15 to 1) in the presence or absence of multispecific constructs and followed over time. Data were analysed after 18h after start of the experiment and shown in *Figure 16*.

[0554] The IC_{50} values obtained in this assay are listed in Table 13.

Table 13: Overview IC_{50} of the HER2/CD3 constructs in the T cell mediated HER2-Positive Tumour Killing assay

xCELLigence based cytotoxicity (readout 18h) - SKBR3 (E/T=15:1)											
Cluster	ID monovalent Nb	ID construct (HER2xCD3)	n	IC_{50} (M)	95% LCI	95% UCI	ID construct (CD3xHER20)	n	IC_{50} (M)	95% LCI	95% UCI
A	T0170117G03	T017000101	1	2.6E-11	2.2E-11	3.1E-11	T017000100	1	9.5E-12	8.1E-12	1.1E-11
xCELLigence based cytotoxicity (readout 18h) - MCF-7 (E/T=15:1)											
Cluster	ID monovalent Nb	ID construct (HER2xCD3)	n	IC_{50} (M)	95% LCI	95% UCI	ID construct (CD3xHER20)	n	IC_{50} (M)	95% LCI	95% UCI
A	T0170117G03	T017000101	1	1.1E-10	7.3E-11	1.8E-10	T017000100	1	6.9E-11	4.5E-11	1.0E-10
xCELLigence based cytotoxicity (readout 18h) - MDA-MB-468(E/T=15:1)											
Cluster	ID monovalent Nb	ID construct (HER2xCD3)	n	IC_{50} (M)	95% LCI	95% UCI	ID construct (CD3xHER2)	n	IC_{50} (M)	95% LCI	95% UCI
A	T0170117G03	T017000101	1	/	/	/	T017000100	1	/	/	/

[0555] The data indicate specific killing of HER2 positive tumour cell lines by directing human primary T cells to the tumour cells via the CD3 Nanobody. Hence, the CD3 building blocks are broadly applicable for directing CTLs to tumours. Despite the large difference in tumour antigen density on SKBR3 and MCF-7 cells, both are efficiently killed by the addition of multispecific Nanobody constructs.

Example 16 Effect of CD20/CD3 polypeptides on $IFN-\gamma$ release by human T cells in the xCELLigence killing assay

[0556] The CD20xCD3 polypeptides were evaluated for their capacity to induce cytokine secretion in the human T cell mediated CHO_K1 human CD20 killing assay based on xCELLigence as described in Example 10. The release of the cytokine $IFN-\gamma$ was measured by ELISA. Briefly, CHO-K1 human CD20 cells were seeded in 96 E plate and after 20h, purified human primary T cells with or without bispecific CD20XCD3/irrelevant constructs were added to the E plates as described in Example 13. 72h after the addition of the human primary T cells/constructs to the E-plates, $IFN-\gamma$ production by the human primary T cells was measured. Maxisorp 96-well ELISA plates (Nunc) were coated with anti-human $IFN-\gamma$ antibody (BD Bioscience #551221). After overnight incubation, plates were washed and blocked with PBS + 2% BSA for 1h at room temperature. Next, plates were incubated with 100 μ l of the supernatants (2 fold diluted) and 1 μ g/ml biotinylated anti-human $IFN-\gamma$ antibody (BD Bioscience, #554550) 2h 30min while shaking, washed again and incubated with streptavidin-HRP (Dakocytomation #P0397). After 30 min, TMB One Solution (Promega #G7431) was added. The reaction was stopped with 2M H_2SO_4 and the Nanobody dose dependent production of $IFN-\gamma$ was determined by measurement the OD at 405nm using the Tecan sunrise 4.

[0557] The results are shown in *Figure 17*. The EC_{50} values obtained in this assay are listed in Table 14.

Table 14: EC_{50} (M) of the CD20/CD3 dependent $IFN-\gamma$ secretion by human T cells in the human T cell mediated xCELLigence based killing assay.

ID monovalent Nb	ID construct (CD20xCD3)	n	EC_{50} (M)	95% LCI	95% UCI
T0170117G03	T017000062	1	6.2E-10	5.3E-10	7.5E-10
T0170060E11	T017000053	1	9.1E-10	7.2E-10	1.1E-09

[0558] The bispecific CD20/CD3 polypeptide showed a dose dependent production of IFN- γ . Incubation with the irrelevant construct or the condition without bispecific construct did not induce any IFN- γ production.

Example 17 *In vivo* proof-of-concept in a PBMC B cell depletion model

[0559] In this B-cell depletion model, human PBMC were injected intraperitoneally to NOG mice. PBMC-derived B cell killing by polypeptide-mediated recruitment of T cells present in the PBMC population was evaluated reflecting the potential of multispecific polypeptides to activate T cells by direct linkage of T cells via CD3 to target B cells via CD20, resulting in target cell killing.

[0560] The *in vivo* efficacy of a CD3/CD20 multispecific polypeptides (T017000084, CD20xCD3 binding, cluster A) on B cell depletion in a PBMC NOG mouse model was evaluated and compared with the irrelevant polypeptide T017000088. The study demonstrated a clear effect on PBMC-derived B cell depletion in spleen.

[0561] In detail, the B cell depletion was evaluated in mice, intraperitoneally injected with 3×10^7 PBMCs in 500 μ L of PBS at day 3 (D3) after a whole body irradiation of mice with a γ -source (1.44 Gy, 60Co) on day 0 (D0) and randomization of the mice into groups each of 12 animals. The treatment started on D3 one hour after PBMC injection and was repeated for 5 consecutive days, in total until day 7 (D7) (Figure 18). One dose level of the CD3/CD20 binding NB was tested (24mg/kg).

[0562] On day 18 (D18), mice were sacrificed and the spleen was collected for FACS analysis (mCD45, hCD45, hCD19, hCD20) to analyze and quantify the presence of PBMC-derived human B cells (hCD19+ hCD20+ hCD45+ mCD45-).

[0563] Results for PBMC-derived B cell depletion are represented in Figure 19. In the spleen, B cell counts in the group treated with T017000084 were clearly different from the irrelevant polypeptide-treated group at the dose level tested. The dose is estimated to be on the maximum effect.

[0564] In conclusion, these results demonstrate that CD3/CD20 binding multispecific polypeptides are clearly able to decrease PBMC-derived B cells in spleen in this model. This confirmed the polypeptide-induced T cell activation by cross-linking T cells to target B cells and killing of the latter.

Example 18: *In vivo* proof-of-concept in a Ramos B-cell depletion model

[0565] In this B-cell depletion model, Ramos cells (a Burkitt's lymphoma cell line) and human PBMC were injected respectively intravenously and intraperitoneally to NOG mice. Ramos B cell and PBMC-derived B cell killing by polypeptide-mediated recruitment of T cells present in the PBMC population was evaluated reflecting the potential of multispecific polypeptides to activate T cells by direct linkage of T cells via CD3 to target B cells via CD20, resulting in target cell killing.

[0566] The *in vivo* efficacy of the multispecific polypeptide T017000084 (CD20xCD3 binding) on B cell depletion in a Ramos NOG mouse model was evaluated and compared with the irrelevant bispecific polypeptide T017000088 (irrelevant Nanobody + CD3 binding Nanobody). The study demonstrated a statistically significant effect in bone marrow and spleen on Ramos B-cell depletion and on PBMC derived B cell depletion in spleen.

[0567] In detail, the B cell depletion was evaluated in mice, intravenously injected with 10^6 Ramos cells in 200 μ L of Roswell Park Memorial Institute (RPMI) medium 1640 at day one (D1). This injection took place 24 hours after a whole body irradiation of mice with a γ -source (1.44 Gy, 60Co) (D0). 10^7 PBMCs (500 μ L in PBS) were injected on D3 (*i.e.* two days after tumor cell injection) after randomization of the mice into groups each of 12 animals. The treatment started on D3 one hour after PBMC injection and was repeated for 5 consecutive days in total until D7 (Figure 20). One dose level of the CD3/CD20 binding polypeptide was tested (24mg/kg).

[0568] On D20 or on D21, mice were sacrificed and spleen and bone marrow (femur) were collected for FACS analysis (mCD45, hCD45, hCD19, hCD20, hCD10) to analyze and quantify the presence of Ramos B cells (hCD19+ hCD20+ hCD45+ mCD45 -hCD10+) and PBMC-derived B cells (hCD19+ hCD20+ hCD45+ mCD45- hCD10-).

[0569] Results for Ramos B cell depletion are represented in Figure 21. Mice treated with an irrelevant bispecific polypeptide were considered as control group for analyses. Statistical analysis has been performed with F-tests from the mixed-effects ANOVA analysis. For the bone marrow and spleen, B cell counts in the group treated with T017000084 were statistically significantly different from the irrelevant polypeptide-treated group at the tested dose level. In the spleen, the dose is close to or estimated to be on the maximum effect.

[0570] Results for PBMC-derived B cell depletion are represented in Figure 22. Both in bone marrow and in spleen, a statistically significant difference in human B cell numbers was seen for T017000084 versus the irrelevant polypeptide at the tested dose level. The dose is estimated to be on the maximum effect.

[0571] In conclusion, these results demonstrate that CD3/CD20 bispecific polypeptides are able to significantly decrease Ramos B cells and PBMC-derived B cells in spleen and bone marrow in this model. This confirms the Nanobody-induced T cell activation by cross-linking T cells to target B cells and killing of the latter.

Example 19 Targeting of tumour cells with multispecific T cell engaging polypeptides

[0572] The therapeutic activity of T cell engaging strategy can be improved by the simultaneous targeting of multiple tumour associated antigens. Often tumour cells create an escape mechanism by the down-regulation of targeted antigens within a therapy. The simultaneous targeting of multiple antigens is likely to reduce the probability of generating tumour escape variants. The individual affinity of the respective tumour targeting Nanobodies may be varied such that preferable binding to either a single marker or simultaneous binding to both tumour markers is achieved. Antigens present on different cell populations can be combined or even soluble proteins can be targeted in combination with a tumour associated antigen.

[0573] As the Nanobody platform is ideally suited to combine different specificities into a multispecific format, the CD3 Nanobodies of the invention are combined into formats illustrating these concepts, i.e. with different tumour antigen binding Nanobodies in a multispecific polypeptide.

[0574] For the double tumour antigen targeting concept, a Nanobody reactive towards a first tumour antigen (TA1, e.g. CEA) is linked to a second Nanobody with different specificity (TA2, e.g. EGFR), different from TA1, in combination with a CD3 reactive Nanobody. The specific order of the building blocks is varied within the format as well as the applied linker lengths in between the different building blocks. Combinations of TA1 and TA2 which are tested are depicted in Table 15.

Table 15: Combination of CD3, TA1, TA2 and Alb binding building blocks in multispecific polypeptides.

T-cell ISV	TA1 ISV	TA2 ISV	ALB-ISV
CD3	CEA	Irr	+
CD3	CEA	Irr	-
CD3	CEA	EGFR	+
CD3	CEA	EGFR	-
CD3	Irr	EGFR	+
CD3	Irr	EGFR	-

[0575] In order to test half-life extension, an albumin binding Nanobody is included as well in the polypeptides as set out in Table 15.

[0576] To demonstrate the specific killing, a mixed cell culture assay system is used where TA1 single positive (e.g. MC38-huCEA or MKN45) and TA2 single positive tumour cells (e.g. Hela or Her14) are co-incubated. The expression level of the respective tumour antigens was determined in different cell lines and is represented in Figure 23. Upon addition of the polypeptides of the invention, primary human T cells and albumin if required, the T cell mediated cytotoxicity is monitored based on a cytometric read out. A comparison is made with respect to double negative cells or formats containing one or more irrelevant Nanobodies.

[0577] In order to verify the specific killing, the induced killing of double positive tumour (for TA1 and TA2, e.g. LS174T or LoVo) cells is compared with the induced killing of single positive tumour cells. For this, a T cell mediated cytotoxicity assay is used as described above with a single type of tumour cells positive for both markers (cf. Example 17).

Example 20 Targeting of tumour cells with multispecific T cell engaging polypeptides

[0578] As mentioned above, the therapeutic activity of T cell engaging strategy can be improved by the simultaneous targeting of multiple tumour associated antigens. Not only tumour cells create an escape mechanism by the down-regulation of targeted antigens within a therapy, but also by introducing (point-)mutations. Also in this case, simultaneous targeting of multiple epitopes on an antigen is likely to reduce the probability of generating tumour escape variants. Moreover, targeting multiple epitopes on a single antigen can increase the affinity of binding (avidity effect).

[0579] As the Nanobody platform is ideally suited to combine different specificities into a multivalent format, the anti-CD3 Nanobodies of the invention are combined into formats illustrating these concepts, i.e. with different tumour antigen binding Nanobodies in a multispecific polypeptide.

[0580] For the multivalent tumour antigen targeting concept, two Nanobodies reactive towards an antigen are linked (TA1 and TA2, respectively), followed by a CD3 reactive Nanobody. The specific order of the building blocks is varied within the format as well as the applied linker lengths in between the different building blocks. Combinations of TA1 and TA2 which are tested are depicted in Table 16.

Table 16: Combination of CD3, TA1, TA2 and Alb binding building blocks in multispecific polypeptides.

T-cell ISV	TA1 ISV	TA2 ISV	ALB-ISV
CD3	EGFR-1 (7D12)	EGFR-2 (9G08)	+
CD3	EGFR-1 (7D12)	EGFR-2 (9G08)	-
CD3	Her2-1 (5F07)	Her2-2 (47D05)	+
CD3	Her2-1 (5F07)	Her2-2 (47D05)	-

[0581] In order to test half-life extension, an Alb Nanobody is included as well in the polypeptides as set out in Table 16.

[0582] The potency and efficacy of these multivalent formats is evaluated and compared with the respective bispecific formats in an in vitro tumour cell killing assay comparable to the assay described in Example 10 but with the relevant cell lines (e.g. Hela, Her14, Ls174T, SKBR3, MCF7). Additionally, the effector-target ratio is varied such that an estimate is made whether a multivalent/multispecific polypeptide has a higher efficacy with lower effector target ratios.

TABLES

[0583]

Table A- 1: Sequence alignment of CD3 cluster A binders

T0170PMP117G03 :	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAILVW SGGNTYYEDSVKGRFTISRDNAKNTMYLQMTSLKPEDSATYYCAAKIRPYIFKI- AGQYDYWGQGQTQVTVSS
T0170PMP061F04 :	A..S.....D....F.....
T0170PMP081D02 :	5...L...N...T.L..... A..S.....D....F.....SV..L..N...T.L.....
T0170PMP120D07 :	A.....D....F.....S..L..NE..T.L.....
T0170PMP118D11 :	A.....D....F.....S..L..NE.G.T.L..... L.....
T0170PMP062A11 :	A.....D....F..... 5...LS.H.N...T.V.....
T0170PMP118A08 :	...P.....A.....D....F.....
T0170PMP122C07 :	5...LS.H.N...T.V..... A.....D....F.....
T0170PMP062D09 :	5...LS.HAN...T.V.....L... S..N.....D.S.F.....S.I..N..T.V.....L
T0170PMP062G08 :	N...A..S..G...T.E.A..F.....L..N...T.L..... L.....
T0170PMP126E04 :	N...A..S.....T.E.A..F.....L..N...T.L..... L.....
T0170PMP116E01 :	N...A..S.....T.E.A..FR.....L..N...T.L..... L.....
T0170PMP117E03 :	N.R...A..S.....T.E.A..F.....L..N...T.L..... L.....
T0170PMP062B10 :	S...A..S.....T.E.A..F.....L..M...T.L..... L.....
T0170PMP118E11 :	N...A..S.....T.E.A..F.....L..N...T.L...T.....
T0170PMP075A10 :	D...A..S.....T.E.A..F.....L..N...T.L.....
T0170PMP062C06 :	N...GA..S.....T.E.A..F.....L..N...T.L.....

55 50 45 40 35 30 25 20 15 10 5

(continued)

T0170PMP112G06 : N...A...S...T.E.A...F...L...N.R...T.L...
 T0170PMP061A09 : L...T...N...A...P...T.E.P...F...L.R.R.E...T.L...
 T0170PMP061B06 : T...N...A...P...T.E.P...F...L.R.R.E...T.L...
 T0170PMP111C01 : T...N...A...P...T.E.P...F.A...L.R.R.E...T.L...
 T0170PMP061D06 : T...N...A...P...T.E.P...F...L.R.R.E...T.L...
 T0170PMP061E09 : T...N...A...P...T.E.P...F...L.R.R.E...T.L...V...
 T0170PMP078A07 : T...N.R...A...P...T.E.P...F...L.R.R.E...T.L...
 T0170PMP061A04 : T...V...A...P...T.E...F...L...G...T.L...P...
 T0170PMP115A03 : T...V...A...P...T.E...F...L...T.L...P...
 T0170PMP061F09 : P...T...V...A...P...T.E...F...L...T.L...P...
 T0170PMP112D04 : T...V...A...P...G...T.E...F...L...T.L...P...
 T0170PMP114E06 : T...V.P...A...P...T.E...F...L...T.L...P...
 T0170PMP113G04 : T...V...A...P...T.E...F...L...A...T.L...P...
 T0170PMP061D09 : L.T...V...A...P...T.E...F...L...T.L...P...
 T0170PMP062G05 : T...V...A...P...T.E...F...S.L...T.L...P...
 T0170PMP114C05 : T...V...A...P...T.E...L...L...T.L...P...
 T0170PMP117G05 : T...V...A...P...T.E...F...L...T.L...VP...
 T0170PMP061F07 : F...A...P...T.E...F...L...T.L...L...

5
10
15
20
25
30
35
40
45
50
55

(continued)

T0170PMP061C09 :
T0170PMP124E06 :
T0170PMP111B02 :
T0170PMP062E08 :
T0170PMP062G03 :

T0170PMP062G10 :

T0170PMP078E10 :

T0170PMP115E06 :

T0170PMP122B02 :

T0170PMP061D07 :

T0170PMP126D09 :
T0170PMP126B03 :
T0170PMP126B02 :
T0170PMP075G11 :
T0170PMP080E07 :

..... R..... D.....
..... A..... R..... D..... L.....
..... R..... R..... D..... P.....
..... D..... A..... V..... TD..... IT..... L.....
..... F..... D..... A..... V..... TD..... IT..... L.....
.....
..... D..... A..... V..... A.TD..... IT..... L.....
.....
..... D..... A..... V..... TD..... VT..... L.....
..... R..... D..... A..... V..... TD..... IT..... L.....
.....
..... D..... A..... V..... TD.A..... IT..... L.....
.....
..... D..... A..... RV..... TD..... IT.....
.....
..... D..... A..... V..... TD..... IT.....
..... D..... V..... TD..... T..... L.....
K..... D..... V..... TD..... T..... L.....
..... D..... V..... TD..... IT..... H.....
..... L..... A..... V..... TD..... IT.....

5	
10	
15	
20	
25	
30	
35	
40	
45	
50	
55	

Table A- 2: Sequence alignment of CD3 cluster B binders

EVQLVESGGGLVQPGGSLRLSCAASGDIYKSFDMGWYRQAPGKQRDLVA
VIGSRGNNRGRRTNYADSVKGRFTISRDTGTGNTVYLLMNKLRPEDTAIYYCN-
TAPLVAGRPPWGRGTLVTVSS

T0170PMP060E11 :

Table A- 3: Sequence alignment of CD3 cluster C binders

T0170PMP033G03 :	EVQLVESGGSVQAGGSLRLSCAASGRTFSTNPMGWFRQVPGKERELIAAVR-	5
	WADGNTFYADSVKGRFTISRDNAKKTVYLQMNSLKSEDTATYYCAAGRPWSAYHS-	10
	PAEYVHWGGGTQVTVSS	15
	L.....S.....S.....	20
T0170PMP044A09 :	L.....S.....A.....	25
T0170PMP043E10 :	L.....S.....S.....	30
T0170PMP044B10 :	L.....S.....R.....L.....	35
		40
		45
		50
		55

Table A- 4: Sequence alignment of CD3 cluster D binders

EVQLVESGGGLVQGGGSLSCAASGRFTSSYAMAWFRQPPGKEREFVASISWSGENT-
NYRNSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAKIAKTPDNNWYWTKSNNY-
NYWGQGTQVTVSS

T0170PMP011A10:

Table A- 5: Sequence alignment of CD3 cluster E binders

T0170PMP052G04 :	EVQLVESGGGAVQPGGSLRLSCAASGIRISRNMMGMWFRQAPGK	5
	QRDLVARITPGGDTYYVDSVKGRFSISKD-	10
	NAKNTVYLQMNSLKPEDTAVYYCNSYSTLGSWGQGTQVTVSS	
T0170PMP062B02 :	V.....RT.RE.NM.S.A.....DS.D.....	
		
T0170PMP114D01 :	V.....RT.RE.NM.S.A.....DS.D.....	
	L.....	
T0170PMP080F02 :	V.....RT.RG.NM.S.A.....DS.D.....	
		
T0170PMP122A11 :	S.M....	
	S.....R.I.....L.....	
T0170PMP113E06 :	V.....NH.....E.M.S.V.....N.L.....	
	R.....	
T0170PMP061E10 :	V.....THT.....E.EM.Q.S.K.I.T.....F.R.D.....	
	D.....V.L.....	
T0170PMP061D03 :	V.....THT.....E.EM.Q.S.K.I.T.....F.R.D.....	
	D.....V.....	
T0170PMP113E03 :	V.....THT.....E.EM.Q.S.K.I.T.....F.R.D.....	
	DG.....V.....	

Table A- 6: Sequence alignment of CD3 cluster F binders

T0170PMP050A11 :	EVQLVESGGGLVQAGGSLRLSCAASGRSFNMNPLGWFRQSPGKEREFVAAHRWS-	5
	DGNTYYVDSVKGRFTISRDNAKNTVYLQMNSLKSEDTAVYYCAAGRPSAFR-	
	SPGEVYVWGQGTQVTVSS	
T0170PMP044A06 :	T.S.T.M.....N.....A.....A.....K.....SY.D.....	
T0170PMP044D11 :	A.T.M.....FA.....SY.D.....	
T0170PMP043E08 :	A.S.M.....R.....5.....SY.T.....L.....	
T0170PMP043E06 :	A.....ST.M.....F.R.....A.....H.....AH.N.....	
T0170PMP043E07 :	SA.M.....F.....S.....A.....H.....AH.M.....	
T0170PMP039D06 :	G.S.T.M.....A.....H.....DY.A.S.I.....	
T0170PMP044F10 :	R.....G.S.T.M.....A.....H.....D.A.S.I.S.P.....	
T0170PMP044B11 :	A.T.M.....L.V.H.S.T.....YH.N.....L.....	
T0170PMP044C08 :	A.T.M.....	
T0170PMP043B03 :	L.V.H.S.T.....C.....YH.N.....	
	F.....A.S.T.M.....G.V.....S.SA.....VF.....YH.K.....	
	L.....	
T0170PMP039E06 :	D.....A.S.T.M.....S.FVA.....S.....A.....YH.R.I..R.....	
T0170PMP049A04 :	D.....A.S.T.M.....S.FVA.....S.....A.....YH.R.I..R.....	
	L.....	
T0170PMP043F09 :	A.....A.S.T.M.....Q.L.V.A.....T.....A.....K.....L.N.....A.....YHAK.....	
	L.....	
T0170PMP044C11 :	A.....A.S.T.M.....Q.L.V.A.....T.....A.....K.....L.N.....A.....YHAK.I.....	

Table A-7: Amino acid sequences of monovalent anti-CD3 Nanobodies ("ID" refers to the SEQ ID NO as used herein)

Name	ID	Amino acid sequence
T0170PMP117G03	1	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDSVKGRFTISRDNAKNT MYLQMTSLKPEDSATYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP061F04	2	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQSPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTLY LQMTNLKPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP081D02	3	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQSPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSVKNLTLY LQMTNLKPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP120D07	4	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTL YLQMTNLEPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP118D11	5	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTL YLQMTNLEPGDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP062A11	6	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTLS LHMTNLKPEDTAVYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP118A08	7	EVQPVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTL SLHMTNLKPEDTAVYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP122C07	8	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNTLS LHMANLKPEDTAVYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP062D09	9	EVQLVESGGGPVQSGGSLRLSCANSRTYRGYSMAWFRQAPGKEREFVAAIVWSDGNSYYEDFVKGRFTISRDSAKNIM YLQMTNLKPEDTAVYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP062G08	10	EVQLVESGGGPVQAGGSLRLSCANSRTYRGYSMAWFRQSPGKERGFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTL YLQMTNLKPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP126E04	11	EVQLVESGGGPVQAGGSLRLSCANSRTYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTL YLQMTNLKPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS
T0170PMP116E01	12	EVQLVESGGGPVQAGGSLRLSCANSRTYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVGRFTISRDNAKNTL YLQMTNLKPEDTALYYCAAKIRPYIFIKAGQDYWGQGTQVTVSS

(continued)

Name	ID	Amino acid sequence
T0170MMP117E03	13	EVQLVESGGGPVQAGGSLRLSCANSRRTRYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY LQMTNLKPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP062B10	14	EVQLVESGGGPVQAGGSLRLSCASSGRTYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY LQMTNLKPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP118E11	15	EVQLVESGGGPVQAGGSLRLSCANSGRTRYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY YLQMTNLKPEDTALYYCAAKTRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP075A10	16	EVQLVESGGGPVQAGGSLRLSCADSGRTYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY YLQMTNLKPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP062C06	17	EVQLVESGGGPVQAGGSLRLSCANSGRTRYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY YLQMTNLKPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP112G06	18	EVQLVESGGGPVQAGGSLRLSCANSGRTRYRGYSMAWFRQSPGKEREFVAAITWSEGNAYYEDFVKGRFTISRDNAKNTLY YLQMTNLKPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP061A09	19	EVQLVESGGGLVQAGGSLTSCANSGRTRYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFVKGRFTISRDNAKNTLY LRMTRLEPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP061B06	20	EVQLVESGGGPVQAGGSLTSCANSGRTRYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFVKGRFTISRDNAKNTLY LRMTRLEPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP111C01	21	EVQLVESGGGPVQAGGSLTSCANSGRTRYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFAKGRFTISRDNAKNTLY LRMTRLEPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP061D06	22	EVQLVESGGGPVQAGGSLTSCANSGRAYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFVKGRFTISRDNAKNTLY YLRMTRLEPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS
T0170MMP061E09	23	EVQLVESGGGPVQAGGSLTSCANSGRTRYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFVKGRFTISRDNAKNTLY LRMTRLEPEDTALYYCAAKIRPYIFIKVAGQYDYWGQGTQVTVSS
T0170MMP078A07	24	EVQLVESGGGPVQAGGSLTSCANSRRTRYRGYSMAWFRQPPGKEREFVAAITWSEGNPNYYEDFVKGRFTISRDNAKNTLY LRMTRLEPEDTALYYCAAKIRPYIFIKIAGQYDYWGQGTQVTVSS

(continued)

Name	ID	Amino acid sequence
T0170PMP061A04	25	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTGLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP115A03	26	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP061F09	27	EVQPVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP112D04	28	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP114E06	29	EVQLVESGGGPVQTGGSLRLSCVAPGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP113G04	30	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMASLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP061D09	31	EVQLVESGGGLVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTQVTVSS
T0170PMP062G05	32	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKSTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTQVTVSS
T0170PMP114C05	33	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDLVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTQVTVSS
T0170PMP117G05	34	EVQLVESGGGPVQTGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTQVTVSS
T0170PMP061F07	35	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNTYYEDFVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAAKIRPYIFKIPGQYDYWGQGTLLTVSS
T0170PMP061C09	36	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGREREFVAAIVWSDGNTYYEDSVKGRFTISRDNAKNT MYLQMTSLKPEDSATYYCAAKIRPYIFKIPGQYDYWGQGTQVTVSS

(continued)

Name	ID	Amino acid sequence
T0170MP124E06	37	EVQLVESGGGPAQAGGSLRLSCAASGRTYRGYSMGWFRQAPGREREFVAAIVWSDGNTYYEDSVKGRFTISRDNKNT MYLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP111B02	38	EVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRRAPGREREFVAAIVWSDGNTYYEDPVKGRFTISRDNKNT MYLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTQTVSS
T0170MP062E08	39	EVQLVESGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP062G03	40	EVQLVEFGGPPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP062G10	41	EVQLVESGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIAWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP078E10	42	EVQLVESGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTVKNIT MYLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP115E06	43	EVQLVESRGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP122B02	44	EVQLVESGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS
T0170MP061D07	45	EVQLVESGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRFRRVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTM YLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTQTVSS
T0170MP126D09	46	EVQLVSGGGPVQAGDSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDTKNTMY LQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTQTVSS
T0170MP126B03	47	EVQLVESGGGPVQAGDSLRLSCAASGRTYRGYSMGWFRQVPGKEREFVAAIVWTDGNTYYEDSVKGRFTISRDNKNT MYLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYDWGGGTLTVSS

(continued)

Name	ID	Amino acid sequence
T0170PMP126B02	48	KVQLVESGGGPVQAGDSRLSCAASGRTRYGYSMGWFRQVPGKEREFVAAIIVWTDGNTYYEDSVKGRFTISRDNKTNT MYLQMTSLKPEDSATYYCAAKIRPIYIFIKIAGQDYWGQGTLVTVSS
T0170PMP075G11	49	EVQLVESGGGPVQAGDSRLSCAASGRTRYGYSMGWFRQVPGKEREFVAAIIVWTDGNTYYEDSVKGRFTISRDNKTNTM YLHMTSLKPEDSATYYCAAKIRPIYIFIKIAGQDYWGQGTLVTVSS
T0170PMP080E07	50	EVQLVESGGGLVQAGGSLRLSCAASGRAYRGYSMGWFRQVPGKEREFVAAIIVWTDGNTYYEDSVKGRFTISRDNKTNTM YLQMTSLKPEDSATYYCAAKIRPIYIFIKIAGQDYWGQGTLVTVSS
T0170PMP060E11	51	EVQLVESGGGLVQPGGSLRLSCAASGDIYKSFDMGWYRQAPGKQKQDLVAVIGSRGNRGRNTYADSVKGRFTISRDTGTG NTVYLLMNKLRPEDTAIYYCNTAPLVAGRPWGRTLVTVSS
T0170PMP011A10	52	EVQLVESGGGLVQGGGSLSCAASGRFTSSYAMAWFRQPPGKEREFVASISWSENTNYRNSVKGRFTISRDNNAKNTVY LQMNSLKPEDTAVYYCAAKIAKTPDNWYWTKSNNYNYWGQGTQVTVSS
T0170PMP033G03	53	EVQLVESGGGSVQAGGSLRLSCAASGRFTSTNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDNNAKKT VYLQMNSLKSEDTATYYCAAGRPWSAYHSPAEEYVHWGQGTQVTVSS
T0170PMP044A09	54	EVQLVESGGGLVQAGGSLRLSCAASGRFTSTNPMGWFRQSPGKERSLIAAVRWADGNTFYADSVKGRFTISRDNNAKKT VYLQMNSLKSEDTATYYCAAGRPWSAYHSPAEEYVHWGQGTQVTVSS
T0170PMP043E10	55	EVQLVESGGGLVQAGGSLRLSCAASGRFTSTNPMGWFRQSPGKERSLIAAARWADGNTFYADSVKGRFTISRDNNAKKT VYLQMNSLKSEDTATYYCAAGRPWSAYHSPAEEYVHWGQGTQVTVSS
T0170PMP044B10	56	EVQLVESGGGLVQAGGSLRLSCAASGRFTSTNPMGWFRQSPGKERSLIAAVRWADGNTFYADSVKGRFTISRDNNAKKT VYLQMNSLRSEDTATYYCAAGRPWSAYHSPAEEYVHWGQGTQVTVSS
T0170PMP052G04	57	EVQLVESGGGAVQPGGSLRLSCAASGIRISRNMMMGWFRQAPGKQKQDLVARITPGGDTYYVDSVKGRFSISKDNAKNTVY LQMNSLKPEDTAVYYCNSYTLGSGWGQGTQVTVSS
T0170PMP062B02	58	EVQLVESGGGAVQPGGSLRLSCVASGIRISRNMMMGWFRRTPTGRERNMVARISPGGATYYVDSVKGRFSISKDDSKNTVYL QMDSLKPEDTAVYYCNSYTLGSGWGQGTQVTVSS
T0170PMP114D01	59	EVQLVESGGGAVQPGGSLRLSCVASGIRISRNMMMGWFRRTPTGRERNMVARISPGGATYYVDSVKGRFSISKDDSKNTVYL QMDSLKPEDTAVYYCNSYTLGSGWGQGTQVTVSS

(continued)

Name	ID	Amino acid sequence
T0170MP080F02	60	EVQLVESGGGAVQPGGSLRLSCVASGIRISRNMMGWFRRTPGRGRNMVARISPGGATYYVDSVKGRFSISKDDSKNTVY LQMIDSLKPEDTAVYYCNSYSTLGSGWGGGTQTVSS
T0170MP122A11	61	EVQLVESGGGAVQPGGSLRLSCAASGIRISRNMMGWFRQAPGKSRDMVARISPGGDTYYVDSVKGRFSISKDNAKNTVY LQMINSLRPEDITAVYYCNSYSTLGSGWGGGTQTVSS
T0170MP113E06	62	EVQLVESGGGAVQPGGSLRLSCVASGIRISNMMGWFRQAPGEQRDMMVARISPGGDTYYVDSVKGRFSISKDNAKNTV YLMNNLKLEDTAVYYCNSYRTLGSGWGGGTQTVSS
T0170MP061E10	63	EVQLVESGGGVVQPGGSLRLSCAASGIRISTHTMGWFRQAPEKQREMVAQISPGGKTYIDSVKGRFTISKDNAKNTVFL RMNDLKPD DTA VYYCNSYSTLGSGWGGGTQTVSS
T0170MP061D03	64	EVQLVESGGGVVQPGGSLRLSCAASGIRISTHTMGWFRQAPEKQREMVAQISPGGKTYIDSVKGRFTISKDNAKNTVFL RMNDLKPD DTA VYYCNSYSTLGSGWGGGTQTVSS
T0170MP113E03	65	EVQLVESGGGVVQPGGSLRLSCAASGIRISTHTMGWFRQAPEKQREMVAQISPGGKTYIDSVKGRFTISKDNAKNTVFL RMNDLKPDGTAVYYCNSYSTLGSGWGGGTQTVSS
T0170MP050A11	66	EVQLVESGGGLVQAGGSLRLSCAASGRSFNMNPLGWFQRQSPGKEREFVAAHRWSDGNTYYVDSVKGRFTISRDNNAKNT VYLMNSLKSEDTAVYYCAAGR PWSAFRSPGEYVYVWGQGTQTVSS
T0170MP044A06	67	EVQLVESGGGLVQAGGSLRLSCAASGRFTSTNPMGWFRQSPGNEREFVAAHRWSDGNTYYADSVKGRFAISRDNNAKKT VYLMNSLKSEDTAVYYCAAGR PWSYRSPDEYVYVWGQGTQTVSS
T0170MP044D11	68	EVQLVESGGGLVQAGGSLRLSCAASGRAFNTPMGWFRQFAGKEREFVAAHRWSDGNTYYVDSVKGRFTISRDNNAKNT VYLMNSLKSEDTAVYYCAAGR PWSYRSPDEYVYVWGQGTQTVSS
T0170MP043E08	69	EVQLVESGGGLVQAGGSLRLSCAASGRAFSMNPMGWFRQSPGREREFVAAHRWSDGNTYYVDSVKGRFTISRDNNAKNT VYLMSSLKSEDTAVYYCAAGR PWSYRSPTEYVYVWGQGTQTVSS
T0170MP043E06	70	EVQLVESGGGAVQAGGSLRLSCAASGRSFSNPMGWFRQFPRKEREFVAAHRWSDGNTYYADSVKGRFTISRDNNAKHT VYLMNSLKSEDTAVYYCAAGR PWSAAHSPNEYVYVWGQGTQTVSS
T0170MP043E07	71	EVQLVESGGGLVQAGGSLRLSCAASGRSFSANPMGWFRQFPGKERESVAAHRWSDGNTYYADSVKGRFTISRDNNAKHT VYLMNSLKSEDTAVYYCAAGR PWSAAHSPNEYVYVWGQGTQTVSS

(continued)

Name	ID	Amino acid sequence
T0170PMP039D06	72	EVQLVESGGGLVQAGGSLRLSCAASGRGFSTNPMGWFRQSPGKEREFVAAHRWSDGNTYYVDSVKGRFAISRDNAKNT VHLQMNSLKSEDTAVYYCAAGRPWSDYRAPSEYIYWGGGTQVTVSS
T0170PMP044F10	73	EVQLVESGGGLVQAGGSLRLSCAASGRGFSTNPMGWFRQSPGKEREFVAAHRWSDGNTYYVDSVKGRFAISRDNAKNT VHLQMNSLKSEDTAVYYCAAGRPWSDFRAPSEIYSGPGTQVTVSS
T0170PMP044B11	74	EVQLVESGGGLVQAGGSLRLSCAASGRAFNTPMGMWFRQSPGKEREFVAAVRWHDGSTYYTDSVKGRFTISRDNAKNT VYLQMNSLKSEDTAVYYCAAGRPWSAYHSPNEIYVWGGGTQVTVSS
T0170PMP044C08	75	EVQLVESGGGLVQAGGSLRLSCAASGRAFNTPMGMWFRQSPGKEREFVAAVRWHDGSTYYTDSVKGRFTISRDNAKNT VCLQMNSLKSEDTAVYYCAAGRPWSAYHSPNEIYVWGGGTQVTVSS
T0170PMP043B03	76	EVQLVEFGGGLVQAGGSLRLSCAASGRAFNTPMGMWFRQSPGKEREFVAVRWSDGSTYSADSVKGRFTVFRDNAKNT VYLQMNSLKSEDTAVYYCAAGRPWSAYHSPKEIYVWGGGTQVTVSS
T0170PMP039E06	77	EVQLVESGGGLVQAGDLSRLSCAASGRAFNTPMGMWFRQSPGKEREFVAAHRWSDGSTFVADSVKGRFTISRDNAKNT VSLQMNSLKSDTAVYYCAAGRPWSAYHSPREIYVWGRGTQVTVSS
T0170PMP049A04	78	EVQLVESGGGLVQAGDLSRLSCAASGRAFNTPMGMWFRQSPGKEREFVAAHRWSDGSTFVADSVKGRFTISRDNAKNT VSLQMNSLKSDTAVYYCAAGRPWSAYHSPREIYVWGRGTQVTVSS
T0170PMP043F09	79	EVQLVESGGGLVQAGASLRLSCAASGRAFNTPMGMWFRQSPGQEREFVAAVRWADGNTYYTDSVKGRATISRDNAKKT VYLQNNLKSEDAAVYYCAAGRPWSAYHAPKEIYVWGGGTQVTVSS
T0170PMP044C11	80	EVQLVESGGGLVQAGASLRLSCAASGRAFNTPMGMWFRQSPGQEREFVAAVRWADGNTYYTDSVKGRATISRDNAKKT VYLQNNLKSEDAAVYYCAAGRPWSAYHAPKEIYVWGGGTQVTVSS

Table A-8: Sequences for CDRs and frameworks, plus preferred combinations as provided in formula I, namely FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. "ID" refers to the given SEQ ID NO. The first column refers to the SEQ ID NO of the complete ISV, i.e. FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. CDR1, CDR2 and CDR3 were determined according to Kontermann, 2010.

I Na	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
Dme	D	D	D	D	D	D	D
1T0 17 OP MP 11 7G 03	1 EVQLVESGGGPVQ 4 AGGSLRLSCAAS 4	8 GRTRYGY 1 SMG	1 WFRQAPGK 7 ERFVA 4	1 AIVWSG 0 GNTY 1	2 YEDSVKGRFTISRDNKNTM 0 YLQMTSLKPEDSATYYCAA 0	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTVSS 3
2T0 17 OP MP 06 1F 04	1 EVQLVESGGGPVQ 4 AGGSLRLSCAAS 4	8 GRTRYGY 2 SMA	1 WFRQSPGKE 7 REFVA 5	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLY 0 LQMTNLKPEDTALYYCAA 1	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTVSS 3
3T0 17 OP MP 08 1D 02	1 EVQLVESGGGPVQ 4 AGGSLRLSCAAS 4	8 GRTRYGY 2 SMA	1 WFRQSPGKE 7 REFVA 5	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLY 0 LQMTNLKPEDTALYYCAA 2	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTVSS 3
4T0 17 OP MP 12 OD 07	1 EVQLVESGGGPVQ 4 AGGSLRLSCAAS 4	8 GRTRYGY 2 SMA	1 WFRQAPGK 7 ERFVA 4	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLY 0 LQMTNLKPEDTALYYCAA 3	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTVSS 3

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
5T0 1 17 4 0P 4 MP 11 8D 11	EVQLVESGGGPVQ AGGSIRLSCAAS	8 GRTYRGY 2 SMA	1 WFRQAPGK 7 EREFVA 4	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLY 0 LQMTNLEPGDTALYYCAA 4	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 VTVSS 4
6T0 1 17 4 0P 4 MP 06 2A 11	EVQLVESGGGPVQ AGGSIRLSCAAS	8 GRTYRGY 2 SMA	1 WFRQAPGK 7 EREFVA 4	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLS 0 LHMTNLKPEDTAVYYCAA 5	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTSS 3
7T0 1 17 4 0P 5 MP 11 8A 08	EVQPVESGGGPVQ AGGSIRLSCAAS	8 GRTYRGY 2 SMA	1 WFRQAPGK 7 EREFVA 4	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLS 0 LHMTNLKPEDTAVYYCAA 5	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 QVTSS 3
8T0 1 17 4 0P 4 MP 12 2C 07	EVQLVESGGGPVQ AGGSIRLSCAAS	8 GRTYRGY 2 SMA	1 WFRQAPGK 7 EREFVA 4	1 AIVWSD 0 GNTY 2	2 YEDFVKGRFTISRDSAKNTLS 0 LHMANLKPEDTAVYYCAA 6	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 VTVSS 4

(continued)

I Na I	FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
Dme D		I D	I D	I D	I D	I D	I D
9T0 1	EVQLVESGGGPVQ	8 GRTYRGY	1 WFRQAPGK	1 AIVWSD	2 YEDFVKGRFTISRDSAKNIM	1 KIRPYIFKIAGQY	2 WGQGT
17 4	SGGSLRLSCANS	1 SMG	7 EREFVA	0 GNSY	0 YLQMTNLKPEDTAVYYCAA	2 DY	4 VTVSS
0P 6			4	3	7	3	4
MP							
06							
2D							
09							
1T0 1	EVQLVESGGGPVQ	8 GRTYRGY	1 WFRQSPGKE	1 AITWSEG	2 YEDFVKGRFTISRDNAKNTL	1 KIRPYIFKIAGQY	2 WGQGT
017 4	AGGSLRLSCANS	2 SMA	7 RGFVA	0 NAY	0 YLQMTNLKPEDTALYYCAA	2 DY	4 VTVSS
0P 7			6	4	8	3	4
MP							
06							
2G							
08							
1T0 1	EVQLVESGGGPVQ	8 GRTYRGY	1 WFRQSPGKE	1 AITWSEG	2 YEDFVKGRFTISRDNAKNTL	1 KIRPYIFKIAGQY	2 WGQGT
117 4	AGGSLRLSCANS	2 SMA	7 REFVA	0 NAY	0 YLQMTNLKPEDTALYYCAA	2 DY	4 VTVSS
0P 7			5	4	8	3	4
MP							
12							
6E							
04							
1T0 1	EVQLVESGGGPVQ	8 GRTYRGY	1 WFRQSPGKE	1 AITWSEG	2 YEDFVKGRFTISRDNAKNTL	1 KIRPYIFKIAGQY	2 WGQGT
217 4	AGGSLRLSCANS	2 SMA	7 REFVA	0 NAY	0 YLQMTNLKPEDTALYYCAA	2 DY	4 VTVSS
0P 7			5	4	9	3	4
MP							
11							
6E							
01							

(continued)

I Na Dme	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
1T0 1 317 4 0P 7 MP 11 7E 03	EVQLVESGGGPVQ AGGSLRLSCANS	8 RRTYRGY 3 SMA	1 WFRQSPGKE 7 REFVA 5	1 AITWSEG; 0 NAY 4	2 YEDFVKGRFTISRDNAKNTL 0 YLQMTNLKPEDTALYYCAA 8	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 4 VTVSS
1T0 1 417 4 0P 8 MP 06 2B 10	EVQLVESGGGPVQ AGGSLRLSCASS	8 GRTYRGY 2 SMA	1 WFRQSPGKE 7 REFVA 5	1 AITWSEG; 0 NAY 4	2 YEDFVKGRFTISRDNAKNTL 0 YLQMTNLKPEDTALYYCAA 8	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 4 VTVSS
1T0 1 517 4 0P 7 MP 11 8E 11	EVQLVESGGGPVQ AGGSLRLSCANS	8 GRTYRGY 2 SMA	1 WFRQSPGKE 7 REFVA 5	1 AITWSEG; 0 NAY 4	2 YEDFVKGRFTISRDNAKNTL 0 YLQMTNLKPEDTALYYCAA 8	1 KTRPYIFKIAGQY 2 DY 4	2 WGQGT 4 3 QVTVSS
1T0 1 617 4 0P 9 MP 07 5A 10	EVQLVESGGGPVQ AGGSLRLSCADS	8 GRTYRGY 2 SMA	1 WFRQSPGKE 7 REFVA 5	1 AITWSEG; 0 NAY 4	2 YEDFVKGRFTISRDNAKNTL 0 YLQMTNLKPEDTALYYCAA 8	1 KIRPYIFKIAGQY 2 DY 3	2 WGQGT 4 3 QVTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
1T0 1 717 4 0P 7 MP 06 2C 06	8 4 GMA	1 7 5 REFVA	1 0 4 REFVA	2 0 8 NAY	2 0 8 YEDFVKGRFTISRDNAKNTL YLQMTNLKPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 3 WQQT QVTSS
1T0 1 817 4 0P 7 MP 11 2G 06	8 2 SMA	1 7 5 REFVA	1 0 4 REFVA	2 1 0 NAY	2 1 0 YEDFVKGRFTISRDNAKNTL YLQMTNLKPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 3 WQQT QVTSS
1T0 1 917 5 0P 0 MP 06 1A 09	8 2 SMA	1 7 7 REFVA	1 0 5 REFVA	2 1 1 NPY	2 1 1 YEDFVKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 4 WQQT VTVSS
2T0 1 017 5 0P 1 MP 06 1B 06	8 2 SMA	1 7 7 REFVA	1 0 5 REFVA	2 1 1 NPY	2 1 1 YEDFVKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 4 WQQT VTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
2T0 1 117 5 0P 1 MP 11 1C 01	8 2 SMA	1 7 7 REFVA	1 0 5 REFVA	1 0 5 NPY	2 1 2 YEDFAKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 4 WGQGT VTVSS
2T0 1 217 5 0P 1 MP 06 1D 06	8 5 SMA	1 7 7 REFVA	1 0 5 REFVA	1 0 5 NPY	2 1 1 YEDFVKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 3 WGQGT QVTVSS
2T0 1 317 5 0P 1 MP 06 1E 09	8 2 SMA	1 7 7 REFVA	1 0 5 REFVA	1 0 5 NPY	2 1 1 YEDFVKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 5 KIRPYIFKVAGQ YDY	2 4 3 WGQGT QVTVSS
2T0 1 417 5 0P 1 MP 07 8A 07	8 3 SMA	1 7 7 REFVA	1 0 5 REFVA	1 0 5 NPY	2 1 1 YEDFVKGRFTISRDNAKNTL YLRMTRLEPEDTALYYCAA	1 2 3 KIRPYIFKIAGQY DY	2 4 3 WGQGT QVTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
2T0 517 0P MP 06 1A 04	1 EVQLVESGGGPVQ TGGSLRLSCVAS	8 2 GRTYRGY SMA	1 7 WFRQPPGKE REFVA	1 0 6 AITWSEG NTY	2 1 3 YEDFVKGRFTISRDNAKNTL YLQMTSLKPEDTALYYCAA	1 2 6 KIRPYIFKIPGQY DY	2 4 4 WGQGT L VTVSS
2T0 617 0P MP 11 5A 03	1 EVQLVESGGGPVQ TGGSLRLSCVAS	8 2 GRTYRGY SMA	1 7 WFRQPPGKE REFVA	1 0 6 AITWSEG NTY	2 1 4 YEDFVKGRFTISRDNAKNTL YLQMTSLKPEDTALYYCAA	1 2 6 KIRPYIFKIPGQY DY	2 4 4 WGQGT L VTVSS
2T0 717 0P MP 06 1F 09	1 EVQPVESGGGPVQ TGGSLRLSCVAS	8 2 GRTYRGY SMA	1 7 WFRQPPGKE REFVA	1 0 6 AITWSEG NTY	2 1 4 YEDFVKGRFTISRDNAKNTL YLQMTSLKPEDTALYYCAA	1 2 6 KIRPYIFKIPGQY DY	2 4 4 WGQGT L VTVSS
2T0 817 0P MP 11 2D 04	1 EVQLVESGGGPVQ TGGSLRLSCVAS	8 2 GRTYRGY SMA	1 7 WFRQPPGKE RGFVA	1 0 6 AITWSEG NTY	2 1 4 YEDFVKGRFTISRDNAKNTL YLQMTSLKPEDTALYYCAA	1 2 6 KIRPYIFKIPGQY DY	2 4 4 WGQGT L VTVSS

(continued)

I Na Dme	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
2T0 917 0P 4 MP 11 4E 06	EVQLVESGGGPVQ TGGSLRLSCVAP	8 2 SMA	1 7 REFVA	1 0 6	2 1 4	1 2 6	2 4 4
3T0 017 0P 2 MP 11 3G 04	EVQLVESGGGPVQ TGGSLRLSCVAS	8 2 SMA	1 7 REFVA	1 0 6	2 1 5	1 2 6	2 4 4
3T0 117 0P 5 MP 06 1D 09	EVQLVESGGGLVQ TGGSLRLSCVAS	8 2 SMA	1 7 REFVA	1 0 6	2 1 4	1 2 6	2 4 3
3T0 217 0P 2 MP 06 2G 05	EVQLVESGGGPVQ TGGSLRLSCVAS	8 2 SMA	1 7 REFVA	1 0 6	2 1 6	1 2 6	2 4 3

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
3T0 317 0P MP 11 4C 05	8 2 2 2 2 2 2	GRTRYG SMA	WFRQPPGKE REFVA	AITWSEG NTY	YEDLVKGRFTISRDNAKNTLY LQMTSLKPEDTALYYCAA	KIRPYIFKIPGQY DY	WGQGT QVTVSS
3T0 417 0P MP 11 7G 05	8 2 2 2 2 2 2	GRTRYG SMA	WFRQPPGKE REFVA	AITWSEG NTY	YEDFVKGRFTISRDNAKNTLY YLQMTSLKPEDTALYYCAA	KIRPYIFKVPQG YDY	WGQGT QVTVSS
3T0 517 0P MP 06 1F 07	8 6 4 4 4 4 4	GRTRYG SMA	WFRQPPGKE REFVA	AITWSEG NTY	YEDFVKGRFTISRDNAKNTLY YLQMTSLKPEDTALYYCAA	KIRPYIFKIAGQY DY	WGQGT VTVSS
3T0 617 0P MP 06 1C 09	8 1 4 4 4 4 4	GRTRYG SMG	WFRQAPGR EREVA	AIVWSD GNTY	YEDSVKGRFTISRDNAKNTMY YLQMTSLKPEDSATYYCAA	KIRPYIFKIAGQY DY	WGQGT QVTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
3T0 717 5 0P 6 MP 12 4E 06	EVQLVESGGGPAQ AGGSLRLSCAAS	GRTRYGY SMIG	WFRQAPGR EREFVA	AIVWSD GNTY	YEDSVKGRFTISRDNKNTM YLQMTSLKPEDSATYCAA	KIRPYIFKIAGQY DY	WGQGT VTVSS
3T0 817 4 0P 4 MP 11 1B 02	EVQLVESGGGPVQ AGGSLRLSCAAS	GRTRYGY SMIG	WFRRAPGRE REFVA	AIVWSD GNTY	YEDPVKGRFTISRDNKNT MYLQMTSLKPEDSATYCA A	KIRPYIFKIAGQY DY	WGQGT QVTSS
3T0 917 5 0P 7 MP 06 2E 08	EVQLVESGGGPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIVWTD GNTY	YEDSVKGRFTISRDKNTMY LQMTSLKPEDSATYCAA	KIRPYIFKIAGQY DY	WGQGT VTVSS
4T0 017 5 0P 8 MP 06 2G 03	EVQLVEFGGPPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIVWTD GNTY	YEDSVKGRFTISRDKNTMY LQMTSLKPEDSATYCAA	KIRPYIFKIAGQY DY	WGQGT VTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
4T0 1 117 5 0P 7 MP 06 2G 10	EVQLVESGGGPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIAWTD GNTY	YEDSVKGRFTISRDTKNTMY LQMTSLKPEDSATYYCAA	KIRPYIFKIAGQY ; DY	WGQGT VTVSS
4T0 1 217 5 0P 7 MP 07 8E 10	EVQLVESGGGPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIVWTD GNTY	YEDSVKGRFTISRDTKNTMY YLQMTSLKPEDSATYYCAA	KIRPYIFKIAGQY ; DY	WGQGT VTVSS
4T0 1 317 5 0P 9 MP 11 5E 06	EVQLVESGGGPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIVWTD GNTY	YEDSVKGRFTISRDTKNTMY LQMTSLKPEDSATYYCAA	KIRPYIFKIAGQY ; DY	WGQGT VTVSS
4T0 1 417 5 0P 7 MP 12 2B 02	EVQLVESGGGPVQ AGDSLRLSCAAS	GRAYRGY SMIG	WFRQVPGK EREFVA	AIVWTD GNAY	YEDSVKGRFTISRDTKNTMY LQMTSLKPEDSATYYCAA	KIRPYIFKIAGQY ; DY	WGQGT VTVSS

(continued)

I Na	I D	FR1	I D	CDR1	I D	FR2	I D	CDR2	I D	FR3	I D	CDR3	I D	FR4
4T0	1	EVQLVESGGGPVQ	8	GRAYGY	1	WFRQVPGKE	1	AIVWTD	2	YEDSVKGRFTISRDNKNTMY	1	KIRPYIFKIAGQY :	2	WGQGT
517	5	AGDSLRLSCAAS	7	SMIG	8	REFVA	0	GNTY	1	LQMTSLKPEDSATYCAAA	2	DY	4	QVTVSS
0P	7				2		7		9		3		3	
MP														
06														
1D														
07														
4T0	1	EVQLVSGGGPVQA	8	GRAYGY	1	WFRQVPGK	1	AIVWTD	2	YEDSVKGRFTISRDNKNTMY	1	KIRPYIFKIAGQY :	2	WGQGT
617	6	GDSLRLSCAAS	7	SMIG	8	EREFA	0	GNTY	1	LQMTSLKPEDSATYCAAA	2	DY	4	QVTVSS
0P	0				1		7		9		3		3	
MP														
12														
6D														
09														
4T0	1	EVQLVESGGGPVQ	8	GRTYRGY	1	WFRQVPGK	1	AIVWTD	2	YEDSVKGRFTISRDNKNTMY	1	KIRPYIFKIAGQY :	2	WGQGT
717	5	AGDSLRLSCAAS	1	SMIG	8	EREFA	0	GNTY	2	YLQMTSLKPEDSATYCAAA	2	DY	4	VTVSS
0P	7				1		7		1		3		4	
MP														
12														
6B														
03														
4T0	1	KVQLVESGGGPVQ	8	GRTYRGY	1	WFRQVPGK	1	AIVWTD	2	YEDSVKGRFTISRDNKNTMY	1	KIRPYIFKIAGQY :	2	WGQGT
817	6	AGDSLRLSCAAS	1	SMIG	8	EREFA	0	GNTY	2	YLQMTSLKPEDSATYCAAA	2	DY	4	VTVSS
0P	1				1		7		1		3		4	
MP														
12														
6B														
02														

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
4T0 1 917 5 0P 7 MP 07 5G 11	EVQLVESGGGPVQ AGDSLRLSCAAS	GRTRYG SMG	WFRQVPGK EREVA	AIVWTD GNTY	YEDSVKGRFTISRDTKNTMY LHMTSLKPEDSATYCAA	KIRPYIFKIAGQY DY	WGQGT QVTVSS
5T0 1 017 6 0P 2 MP 08 0E 07	EVQLVESGGGLVQ AGGSLRLSCAAS	GRAYRGY SMG	WFRQVPGK EREVA	AIVWTD GNTY	YEDSVKGRFTISRDTKNTMY LQMTSLKPEDSATYCAA	KIRPYIFKIAGQY DY	WGQGT QVTVSS
5T0 1 117 6 0P 3 MP 06 0E 11	EVQLVESGGGLVQ PGGSLRLSCAAS	GDIYKSF DMG	WYRQAPGK QRDLVA	VIGSRGN NRGRTN	YADSVKGRFTISRDTGTNTV YLLMNKLRPEDTAIYYCNT	APLVAGRP	WGRGTL VTVSS
5T0 1 217 6 0P 4 MP 01 1A 10	EVQLVESGGGLVQ GGGSLRLSCAAS	GRTFSSY AMA	WFRQPPGKE REFVA	SISWSGE NTN	YRNSVKGRFTISRDNKNTV YLQMNSLKPEDTAVYYCAA	KIAKTPDNWY WTKSNNNY	WGQGT QVTVSS

(continued)

I Na	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
Dme	D	D	D	D	D	D	D
5T0 1 317 6 0P 5 MP 03 3G 03	EVQLVESGGGVQ AGGSLRLSCAAS	GRTEFTN : PMG	1 AFRQVPGK 8 RELIA 4	1 AVRWD 1 GNTF 2	2 YADSVKGRFTISRDNKKT 2 YLQMNSLKSEDTATYCAA 5	1 GRPWSAYHSPA 3 EYVH 0	2 WQGT 4 QVTSS 3
5T0 1 417 6 0P 2 MP 04 4A 09	EVQLVESGGGLVQ AGGSLRLSCAAS	GRTEFTN : PMG	1 AFRQSPGKE 8 RSLIA 5	1 AVRWD 1 GNTF 2	2 YADSVKGRFTISRDNKKT 2 YLQMNSLKSEDTATYCAA 5	1 KIAKTPDNWY 3 WTKSNNNY 0 GRPWSAYHSPA EYVH GRPWSAYHSPA EYVH GRPWSAYHSPA EYVH GRPWSAYHSPA EYVH	2 WQGT 4 QVTSS 3
5T0 1 517 6 0P 2 MP 04 3E 10	EVQLVESGGGLVQ AGGSLRLSCAAS	GRTEFTN : PMG	1 AFRQSPGKE 8 RSLIA 5	1 AARWD 1 GNTF 3	2 YADSVKGRFTISRDNKKT 2 YLQMNSLKSEDTATYCAA 5	1 GRPWSAYHSPA 3 EYVH 0	2 WQGT 4 QVTSS 3

(continued)

I Na Dme	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
5T0 1 617 6 0P 2 MP 04 4B 10	EVQLVESGGGLVQ AGGSLRLSCAAS	GRTFSTN : PMIG	1 AFRQSPGKE 8 RSLIA 5	1 AVRWAD 1 GNTF 2	2 YADSVKGRFTISRDNAKKTV 2 YLQMNSLRSEDATYYCAA 6	1 GRPWSAYHSPA 3 EVVH 0	2 WGQGT 4 VTVSS 4
5T0 1 717 6 0P 6 MP 05 2G 04	EVQLVESGGGAVQ PGGSLRLSCAAS	GIRISRN : MMG	1 AFRQAPGK 8 RDLVA 6	1 RITPGGD 1 TY 4	2 YVDSVKGRFSISKDNKNTV 2 YLQMNSLKPEDTAVYYCNS 7	1 YSTLGS 3 1	2 WGQGT 4 QVTSS 3
5T0 1 817 6 0P 7 MP 06 2B 02	EVQLVESGGGAVQ PGGSLRLSCVAS	GIRISRN : MMG	1 AFRRTPGRE 8 NMVA 7	1 RISPGGA 1 TY 5	2 YVDSVKGRFSISKDDSKNTV 2 YLQMDSLKPEDTAVYYCNS 8	1 YSTLGS 3 1	2 WGQGT 4 QVTSS 3
5T0 1 917 6 0P 7 MP 11 4D 01	EVQLVESGGGAVQ PGGSLRLSCVAS	GIRISRN : MMG	1 AFRRTPGRE 8 NMVA 7	1 RISPGGA 1 TY 5	2 YVDSVKGRFSISKDDSKNTV 2 YLQMDSLKPEDTAVYYCNS 8	1 YSTLGS 3 1	2 WGQGT 4 VTVSS 4

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
6T0 1 017 6 0P 7 MP 08 0F 02	EVQLVESGGGAVQ PGGSLRLSCVAS	GIRISN : MMG	1 WFRRTPGRG 8 NMVA 8	RISPGGA TY	YVDSVKGRFSISKDDSKNTV YLQMDSLKPEDTAVVYCNS	YSTLGS	WGQGT QVTSS
6T0 1 117 6 0P 6 MP 12 2A 11	EVQLVESGGGAVQ PGGSLRLSCAAS	GIRISN : MMG	1 WFRQAPGK 8 RDMVA 9	RISPGGD TY	YVDSVKGRFSISKDNKNTV YLQMNSLRPEDTAIYYCNS	YSTLGS	WGQGT VTVSS
6T0 1 217 6 0P 7 MP 11 3E 06	EVQLVESGGGAVQ PGGSLRLSCVAS	GIRISNH : MMG	1 WFRQAPGE 9 RDMVA 0	RISPGGD TY	WVDSVKGRFSISKDNKNTV YLQMNNLKLEDTAIYYCNS	YRTLGS	WGQGT QVTSS
6T0 1 317 6 0P 8 MP 06 1E 10	EVQLVESGGGVVQ PGGSLRLSCAAS	GIRISTHT : MG	1 WFRQAPEK : 9 QREMVA 1	QISPGGK TY	YIDSVKGRFTISKDNKNTVF : LRMNDLKPDDTAIYYCNS	YSTLGV	WGQGT VTVSS

(continued)

I Na	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
Dme	D	D	D	D	D	D	D
6T0 1 417 6 0P 8 MP 06 1D 03	EVQLVESGGGVVQ PGGSLRLSCAAS	GIRISTHT : MG	WFRQAPEK : QREMVA	QISPGGK TY	YIDSVKGRFTISKDNAKNTVF : LRMINDLKPDGTAIVYVCNS	YSTLGV	WGQGT QVTVSS
6T0 1 517 6 0P 8 MP 11 3E 03	EVQLVESGGGVVQ PGGSLRLSCAAS	GIRISTHT : MG	WFRQAPEK : QREMVA	QISPGGK TY	YIDSVKGRFTISKDNAKNTVF : LRMINDLKPDGTAIVYVCNS	YSTLGV	WGQGT QVTVSS
6T0 1 617 6 0P 2 MP 05 0A 11	EVQLVESGGGLVQ AGGSLRLSCAAS	GRSFNM : NPLG	WFRQSPGKE : REFVA	AHRWSD GNTY	YVDSVKGRFTISRDNAKNTV : YLQMNSLKSEDTAVYYCAA	GRPWSAFRSPG EYVY	WGQGT QVTVSS
6T0 1 717 6 0P 2 MP 04 4A 06	EVQLVESGGGLVQ AGGSLRLSCAAS	GRTFSTN : PMG	WFRQSPGN : EREFVA	AHRWSD GNTY	YADSVKGRFAISRDNAKKTV : YLQMNSLKSEDTAVYYCAA	GRPWSSYRSPD EYVY	WGQGT QVTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
6T0 1 817 6 0P 2 MP 04 4D 11	EVQLVESGGGLVQ AGGSIRLSCAAS	9 5 NPMG	1 9 3 WFRQFAGKE REFVA	1 1 8 AHRWSD GNTY	2 3 3 YVDSVKGRFTISRDNAKNTV YMQMNSLKSEDTAVYYCAA	1 3 5 GRPWSSYRSPD EYVY	2 4 3 WGQGT QVTVSS
6T0 1 917 6 0P 2 MP 04 3E 08	EVQLVESGGGLVQ AGGSIRLSCAAS	9 6 NPMG	1 9 4 WFRQSPGRE REFVA	1 1 8 AHRWSD GNTY	2 3 5 YVDSVKGRFTISRDNAKNTV YMQMNSLKSEDTAVYYCAA	1 3 6 GRPWSSYRSPD EYVY	2 4 4 WGQGT VTVSS
7T0 1 017 6 0P 9 MP 04 3E 06	EVQLVESGGGAVQ AGGSIRLSCAAS	9 7 PMG	1 9 5 WFRQFPRKE REFVA	1 1 8 AHRWSD GNTY	2 3 6 YADSVKGRFTISRDNAKHTV YMQMNSLKSEDTAVYYCAA	1 3 7 GRPWSAAHSP NEYVY	2 4 3 WGQGT QVTVSS
7T0 1 117 6 0P 2 MP 04 3E 07	EVQLVESGGGLVQ AGGSIRLSCAAS	9 8 PMG	1 9 6 WFRQFPGKE RESVA	1 1 8 AHRWSD GNTY	2 3 6 YADSVKGRFTISRDNAKHTV YMQMNSLKSEDTAVYYCAA	1 3 7 GRPWSAAHSP NEYVY	2 4 3 WGQGT QVTVSS

(continued)

I Na Dme	I FR1	I CDR1	I FR2	I CDR2	I FR3	I CDR3	I FR4
7T0 1 217 6 0P 2 MP 03 9D 06	EVQLVESGGGLVQ AGGSIRLSCAAS	GRGFSTN : PMG	WFRQSPGKE : REFVA	AHRWSD GNTY	YVDSVKGRFAISRDNKNTV : HLQMNSLKSEDTAVVYCAA	1 GRPWSDFRAPS 3 EYIY	WGQGT QVTVSS
7T0 1 317 7 0P 0 MP 04 4F 10	EVQLVESGGGLVR AGGSIRLSCAAS	GRGFSTN : PMG	WFRQSPGKE : REFVA	AHRWSD GNTY	YVDSVKGRFAISRDNKNTV : HLQMNSLKSEDTAVVYCAA	1 GRPWSDFRAPS 3 EYIY	SGPGTQ VTVSS
7T0 1 417 6 0P 2 MP 04 4B 11	EVQLVESGGGLVQ AGGSIRLSCAAS	GRAFNT : NPMG	WFRQSPGKE : REFLA	AVRWH DGSTY	YTDSVKGRFTISRDNKNTV : YLQMNSLKSEDTAVVYCAA	1 GRPWSAYHSPN 4 EYVY	WGQGT VTVSS
7T0 1 517 6 0P 2 MP 04 4C 08	EVQLVESGGGLVQ AGGSIRLSCAAS	GRAFNT : NPMG	WFRQSPGKE : REFLA	AVRWH DGSTY	YTDSVKGRFTISRDNKNTV : CLQMNSLKSEDTAVVYCAA	1 GRPWSAYHSPN 4 EYVY	WGQGT QVTVSS

(continued)

I Na Dme	I FR1 D	I CDR1 D	I FR2 D	I CDR2 D	I FR3 D	I CDR3 D	I FR4 D
7T0 617 0P MP 04 3B 03	1 0 0 0 0 0 0	1 0 0 0 0 0 0	1 9 8 0 0 0 0	1 2 0 0 0 0 0	2 4 0 0 0 0 0	1 4 1 0 0 0 0	2 4 4 0 0 0 0
	EVQLVEFGGGLVQ AGGSRLSCAAS	GRAFSTN PMG	WFRQSPGKE REFVG	AVRWSD GSTY	SADSVKGRFTVFRD VYLQMNSLKSEDTAVYCA A	GRPWSAYHSPK ; EYVY	WGQGT L VTVSS
7T0 717 0P MP 03 9E 06	1 0 0 0 0 0 0	1 0 0 0 0 0 0	1 7 5 0 0 0 0	1 2 1 0 0 0 0	2 4 1 0 0 0 0	1 4 2 0 0 0 0	2 4 7 0 0 0 0
	EVQLVESGGGLVQ AGDSLRLSCAAS	GRAFSTN PMG	WFRQSPGKE REFVA	AHRWSD GSTF	VADSVKGRFTISRDN SLQMNSLKSA DTAVYCA	GRPWSAYHSPR ; EYIY	WGRGT Q VTVSS
7T0 817 0P MP 04 9A 04	1 0 0 0 0 0 0	1 0 0 0 0 0 0	1 7 5 0 0 0 0	1 2 1 0 0 0 0	2 4 1 0 0 0 0	1 4 2 0 0 0 0	2 4 5 0 0 0 0
	EVQLVESGGGLVQ AGASRLSCAAS	GRAFSTN PMG	WFRQSPGQ EREFLA	AVRWAD GNTY	YTD SVKGRATISRDN AKKTV YLQLNLSKSEDA AVYCA	GRPWSAYHAPK ; EYIY	WGQGT L VTVSS

5

10

15

20

25

30

35

40

45

50

55

(continued)

I	Na	I	FR1	I	CDR1	I	FR2	I	CDR2	I	FR3	I	CDR3	I	FR4
D	me	D		D		D		D		D		D		D	
8	T0	1	EVQLVESGGGLVQ	1	GRAFSTN	1	WFRQSPGQ	1	AVRWAD	2	YTDSVKGRATISRDN	1	GRPWSAYHAPK:	2	WGQGT
0	17	7	AGASLRISCAAS	0	PMG	9	EREFLA	2	GNTY	4	YLNKLNKSEDAAVYCAA	4	EYIY	4	QVTVSS
0	P	3		0		9		2		2		3		3	
	MP														
	04														
	4C														
	11														

Table A-9: Sequences of multispecific polypeptides (with and without tags). "ID" refers to the SEQ ID NO as used herein.

[illegible]

(continued)

ID	Name	Description	Amino acid sequence
254	T017000012	20CD019C07-9GS- cAbLys3-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPDYWGQGLTVTVSSGGGGSGGSDVQLQASGGGSGVQAGGSLRLSCAASGYTIG PYCMGWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQDNAKNTVYLLMNSLEPEDTAIYYCAADSTIYASYECG HG LSTGGYGYDSWGQGTQVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHHHHH
255	T017000016	20CD019C07-35GS- T0170033G03-FLAG3- HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGSGGGGGSEV QLVESGGGSGVQAGGSLRLSCAASGRTFTSTNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDN AKKT VYLQ MNSLKSEDTATYYCAAGRPWSAYHSPA EYVHWGQGLTVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHHHHH
256	T017000017	20CD019C07-35GS- T0170011A10-FLAG3- HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGSGGGGGSEV QLVESGGGLVQGGGSLRLSCAASGRTFSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDN AKNT VYLQM NSLKPEDTAVYYCAAKIAKTPDNWYWT KSNNNYWGQGLTVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHHHHH HH
257	T017000018	20CD019C07-35GS- cAbLys3-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGSGGGGGSDV QLQASGGGSGVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQDN AKNT VYLL MNSLEPEDTAIYYCAADSTIYASYECG HGLSTGGYGYDSWGQGTQVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHH HHHH
258	T017000020	T0170033G03-9GS- 20CD019C07-FLAG3- HIS6	EVQLVESGGGSGVQAGGSLRLSCAASGRTFTSTNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDN AKKT VYL QMNSLKSEDTATYYCAAGRPWSAYHSPA EYVHWGQGLTVTVSSGGGGSGGSEVQLVESGGLVQPGGSLRLSCTFSGGT FSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQMNSLKPEDTAVYYCAAVRQMVMYTPD YWGQGLTVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHHHHH
259	T017000021	T0170033G03-35GS- 20CD019C07-FLAG3- HIS6	EVQLVESGGGSGVQAGGSLRLSCAASGRTFTSTNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDN AKKT VYL QMNSLKSEDTATYYCAAGRPWSAYHSPA EYVHWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGSGGGGGSGGGG GSEVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY L QMNSLKPEDTAVYYCAAVRQMVMYTPDYWGQGLTVTVSSGAADYKDHGDYKDHIDYKDDDDKGA AHHHHH

(continued)

ID	Name	Description	Amino acid sequence
260	T017000022	T0170011A10-35GS-20CD019C07-FLAG3-HIS6	EVQLVESGGGLVQGGGSLSCAASGRTFSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAAKIAKTPDNWYWTKSNNYVWGQGLTVTSGGGGSGGGSGGGSGGGSGGGSGGG SGGGGSEVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKDRTFISEDV KNAVYLQMNSLKPEDTAVYYCAAVRQMVMYMTVPDYWGQGLTVTSVSSGAADYKDHGDYKDHIDYKDDDDKGAHHH HHH
261	T017000023	cAbLys3(D1E)-35GS-20CD019C07-FLAG3-HIS6	EVQLQASGGGVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQDIAKNTVY LLMNSLEPEDTAIYYCAADSTIYASYECGHLSTGGYDWSWQGTQVTVSSGGGGSGGGSGGGSGGGSGGGSGGG GGSGGGGSEVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKDRTFISED SVKNAVYLQMNSLKPEDTAVYYCAAVRQMVMYMTVPDYWGQGLTVTSVSSGAADYKDHGDYKDHIDYKDDDDKGAHH HHHH
262	T017000024	T0170033G03-35GS-cAbLys3-FLAG3-HIS6	EVQLVESGGGVQAGGSLRLSCAASGRTFSTNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDNAKTVYL QMNSLKSEDTATYYCAAGRPWYAYHSPAELVHWGQGLTVTSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGG GSDVQLQASGGGVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQDIAKNT VYLLMNSLEPEDTAIYYCAADSTIYASYECGHLSTGGYDWSWQGTQVTVSSGAADYKDHGDYKDHIDYKDDDDKDG AAHHHHHH
263	T017000026	T0170011A10-9GS-20CD019C07-FLAG3-HIS6	EVQLVESGGGLVQGGGSLSCAASGRTFSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAAKIAKTPDNWYWTKSNNYVWGQGLTVTSGGGGSGGGSEVQLVESGGGLVQPGGSLRLSC TFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKDRTFISEDVKNNAVYLQMNSLKPEDTAVYYCAAVRQMY MTVVPDYWGQGLTVTSVSSGAADYKDHGDYKDHIDYKDDDDKGAHHHHHH
264	T017000027	T0170011A10-35GS-cAbLys3-FLAG3-HIS6	EVQLVESGGGLVQGGGSLSCAASGRTFSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAAKIAKTPDNWYWTKSNNYVWGQGLTVTSGGGGSGGGSGGGSGGGSGGGSGGGSGGG SGGGGSDVQLQASGGGVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQD NAKNTVYLLMNSLEPEDTAIYYCAADSTIYASYECGHLSTGGYDWSWQGTQVTVSSGAADYKDHGDYKDHIDYKDD DDDKGAHHHHHHH

(continued)

[illegible]

(continued)

[illegible]

(continued)

ID	Name	Description	Amino acid sequence
273	T017000052	20CD019C07-35GS-T0170061F04-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRSCAASGRTRYGYSMAWFRQSPGKEREFVAIVWSDGNTYYEDFVKGRFTISRDSAKNTLYLQM TNLKPEDTALYYCAAKIRPYFIKAGQDYWGQGTLLTVSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHHHH
274	T017000053	20CD019C07-35GS-T0170060E11-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQPGGSLRSCAASGDIYKSFDMGWYRQAPGKQRDILVAVIGSRGNRRNTNADSVKGRFTISRDTGNTV YLLMNLKRPEDTAIYYCNTAPLVAGRPWGRGTLTVTSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHHHH
275	T017000056	20CD019C07-35GS-T0170052G04-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGAVQPGGSLRSCAASGRISRNMMGWFRQAPGKQRDILVARITPGGDTYYVDSVKGRFSISKDNAKNTVYLQM NSLKPEDTAVYYCNSYSTLGSWGQGTLLTVSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHHHH
276	T017000057	20CD019C07-35GS-T0170050A11-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQAGGSLRSCAASGRSFNMNPLGWFRQSPGKEREFVAHRWSDGNTYYVDSVKGRFTISRDNAKNTVYLQ MNSLKSEDTAVYYCAAGRPWSAFRSPGEVYWGGQTLTVTSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHHHH
277	T017000059	20CD019C07-35GS-T0170033G03-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGSVQAGGSLRSCAASGRTFTSNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDNAKTIVYLQ MNSLKSEDTATYYCAAGRPWSAYHSPA EYVHWGGQTLTVTSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHHHH
278	T017000061	20CD019C07-35GS-T0170011A10-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVY LQ MNSLKPEDTAVYYCAAVRQMVMYTPVDYWGGQTLTVTSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQGGGSLRSCAASGRTFSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYLQM NSLKPEDTAVYYCAAKIAKIATYPDNWYWTKSNNYNYWGQGTLLTVSSGAADYKDHDGDKDHDIDYKDDDDKGAHHHH HH

(continued)

ID	Name	Description	Amino acid sequence
279	T017000062	20CD019C07-35GS-T0170117G03-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSSGNTYYEDSVKGRFTISRDNAKNTMYLQ MTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSSGAADYKDHIDYKDDDDKGAHHHHHH
280	T017000066	20CD019C07-35GS-T0170061D09-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQAGGSLRLSCVASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNYYEDFVKGRFTISRDNAKNTLYLQM TSLKPEDTALYYCAAKIRPYIFIKIPQDYWGQGLTVTVSSGAADYKDHIDYKDDDDKGAHHHHHH
281	T017000071	20CD019C07-35GS-T0170061F07-FLAG3-HIS6	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTFRGYSMAWFRQPPGKEREFVAAITWSEGNYYEDFVKGRFTISRDNAKNTLYLQM TSLKPEDTALYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSSGAADYKDHIDYKDDDDKGAHHHHHH
282	T017000072	T0170061D09-35GS-20CD019C07-FLAG3-HIS6	EVQLVESGGGLVQAGGSLRLSCVSGRTYRGYSMAWFRQPPGKEREFVAAITWSEGNYYEDFVKGRFTISRDNAKNTLYLQ MNSLKPEDTALYYCAAKIRPYIFIKIPQDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ SLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGAADYKDHIDYKDDDDKGAHHHHHH
283	T017000084	20C0019C07(E10)-35GS-T0170117G03-A	DVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQAPGKEREFVAAIVWSSGNTYYEDSVKGRFTISRDNAKNTMYLQ MTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSSA
284	T017000090	RSV007B02-35GS-T0170061F04-FLAG3-HIS6	EVQLVESGGGLVQAGGSLRLSCAASGRTSSYAMGWFRQAPGKEREFVAAISWSDGSTYYADSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAADLTSTNPGSYIYWAYDYWGQGTQVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGG GGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQSPGKEREFVAAIVWSDGNTYYEDFVKGRFTISRDSAKNT LYLQMTNLKPEDTALYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSSGAADYKDHIDYKDDDDKGAHHHHHH

5
10
15
20
25
30
35
40
45
50
55

5
10
15
20
25
30
35
40
45
50
55

[illegible]

(continued)

ID	Name	Description	Amino acid sequence
310	T017000011	20CD019C07-9GS-T0170011A10	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQ MNSLKPEDTAVYYCAAVRQMVMYTVVPDYWGQGLTVTVSSGGGGSGGSEVQLVESGGGLVQGGGSLSCAASGRFTSS YAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAKIAKTPDNNWYWT KSNNNYWGQGLTVTVSS
311	T017000012	20CD019C07-9GS-cAbLys3	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQ MNSLKPEDTAVYYCAAVRQMVMYTVVPDYWGQGLTVTVSSGGGGSGGSDVQLQASGGSVQAGGSLRLSCAASGYTIG PYCMGWFRQAPGKEREGVAAINMGGGITYADS VKGRFTISQDNAKNTVYLLMNSLEPEDTAIYYCAADSTIYASYECGHG LSTGGYGYDSWGQGTQVTVSS
312	T017000016	20CD019C07-35GS-T0170033G03	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQ MNSLKPEDTAVYYCAAVRQMVMYTVVPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGGGGGSEV QLVESGGSVQAGGSLRLSCAASGRFTSTNPMGWFRQVPGERELIAAVRWADGNTFYADSVKGRFTISRDNAKKTIVYLQ MNSLKSEDTAIYYCAAGRPWSAYHSPAETHWGGQGLTVTVSS
313	T017000017	20CD019C07-35GS-T0170011A10	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQ MNSLKPEDTAVYYCAAVRQMVMYTVVPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGGGGGSEV QLVESGGGLVQGGGSLRLSCAASGRFTSSYAMAWFRQPPGKEREFVASISWSGENTNRYNSVKGRFTISRDNAKNTVYLQM NSLKPEDTAVYYCAAKIAKTPDNNWYWT KSNNNYWGQGLTVTVSS
314	T017000018	20CD019C07-35GS-cAbLys3	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQ MNSLKPEDTAVYYCAAVRQMVMYTVVPDYWGQGLTVTVSSGGGGSGGSGGGGGSGGGGGGGGGSDV QLQASGGSVQAGGSLRLSCAASGYTIGPYCMGWFRQAPGKEREGVAAINMGGGITYADS VKGRFTISRDNAKNTVYLL MNSLEPEDTAIYYCAADSTIYASYECGHGLSTGGYGYDSWGQGTQVTVSS
315	T017000020	T0170033G03-9GS-20CD019C07	EVQLVESGGSVQAGGSLRLSCAASGRFTSTNPMGWFRQVPGERELIAAVRWADGNTFYADSVKGRFTISRDNAKKTIVYL QMNSLKSEDTAIYYCAAGRPWSAYHSPAETHWGGQGLTVTVSSGGGGSGGSEVQLVESGGGLVQPGGSLRLSCTFSGGT FSSYTMGWFRQAPGKEREFVAEVRWGGVTTYSNSLKDIFSISED SVKNAVYLQMNSLKPEDTAVYYCAAVRQMVMYTVVPD YWGGQGLTVTVSS

5
10
15
20
25
30
35
40
45
50
55

5
10
15
20
25
30
35
40
45
50
55

[illegible]

(continued)

[illegible]

(continued)

ID	Name	Description	Amino acid sequence
334	T017000059	20CD019C07-35GS-T0170033G03	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGSVQAGGSLRLSCAASGRTFTSNPMGWFRQVPGKERELIAAVRWADGNTFYADSVKGRFTISRDN AKKTIVYLQ MNSLKSEDTATYCAAGRPSWYHSPA EYHWGQGTLTVTVSS
335	T017000061	20CD019C07-35GS-T0170011A10	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQAGGSLRLSCAASGRTFTSSYAMAWFRQPPGKEREFVASISW'GENTNRYNSVKGRFTISRDN AKNTVYLQM NSLKPEDTAVYYCAAKIAKTYPDN WYWTKSNNYNYWGQGLTVTVSS
336	T017000062	20CD019C07-35GS-T0170117G03	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRQAPGKEREFVAAIVW'SGGNTYEDSVKGRFTISRDN AKNTMYLQ MTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSS
337	T017000066	20CD019C07-35GS-T0170061D09	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQTGGSRLSCV ASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGN TYEDFVKGRFTISRDN AKNTLYLQM TSLKPEDTALYYCAAKIRPYIFIKIPGQDYWGQGLTVTVSS
338	T017000071	20CD019C07-35GS-T0170061F07	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTFRGYSMAWFRQPPGKEREFVAAITWSEGN TYEDFVKGRFTISRDN AKNTLYLQM TSLKPEDTALYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSS
339	T017000072	T0170061D09-35GS-20CD019C07	EVQLVESGGGLVQTGGSRLSCV ASGRTYRGYSMAWFRQPPGKEREFVAAITWSEGN TYEDFVKGRFTISRDN AKNTLYLQ MTSLKPEDTALYYCAAKIRPYIFIKIPGQDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRQAPGKEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQM SLKPEDTAVYYCAAVRQM YMTVPDYWGQGLTVTVSS

(continued)

ID	Name	Description	Amino acid sequence
340	T017000084	20CD019C07(E1D)- 35GS-T0170117G03	DVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRAQPKGEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRAQPKGEREFVAIVWSSGNTYYEDSVKGRFTISRDNAKNTMYLQ MTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSS
341	T017000090	RSV007B02-35GS- T0170061F04	EVQLVESGGGLVQAGDSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAIAISWSDGSTYYADSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAADLTSTNPGSYIYWAYDYWGQGTQVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGG GGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMAWFRQSPGKEREFVAIIVWSDGNTYYEDFVKGRFTISRDSAKNT LYLQMTNLKPEDTALYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSS
342	T017000091	RSV007B02-35GS- T0170117G03	EVQLVESGGGLVQAGDSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVAIAISWSDGSTYYADSVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAADLTSTNPGSYIYWAYDYWGQGTQVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGG GGSEVQLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRAQPKGEREFVAIIVWSSGNTYYEDSVKGRFTISRDNAKN TMYLQMTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSS
343	T017000094	20CD019C07-35GS- T0170117G03-35GS- ALB11	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRAQPKGEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGPVQAGGSLRLSCAASGRTYRGYSMGWFRAQPKGEREFVAIVWSSGNTYYEDSVKGRFTISRDNAKNTMYLQ MTSLKPEDSATYYCAAKIRPYIFIKIAGQDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQPGNSLRLSCAASGFTSFSGMSWVRQAPGKGLEWVSSISGSDTLYADSVKGRFTISRDNAKTTLYLQMN SLRPEDTAVYYCTIGGSLRSRQQGLTVTVSS
344	T017000096	20CD019C07-35GS- T0170060E11-35GS- ALB11	EVQLVESGGGLVQPGGSLRLSCTFSGGTSSYTMGWFRAQPKGEREFVAEVRWGGVTTYNSLKD RFSISEDSVKNAVYLQ MNSLKPEDTAVYYCAAVRQMYMTVPDYWGQGLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSEV QLVESGGGLVQPGGSLRLSCAASGDIYKSFDMGWYRQAPGKQRLVAVIGSRGNRRTNYADSVKGRFTISRDTGNTV YLLMNKLRPEDTAIYYCNTAPLVAGRPWGRGTLTVTVSSGGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSGGGSEVQLV ESGGGLVQPGNSLRLSCAASGFTSFSGMSWVRQAPGKGLEWVSSISGSDTLYADSVKGRFTISRDNAKTTLYLQMNLSLR PEDTAVYYCTIGGSLRSRQQGLTVTVSS

[illegible]

Table A-10: Sequences of components of TCR complex. "ID" refers to the SEQ ID NO as used herein

ID	Name	Amino acid sequence
291	HUMAN CD3 DELTA (P04234)	MEHSTFLSGLVLATLSQVSPFKPIEELEDRVFNCHNTSITWVEGTGTLSDITRLDLGKRILDRGIVRCNGTDIYKDESTVQVHYRMC QSCVELDPATVAGIIVTDVIATLLALGVFCFAGHETGRLSGAADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK
292	HUMAN CD3 GAMMA (P09693)	MEQKGGLAVLILAIILLOGLTQAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMGIFLTEDKKWNLGSNAKDPGRGMYQCKG SQNKSPLQVYVYRMCCQNCIELAEIVSIFVLAVGVYFIAGQDGVQRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRNAATISGFL FRN
293	HUMAN CD3 EPSILON (P07766)	MQSGTHWRVLGLCLLSVGWVGQDGNEMGGITQTPYKVSISGTTVILTCQYPGSEILWQHNDKNIIGGDEDDKNIIGSDEDDHLSLKEFS ELEQSGYVVCYPPNPDPYPIRKGGQRDLYSLGNQRRIRGSKPEDANFCMEMDMVSVATIVVDICITGGILLVYVWSKNRKAKAKP VTRGAGAGGRQGRQNKERPPLYLRARVCE
294	HUMAN CD3 ZETA (P20963)	MKWKALFTAAILQAQLPITEAQSGFLDPKLCYLLDGLFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYNELNLRREYDVLDKRRGR DPEMGGKPQRRKNPQEGLYNELQDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
295	HUMAN TCR ALPHA CONSTANT DOMAIN (P01848)	PNIQNPDPAYQLRDSKSDKSVCLTFDEDSQTNVQSQKSDSVYTDKTVLDMRSMDFKNSAVAWSNKSDFACANAFNNSIIPEDTFF PSPESCDVKLVEKSFETDTNLNLFQNLISVIGFRILLKLVAGFNILLMTLRLWSS
296	HUMAN TCR BETA CONSTANT DOMAIN (P01850)	EDLNKVPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRSATFWQN PRNHFRQCQFYGLSENDEWTDRAKPVTVQVSAEWGRADCGFTSVYQQGVLSTILYEILLGKATLYAVLVSAVLVMAVMVKKRDF
379	HUMAN CD3 GAMMA (P09693)	MEQKGGLAVLILAIILLOGLTQAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMGIFLTEDKKWNLGSNAKDPGRGMYQCKG SQNKSPLQVYVYRMCCQNCIELNAATISGFLFAEIVSIFVLAVGVFIAGQDGVQRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQL RRN
380	HUMAN CD3 EPSILON (P07766)	MQSGTHWRVLGLCLLSVGWVGQDGNEMGGITQTPYKVSISGTTVILTCQYPGSEILWQHNDKNIIGGDEDDKNIIGSDEDDHLSLKEFS ELEQSGYVVCYPRGSKPEDANFYLYLRARVCNCEMEMDMVSVATIVVDICITGGILLVYVWSKNRKAKAKPVTRGAGAGGRQGRQNK ERPPVPNPDPYPIRKGGQRDLYSLGNQRRI
381	HUMAN TCR ALPHA VARIABLE DOMAIN DERIVED FROM 2IAN	IQVEQSPDLIILQEGANSTLRNCFSDSVNNLQWFHQNPWGQLINLFYIPSGTKQNGRLSATTVATERYSLYISSQTTDSGWYFCAALIQ GAQKLVFGQGTRLTIN
382	HUMAN TCR BETA VARIABLE DOMAIN DERIVED FROM 2IAN	NAGVTQTPKFRILKIQSMTLQCTQDMNHNHNYMYWYRQDPGMGLKIYYSVGAGITDKGEVPNGYNVSRSTTEDFPLRLELAAPSQTSV YFCASTYHGTGYFEGEGSWLTW
383	HUMAN TCR ALPHA VARIABLE DOMAIN DERIVED FROM 2XN9	QLLEQSPQLSIQEGENLTYVCNSSVSLSQWYRQEPGEGPVLVTVVTGGEVKKLRLTFQFGDARKDSSLHITAAQPGDGTGLYLCAGA GSQGNLIFGKGTKLSVK

(continued)

ID	Name	Amino acid sequence
384	HUMAN TCR BETA VARIABLE DOMAIN DERIVED FROM 2XN9	DGGITQSPKYLFRKEGQNVTLSC EQNLNHDAMYYRQDPGGQLRLYYSQIVNDFQKGDIAEGYSVREKKESFPLTVTSAQKNPTAFYL CASSRSSEYEQYFGPGTRLTVT
385	HUMAN TCR ALPHA VARIABLE DOMAIN DERIVED FROM 3TOE	GDAKTTQPNMESNEEPEPVHLPCHNSTISGTDYIHWYRQLPSQGPVEYVIHGLTSNVNRRMASLAIAEDRKSSTLILHRATLRDAAVVYCT VYGGATNKLI FG TGTL LAVQ
386	HUMAN TCR BETA VARIABLE DOMAIN DERIVED FROM 3TOE	VVSQHPSWWIAKSGTSVKIECRSLDFQATTMFWYRQFPKQSLMLMATSNEGSKATYEQGVKDKFLINHASLTSLTTLTVTSAHPEDSSFYI CSARGGSYN SPLHFGNGTRLTVT

Table A-11: Sequences of TAA building blocks. "ID" refers to the SEQ ID NO as used herein

ID	Name	Amino acid sequence
297	HER2005F07 (Q108L)	EVQLVESGGGLVQAAGGSLRLSCAASGIFSTMTGMWYRQAPGKQRELVALISSIGDITYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYCKRFRRTAAAGTDYWGQGTLVTVSS
298	HER2047D05 (L108Q)	EVQLVESGGGLVQPGGSLRLSCAASGSIFGFNDMAWYRQAPGKQRELVALISRVGVTSSADSVKGRFTISRNVNAKDTVYLQMNSLKPEDTAVYYCYMDQRLDGSGLAYWGQGTQVTVSS
299	EGFR009G08	EVQLVESGGGLVQAAGGSLRLSCAASGRFTSSYAMGMWFRQAPGKEREFVAINWSSGTTYADSVKGRFTISRDNAKNTMYLQMNSLKPEDTAVYYCAAGYQINSNINFKDYEDYWGQGTLVTVSS
300	NbCEAS (CEA#1)	EVQLVESGGGSVQAAGGSLRLSCAASGDTYGSYWMGMWFRQAPGKEREGVAAINRGGGTYVYADSVKGRFTISRDTAKNTVYLQMNSLRPDDTADYYCAASGVLGGLHEDWFNWYGQGTTLVTVSS
301	T023200005 (CEA#5)	EVQLVESGGGSVQAAGGSLRLSCAASGDTYGSYWMGMWFRQAPGQEREAAVAINRGGGTYVYADSVKGRFTISRDNAKNTLYLQMNSLRPDDTADYYCAASGVLGGLHEDWFNWYGQGTTLVTVSS
302	7D12 (EGFR#1)	EVQLVESGGGSVQQTGGSLRLTCAASGRTSRSYGMGMWFRQAPGKEREFVSGISWRGDSGTGYADSVKGRFTISRDNAKNTVDLQMNSLKPEDTAIYYCAAAAGSAWYGTLYEYDWYGQGTTLVTVSS
303	T023200033 (EGFR#33)	EVQLVESGGGSVQAAGGSLRLTCAASGTSRSYGMGMWFRQAPGKEREFVSGISWRGDSGTGYADSVKGRFTISRDNAKNTVDLQMNSLKPEDTAIYYCAAAAGSTWYGTLYEYDWYGQGTTLVTVSS
304	20CD019C07	EVQLVESGGGLVQPGGSLRLSCTFSGGTFSYTMGMWFRQAPGKEREFVAAEVRWGGVTTYNSILKDRFSIEDSVKNAVYLMNSLKPEDTAVYYCAAVRQMVMYTPDPYWGQGTTLVTVSS
387	cAblys3	DVQLQASGGGSVQAAGGSLRLSCAASGYTIGPYCMGMWFRQAPGKEREGVAAINMGGGITYYADSVKGRFTISQDNAKNTVYLLMNSLEPEDTAIYYCAADSTIVASYECGHLSTGGYGYDSWGQGTQVTVSS
388	RSV007B02	EVQLVESGGGLVQAAGSLRLSCAASGRFTSSYAMGMWFRQAPGKEREFVAAISWSDGTTYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAADLTSTNPGSIYIWAYDYWGQGTQVTVSS

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2012066058 A1 [0013]
- WO 9942077 A2 [0014]
- WO 9404678 A [0171] [0333] [0404]
- WO 06030220 A [0171]
- WO 06003388 A [0171]
- WO 08020079 A [0174] [0177] [0179] [0180] [0181] [0182] [0186] [0187] [0188] [0189] [0190] [0207] [0213]
- WO 9954440 A [0250]
- WO 2007042261 A [0255]
- WO 07118670 A [0329]
- WO 12175741 A [0331]
- WO 9101743 A [0390]
- WO 0145746 A [0390]
- WO 02076489 A [0390]
- WO 08068280 A [0390]
- WO 09127691 A [0390]
- WO 11095545 A [0390]
- WO 9923221 A [0401]
- WO 9942077 A [0404] [0425]
- WO 06040153 A [0404]
- WO 06122825 A [0404] [0405]
- WO 04081026 A [0406]
- WO 9429457 A [0425]
- WO 9634103 A [0425]
- WO 9402610 A [0426]
- WO 9522618 A [0426]
- US 7004940 B [0426]
- WO 03014960 A [0426]
- WO 04041867 A [0434]
- WO 04041865 A [0434] [0487] [0489]
- WO 09068627 A [0434]
- WO 0425591 A [0434]
- WO 10125187 A [0434]
- WO 11003622 A [0434]
- WO 12056000 A [0434]
- WO 04041863 A [0487] [0489]
- WO 04062551 A [0487] [0489]
- WO 05044858 A [0487]
- WO 03035694 A [0489]
- WO 06122787 A [0543]

Non-patent literature cited in the description

- CALL et al. *Molecular Immunology*, 2004, vol. 40, 1295-1305 [0007]
- NAGORSEN et al. *Pharmacology & Therapeutics*, 2012, vol. 136, 334-342 [0009]
- GARBER. *Nature reviews*, 2014, vol. 13, 799-801 [0012]
- WARD et al. *Nature*, 1989, vol. 341, 544-6 [0171]
- HOLT et al. *Trends Biotechnol.*, 2003, vol. 21 (11), 484-490 [0171]
- PRESTA. *Adv. Drug Deliv. Rev.*, 2006, vol. 58 (5-6), 640-656 [0178]
- LEVIN ; WEISS. *Mol. Biosyst.*, 2006, vol. 2 (1), 49-57 [0178]
- IRVING et al. *J. Immunol. Methods*, 2005, vol. 248 (1-2), 31-45 [0178]
- SCHMITZ et al. *Placenta*, 2000, vol. 21, 106-112 [0178]
- GONZALES et al. *Tumour Biol*, 2005, vol. 26 (1), 31-43 [0178]
- SCHULZ et al. *Principles of Protein Structure*. Springer-Verlag, 1978 [0183]
- CHOU ; FASMAN. *Biochemistry*, 1975, vol. 13, 211 [0183]
- Adv. *Enzymol.*, vol. 47, 45-149 [0183]
- EISENBERG et al. *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 140-144 [0183]
- KYTE ; DOOLITTLE. *J. Molec. Biol.*, 1981, vol. 157, 105-132 [0183]
- GOLDMAN et al. *Ann. Rev. Biophys. Chem.*, 1986, vol. 15, 321-353 [0183]
- DESMYTER et al. *Nature Structural Biology*, 1996, vol. 3, 803 [0183]
- SPINELLI et al. *Natural Structural Biology*, 1996, vol. 3, 752-757 [0183]
- DECANNIERE et al. *Structure*, 1999, vol. 7, 361 [0183]
- OBER et al. *Intern. Immunology*, 2001, vol. 13, 1551-1559 [0201]
- JONSSON et al. *Ann. Biol. Clin.*, 1993, vol. 51, 19-26 [0201]
- JONSSON et al. *Biotechniques*, 1991, vol. 11, 620-627 [0201]
- JOHNNSSON et al. *J. Mol. Recognit.*, 1995, vol. 8, 125-131 [0201]
- JOHNNSSON et al. *Anal. Biochem.*, 1991, vol. 198, 268-277 [0201]
- DRAKE et al. *Anal. Biochem.*, 2004, vol. 328, 35-43 [0202]

- **FRIGUET et al.** *J. Immunol. Methods*, 1985, vol. 77, 305-19 [0204]
- **KENNETH et al.** *Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists*, 1996 [0207]
- **PETERS et al.** *Pharmacokinetic analysis: A Practical Approach*, 1996 [0207]
- **GIBALDI ; PERRON ; DEKKER M.** *Pharmacokinetics*. 1982 [0207]
- **KABAT et al.** *Sequence of proteins of immunological interest*. US Public Health Services [0213]
- **RIECHMANN ; MUYLDERMANS.** *J. Immunol. Methods*, 2000, vol. 240 (1-2), 185-195 [0213]
- *Antibody Engineering*. Springer Verlag Heidelberg Berlin, 2010, vol. 2, 33-51 [0215]
- **KUHNS et al.** *Immunity*, 2006, vol. 24, 133-139 [0246]
- **SCHLERETH et al.** *Cancer Immunol. Immunother.*, 2005, vol. 20, 1-12 [0250]
- **ATKINSON ; BLEACKLEY.** *Crit. Rev. Immunol.*, 1995, vol. 15 (3-4), 359-384 [0255]
- **CUNNINGHAM ; WELLS.** *Science*, 1989, vol. 244, 1081-1085 [0270]
- *Cancer, Principles and practice*. 1997 [0328]
- **DAVIES ; RIECHMANN.** *FEBS letters*, 1994, vol. 339, 285-290 [0333]
- *Protein Engineering*, 1996, vol. 9, 531-537 [0333]
- **QIANQIAN GUO et al.** *Polym. Chem*, 2013, vol. 4, 4584-4587 [0394]
- **FRENKEN et al.** *Res. Immunol.*, 1998, vol. 149, 589-99 [0425]
- **RIECHMANN ; MUYLDERMANS.** *J. Immunol. Met.*, 1999, vol. 231, 25-38 [0425]
- **VAN DER LINDEN.** *J. Biotechnol.*, 2000, vol. 80, 261-70 [0425]
- **JOOSTEN et al.** *Microb. Cell Fact*, 2003, vol. 2, 1 [0425]
- **JOOSTEN et al.** *Appl. Microbiol. Biotechnol.*, 2005, vol. 66, 384-92 [0425]
- **CATTANEO ; BIOCCA.** *Intracellular Antibodies: Development and Applications*. Landes and Springer-Verlag, 1997 [0426]
- **KONTERMANN.** *Methods*, 2004, vol. 34, 163-170 [0426]

Patentkrav

1. Polypeptid, som omfatter et første og et andet variabelt
immunglobulin-enkeltdomæne (immunoglobulin single variable
5 domain - ISV), hvor
- det første ISV har høj affinitet for/binder sig til
differentieringsklynge 3 (CD3), som er til stede på en T-celle;
 - det andet ISV har høj affinitet for/binder sig til et første
antigen på en målcelle;
- 10 hvor det første antigen er forskelligt fra nævnte CD3;
hvor målcellen er forskellig fra T-cellen; og
hvor det første ISV i det væsentlige består af 4
frameworkregioner (de respektive FR1 til FR4) og 3
komplementaritetsbestemmende regioner (de respektive CDR1 til
15 CDR3), hvor:
- (i) CDR1 er valgt fra gruppen bestående af:
 - (a) SEQ ID NO: 81-87 og
 - (b) aminosyresekvenser, som har en forskel på 4, 3, 2 eller 1
aminosyre(r) i forhold til aminosyresekvensen ifølge SEQ ID NO:
20 81; og/eller
 - (ii) CDR2 er valgt fra gruppen bestående af:
 - (c) SEQ ID NO: 101-109 og
 - (d) aminosyresekvenser, som har en forskel på 4, 3, 2 eller 1
aminosyre(r) i forhold til aminosyresekvensen ifølge SEQ ID NO:
25 101; og/eller
 - (iii) CDR3 er valgt fra gruppen bestående af:
 - (e) SEQ ID NO: 123-127 og
 - (f) aminosyresekvenser, som har en forskel på 3, 2 eller 1
aminosyre(r) i forhold til aminosyresekvensen ifølge SEQ ID NO:
30 123.
2. Polypeptid ifølge krav 1, hvor det første antigen på en
målcelle er et tumorantigen, fortrinsvis et tumorassocieret
antigen (TAA).
- 35
3. Polypeptid ifølge krav 1 eller 2, som endvidere omfatter et
tredje ISV, der har høj affinitet for/binder sig til et andet

antigen på en målcelle, hvor det andet antigen er forskelligt fra det første antigen.

4. Polypeptid ifølge krav 3, hvor det andet antigen på en målcelle er et tumorantigen, fortrinsvis et tumorassocieret antigen (TAA).

5. Polypeptid ifølge et hvilket som helst af kravene 2-4, hvor TAA'erne er uafhængigt valgt fra gruppen bestående af melanom-associeret chondroitinsulfatproteoglycan (MCSP), epidermal vækstfaktor-receptor (EGFR), fibroblastaktiveringsprotein (FAP), MART-1, karcinoembryonalt antigen ("CEA"), gp100, MAGE-1, HER-2 og Lewis^x-antigener, CD123, CD44, CLL-1, CD96, CD47, CD32, CXCR4, Tim-3, CD25, TAG-72, Ep-CAM, PSMA, PSA, GD2, GD3, CD4, CD5, CD19, CD20, CD22, CD33, CD36, CD45, CD52 og CD147, vækstfaktorreceptorer, herunder ErbB3 og ErbB4, og cytokinreceptorer, herunder interleukin-2-receptor-gamma-kæde (CD132-antigen), interleukin-10-receptor-alfa-kæde (IL-10R-A), interleukin-10-receptor-beta-kæde (IL-10R-B), interleukin-12-receptor-beta-1-kæde (IL-12R-beta1), interleukin-12-receptor-beta-2-kæde (IL-12-receptor-beta-2), interleukin-13-receptor-alfa-1-kæde (IL-13R-alfa-1) (CD213a1-antigen), interleukin-13-receptor-alfa-2-kæde (interleukin-13-bindingsprotein), interleukin-17-receptor (IL-17-receptor), interleukin-17B-receptor (IL-17B-receptor), interleukin-21-receptor-precursor (IL-21R), interleukin-1-receptor type I (IL-1R-1) (CD121a), interleukin-1-receptor type II (IL-1R-beta) (CDw121b), interleukin-1-receptor-antagonistprotein (IL-1ra), interleukin-2-receptor-alfa-kæde (CD25-antigen), interleukin-2-receptor-beta-kæde (CD122-antigen), interleukin-3-receptor-alfa-kæde (IL-3R-alfa) (CD123-antigen), CD30, IL23R, IGF-1R, IL5R, IgE, CD248 (endosialin), CD44v6, gpA33, Ron, Trop2, PSCA, claudin 6, claudin 18.2, CLEC12A, CD38, ephA2, c-Met, CD56, MUC16, EGFRvIII, AGS-16, CD27L, Nectin-4, SLITRK6, mesothelin, folatreceptor, vævsvfaktor, axl, glypican-3, CA9, Cripto, CD138, CD37, MUC1, CD70, gastrinfrigivelsespeptidreceptor, PAP, CEACAM5, CEACAM6, CXCR7, N-cadherin, FXD2 gamma a, CD21, CD133,

Na/K-ATPase, mIgM (membranbundet IgM), mIgA (membranbundet IgA), Mer, Tyro2, CD120, CD95, CA 195, DR5, DR6, DcR3 og CAIX.

6. Polypeptid ifølge et hvilket som helst af kravene 2-5, hvor det første antigen og det andet antigen er valgt fra gruppen bestående af:

- EGFR som et første antigen og CEA som et andet antigen;
- CD19 som et første antigen og CD20 som et andet antigen;
- CD19 som et første antigen og CD22 som et andet antigen;
- CD123 som et første antigen og Tim-3 som et andet antigen; og
- CD123 som et første antigen og CD69 som et andet antigen.

7. Polypeptid ifølge et hvilket som helst af kravene 1-6, som endvidere omfatter en serumproteinbindende del.

8. Polypeptid ifølge krav 7, hvor den serumproteinbindende del er et ISV, som binder serumalbumin.

9. Polypeptid, som specifikt binder CD3, og som omfatter eller i det væsentlige består af 4 frameworkregioner (de respektive FR1 til FR4) og 3 komplementaritetsbestemmende regioner (de respektive CDR1 til CDR3), hvor:

(i) CDR1 er valgt fra gruppen bestående af:

(a) SEQ ID NO: 81 til 87 eller

(b) aminosyresekvenser, som har en forskel på 4, 3, 2 eller 1 aminosyre(r) i forhold til aminosyresekvensen ifølge en hvilken som helst af SEQ ID NO: 81, forudsat at polypeptidet, som omfatter CDR1 med forskellen på 4, 3, 2 eller 1 aminosyre(r), binder CD3 med ca. samme eller højere affinitet sammenlignet med bindingen med polypeptidet, som omfatter CDR1 uden forskellen på 4, 3, 2 eller 1 aminosyre(r), hvor affiniteten er som målt ved overfladeplasmonresonans; og/eller

(ii) CDR2 er valgt fra gruppen bestående af:

(c) SEQ ID NO: 101 til 109 eller

(d) aminosyresekvenser, som har en forskel på 4, 3, 2 eller 1 aminosyre(r) i forhold til aminosyresekvensen ifølge en hvilken som helst af SEQ ID NO: 101, forudsat at polypeptidet, som omfatter CDR2 med forskellen på 4, 3, 2 eller 1 aminosyre(r),

binder CD3 med ca. samme eller højere affinitet sammenlignet med bindingen med polypeptidet, som omfatter CDR2 uden forskellen på 4, 3, 2 eller 1 aminosyre(r), hvor affiniteten er som målt ved overfladeplasmonresonans; og/eller

5 (iii) CDR3 er valgt fra gruppen bestående af:

(e) SEQ ID NO: 123 til 127 eller

(f) aminosyresekvenser, som har en forskel på 4, 3, 2 eller 1 aminosyre(r) i forhold til aminosyresekvensen ifølge en hvilken som helst af SEQ ID NO: 123, forudsat at polypeptidet, som
10 omfatter CDR3 med forskellen på 4, 3, 2 eller 1 aminosyre(r), binder CD3 med ca. samme eller højere affinitet sammenlignet med bindingen med polypeptidet, som omfatter CDR3 uden forskellen på 4, 3, 2 eller 1 aminosyre(r), hvor affiniteten er som målt ved overfladeplasmonresonans.

15

10. Polypeptid ifølge krav 9, som endvidere omfatter en serumproteinbindende del.

11. Polypeptid ifølge krav 9, hvor den serumproteinbindende del
20 er et ISV, som binder serumalbumin.

12. Nukleinsyre eller nukleinsyresekvens, som koder for et polypeptid ifølge et hvilket som helst af kravene 1-11, eller vektor, som omfatter nukleinsyren eller nukleinsyresekvensen.

25

13. Værtscelle, som er transformeret eller transficeret med nukleinsyren eller nukleinsyresekvensen eller med vektoren ifølge krav 12.

14. Fremgangsmåde til fremstilling af et polypeptid ifølge et hvilket som helst af kravene 1-11, hvilken fremgangsmåde omfatter dyrkning af en værtscelle ifølge krav 13 under betingelser, som muliggør ekspresion af polypeptidet ifølge et hvilket som helst af kravene 1-11 og indvinding af det
30 fremstillede polypeptid fra kulturen.

35

15. Farmaceutisk sammensætning, som omfatter et polypeptid ifølge et hvilket som helst af kravene 1-11.

16. Polypeptid ifølge et hvilket som helst af kravene 1-11 til anvendelse ved behandling af et individ med behov derfor.

5 17. Polypeptid ifølge et hvilket som helst af kravene 1-11 til anvendelse ved forebyggelse, behandling eller lindring af en sygdom valgt fra gruppen bestående af en proliferativ sygdom, en inflammatorisk sygdom, en infektionssygdom og en autoimmun sygdom.

10

18. Polypeptid til anvendelse ifølge krav 17, hvor den proliferative sygdom er cancer.

15 19. Polypeptid til anvendelse ifølge krav 18, hvor canceren er valgt fra gruppen bestående af karcinomer, gliomer, mesotheliomer, melanomer, lymfomer, leukæmier, adenokarcinomer: brystcancer, ovariecancer, cervixcancer, glioblastom, myelomatose (herunder monoklonal gammopati med ubestemt signifikans, asymptomatisk og symptomatisk myelom),
20 prostatacancer og Burkitts lymfom, hoved-halscancer, coloncancer, kolorektal cancer, ikke-småcellet lungecancer, småcellet lungecancer, øsofaguscancer, mavecancer, pancreascancer, hepatobiliær cancer, galdeblærecancer, tyndtarmscancer, rektal cancer, nyrecancer, blærecancer,
25 prostatacancer, peniscancer, uretralcancer, testikelcancer, vaginalcancer, uterus cancer, thyreoideacancer, parathyreoideacancer, binyrecancer, endokrin pancreascancer, karcinoid cancer, knoglecancer, hudcancer, retinoblastomer, Hodgkins lymfom, non-Hodgkins lymfom, Kaposis sarkom,
30 multicentrisk Castlemans sygdom eller AIDS-associeret primært effusionslymfom, neuroektodermale tumorer, rhabdomyosarkom; samt en hvilken som helst metastase af en hvilken som helst af ovennævnte cancere.

DRAWINGS

Drawing

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20





Figure 21

Bone marrow



SPLEEN





Figure 22

Bone marrow



SPLEEN





Figure 23

A



B

